Toxicology – Cyclosporine

Core Concept

Cyclosporine is a calcineurin-inhibitor immunosuppressant with a narrow therapeutic index and extensive drug-interaction potential. Acute oral overdose is often surprisingly well tolerated, whereas clinically important toxicity more commonly develops from chronic excessive exposure, formulation errors, CYP3A4/P-glycoprotein interactions, renal dysfunction, or accidental intravenous overdose.

The characteristic toxicity pattern is:

Excess cyclosporine exposure → renal vasoconstriction + endothelial/neural toxicity → AKI + hypertension + hyperkalemia/hypomagnesemia + tremor/encephalopathy/PRES ± hepatotoxicity

The most important management principles are:

Stop or reduce cyclosporine, identify the cause of excessive exposure, monitor whole-blood concentrations and renal function, correct electrolyte/BP abnormalities, and provide supportive care.

There is no specific antidote, and cyclosporine is not effectively removed by hemodialysis or charcoal hemoperfusion.

Current Uses

Systemic cyclosporine remains an important immunosuppressant in kidney, liver, and heart transplantation. Modified oral formulations are also FDA-labeled for severe active rheumatoid arthritis inadequately responsive to methotrexate and for severe recalcitrant plaque psoriasis in selected adults.

Cyclosporine is also widely used in specialist practice for other immune-mediated diseases.

Modern ophthalmic cyclosporine preparations—including formulations such as Restasis and Cequa—are used for ocular surface inflammatory disease/dry eye. These topical ophthalmic preparations have very different systemic exposure and should not be confused toxicologically with oral or IV cyclosporine.

The older description of routine rectal or pulmonary-aerosol cyclosporine formulations does not reflect standard current U.S. systemic formulations.

Sandimmune Versus Modified Cyclosporine – Critical Formulation Issue

One of the most important practical safety points is that Sandimmune and modified/microemulsion cyclosporine formulations such as Neoral are not bioequivalent and are not freely interchangeable milligram-for-milligram.

Modified cyclosporine has more predictable and generally greater bioavailability. Switching between formulations without appropriate supervision can lead either to excessive exposure and toxicity or to insufficient immunosuppression and graft rejection. Current Sandimmune labeling specifically warns that conversion between Sandimmune and Neoral requires increased concentration monitoring and possible dosage adjustment.

Therefore:

A formulation substitution can itself be the cause of cyclosporine toxicity.

Medication reconciliation should identify the exact formulation, concentration, dose, timing, and whether a recent product switch occurred.

Mechanism of Immunosuppression

Cyclosporine enters lymphocytes and binds the intracellular immunophilin cyclophilin. The cyclosporine–cyclophilin complex then inhibits calcineurin, preventing dephosphorylation and nuclear translocation of NFAT.

This reduces transcription of interleukin-2 and other T-cell activation genes, thereby suppressing activation and proliferation of T lymphocytes.

A useful sequence is:

Cyclosporine + cyclophilin → calcineurin inhibition → ↓ NFAT activation → ↓ IL-2 → ↓ T-cell activation

This is why cyclosporine is classified as a calcineurin inhibitor, along with tacrolimus.

Mechanisms of Toxicity

Cyclosporine toxicity is not simply “too much immunosuppression.” Calcineurin inhibition and related vascular/endothelial effects occur in nonimmune tissues, particularly the kidney, vasculature, and nervous system.

Important toxic mechanisms include:

Renal arteriolar vasoconstriction → ↓ renal blood flow/GFR → acute nephrotoxicity

Endothelial dysfunction + sodium retention + altered vasoactive mediators → hypertension

Tubular dysfunction → hyperkalemia + hypomagnesemia

Cerebral endothelial dysfunction + hypertension → encephalopathy/PRES

Chronic vascular/interstitial injury → arteriolopathy + striped tubulointerstitial fibrosis

Acute nephrotoxicity is often functional and reversible when exposure is reduced, while long-term high exposure can produce structural renal damage.

Acute Versus Chronic Toxicity

Acute and chronic cyclosporine toxicity behave differently.

A single oral overdose frequently causes only transient gastrointestinal or neurologic symptoms and modest renal dysfunction, even when the reported dose is very large.

By contrast, repeated excessive dosing or sustained high concentrations can cause progressive nephrotoxicity, hypertension, electrolyte abnormalities, neurotoxicity, and hepatotoxicity.

Accidental intravenous overdose is substantially more dangerous, because it bypasses variable GI absorption and can produce very high systemic exposure rapidly.

Toxic Dose

There is no reliable universal toxic dose.

Current Sandimmune prescribing information reports that oral doses as large as 10 g, approximately 150 mg/kg, have been associated mainly with vomiting, drowsiness, headache, tachycardia, and in some patients moderately severe but reversible renal impairment.

This means the old statement that “several grams have not produced toxicity” is partly true but potentially misleading:

Large acute oral ingestions may be relatively benign, but serious toxicity is still possible.

Severe neurotoxicity, nephrotoxicity, and hepatotoxicity have been reported after dosing errors, and fatal neurologic toxicity has occurred after massive IV overdose.

Dose alone should therefore never replace clinical assessment and therapeutic drug monitoring.

Intravenous Overdose

Parenteral overdose is more concerning than oral overdose.

Current labeling notes serious intoxication after accidental parenteral overdose, particularly in premature neonates.

A published adult case involving an IV infusion approximately ten times the intended rate developed massive cerebral edema and fatal brainstem compression; the estimated cyclosporine concentration may have approached approximately 1700 ng/mL.

Thus:

IV cyclosporine dosing errors should be treated as potentially severe even before symptoms develop.

Blood Concentrations – Important Unit Correction

The older chapter gives therapeutic cyclosporine concentrations in mg/mL. This is incorrect by roughly six orders of magnitude.

Modern cyclosporine concentrations are typically reported in:

ng/mL

not mg/mL.

For example, a trough might be reported as 100–300 ng/mL, not 100–300 mg/mL.

This is an important medication-safety correction.

Therapeutic Drug Monitoring

Cyclosporine has substantial interpatient and intrapatient pharmacokinetic variability, making therapeutic drug monitoring (TDM) essential during systemic therapy.

Monitoring usually uses whole blood, not plasma, because cyclosporine distributes substantially into erythrocytes and plasma measurements are temperature- and processing-dependent.

Two monitoring strategies are commonly used:

C0 = predose trough concentration

C2 = concentration approximately 2 hours after oral dosing

C2 may better reflect early drug exposure/AUC with modified formulations, although many centers continue to use C0 monitoring.

There Is No Universal Therapeutic or Toxic Level

The historical claim that the “therapeutic trough is 50–300” and toxicity develops “above 500” is too simplistic.

Cyclosporine target concentrations vary substantially according to:

• Transplanted organ
• Time since transplantation
• Immunologic risk
• Concomitant immunosuppression
• Assay technique
• Whether C0 or C2 is measured
• Nontransplant indication

There is no universally valid blood concentration above which toxicity always occurs.

Some patients develop toxicity at concentrations considered acceptable, while others tolerate substantially higher concentrations. In psoriasis trials, blood concentrations did not correlate reliably with either efficacy or renal dysfunction.

Therefore:

A cyclosporine concentration must be interpreted in clinical context—not as a stand-alone toxicity threshold.

Acute Overdose Concentrations

Markedly elevated levels can support the diagnosis after overdose.

A 2021 kidney-transplant medication error produced gastrointestinal and neurologic symptoms with a whole-blood concentration of 693 ng/mL.

A published prolonged overdose produced a trough concentration of 5877 ng/mL, accompanied by abdominal symptoms and renal dysfunction; recovery occurred after cyclosporine was discontinued.

A 2026 pediatric report described a child with a concentration around 1003 ng/mL after acute overdose who remained clinically stable apart from transient gastrointestinal effects, again illustrating that the number alone does not determine severity.

Pharmacokinetic Interactions

Cyclosporine is extensively metabolized by CYP3A4 and is a substrate of P-glycoprotein.

Consequently, inhibition of CYP3A4/P-gp can markedly increase cyclosporine exposure, while induction can markedly decrease exposure and risk graft rejection.

This makes drug interactions one of the most common modern pathways to toxicity.

Drugs That Increase Cyclosporine Concentrations

Clinically important inhibitors or interacting drugs include:

Clarithromycin, erythromycin, azole antifungals such as fluconazole/itraconazole/ketoconazole/voriconazole, diltiazem, verapamil, nicardipine, amiodarone, protease inhibitors, danazol, imatinib, metoclopramide, and others.

The medication list should therefore be reviewed carefully whenever a patient develops otherwise unexplained nephrotoxicity or neurotoxicity.

Grapefruit

Grapefruit and grapefruit juice should be avoided.

They can inhibit intestinal CYP3A activity and increase cyclosporine exposure. Current labeling specifically advises avoidance.

Drugs That Lower Cyclosporine Concentrations

Important enzyme-inducing drugs include:

Rifampin, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, nafcillin, and St. John’s wort.

These can reduce cyclosporine concentrations and potentially precipitate transplant rejection. Current labeling specifically warns that St. John’s wort has caused subtherapeutic concentrations, rejection, and graft loss.

Thus, reducing cyclosporine concentrations is not automatically beneficial even in a toxicity situation, particularly in a transplant recipient.

Cyclosporine as an Interaction Perpetrator

Cyclosporine does not merely have its own concentration altered by other drugs. It also inhibits CYP3A4, P-glycoprotein, and other transport systems, thereby increasing concentrations of many coadministered medications.

Examples include:

• Digoxin
• Colchicine
• Statins
• Dabigatran
• Repaglinide
• Sirolimus
• Some other narrow-therapeutic-index drugs

Colchicine Interaction

Cyclosporine can markedly increase colchicine exposure and the risk of myopathy, neuropathy, rhabdomyolysis, and multiorgan colchicine toxicity, particularly in renal dysfunction.

This interaction is clinically important because gout is common among transplant and CKD patients.

Statin Interaction

Cyclosporine increases exposure to several statins and markedly increases the risk of myopathy and rhabdomyolysis.

Current labeling reports myotoxicity with combinations involving lovastatin, simvastatin, atorvastatin, pravastatin, and, less commonly, fluvastatin. Statin selection and dosing therefore require careful attention to the individual statin’s labeling.

Muscle weakness or elevated CK in a patient receiving cyclosporine plus a statin should not automatically be attributed to the transplant illness itself.

Additive Nephrotoxicity

Cyclosporine nephrotoxicity can be amplified by other nephrotoxic agents, including aminoglycosides, vancomycin, amphotericin B, trimethoprim-sulfamethoxazole, NSAIDs, tacrolimus, methotrexate, and others.

Volume depletion further increases risk.

Thus, rising creatinine in a patient taking cyclosporine may represent:

high cyclosporine exposure + dehydration + another nephrotoxin

rather than a single cause.

Clinical Features of Acute Oral Overdose

Acute oral overdose commonly causes nausea, vomiting, abdominal discomfort, drowsiness, headache, tremor, flushing, tachycardia, and occasionally hypertension.

Moderate transient creatinine elevation may occur.

Serious toxicity is uncommon after a single isolated oral ingestion but cannot be excluded, especially after massive exposure or in patients with impaired metabolism.

Nephrotoxicity

The kidney is the principal target organ of cyclosporine toxicity.

Acute cyclosporine nephrotoxicity is largely related to renal vasoconstriction and decreased renal blood flow/GFR. It may manifest as an otherwise unexplained increase in serum creatinine and BUN, sometimes accompanied by hypertension and electrolyte abnormalities.

Early acute nephrotoxicity is often reversible after dose reduction or discontinuation.

Chronic Nephrotoxicity

Prolonged cyclosporine exposure can produce progressive structural renal damage characterized by arteriolopathy, tubular atrophy, and striped interstitial fibrosis.

Unlike acute functional vasoconstriction, advanced chronic nephrotoxicity may not fully reverse when the drug is stopped.

In a transplant recipient, distinguishing cyclosporine nephrotoxicity from graft rejection can be difficult, and both can occur simultaneously.

Hyperkalemia

Cyclosporine may produce clinically important hyperkalemia, sometimes accompanied by a hyperchloremic metabolic acidosis.

Potassium should therefore be monitored closely during suspected toxicity.

Current labeling discourages use of potassium-sparing diuretics with cyclosporine and urges caution with ACE inhibitors, ARBs, potassium-containing medications, and potassium-rich diets because of additive hyperkalemia risk.

Hypomagnesemia

Cyclosporine can promote renal magnesium loss and hypomagnesemia.

This is particularly relevant in neurotoxicity because hypomagnesemia has been identified as one of several risk factors associated with cyclosporine-related seizures and encephalopathy.

Correct clinically significant magnesium deficiency.

Hyperuricemia

Hyperuricemia can develop during calcineurin-inhibitor therapy and contributes to the high frequency of gout in transplant recipients.

It is generally a chronic therapeutic adverse effect rather than a major acute-overdose manifestation.

Hypertension

Hypertension is one of the most common cyclosporine adverse effects.

Mechanisms include systemic and renal vasoconstriction, sodium retention, sympathetic effects, and altered endothelial mediators.

Significant hypertension can contribute to neurologic toxicity, including PRES.

In toxicity, management begins by reducing or withholding cyclosporine when clinically appropriate and treating blood pressure according to contemporary hypertension/emergency principles.

Treatment of Cyclosporine-Associated Hypertension

The older recommendation that nifedipine is uniquely preferred because it is renoprotective is too narrow.

Dihydropyridine calcium-channel blockers can be useful, but antihypertensive therapy should be individualized. Some calcium-channel blockers—particularly diltiazem and verapamil—can raise cyclosporine concentrations through metabolic inhibition.

Nifedipine can also exacerbate cyclosporine-associated gingival hyperplasia.

For severe hypertensive emergency, use standard titratable IV antihypertensives according to the clinical situation rather than relying on one specific oral agent.

Neurologic Toxicity

Cyclosporine neurotoxicity ranges from mild to severe.

Mild manifestations include:

• Tremor
• Headache
• Paresthesias
• Dizziness
• Confusion

Severe manifestations include:

• Altered consciousness
• Seizures
• Visual disturbances
• Cortical blindness
• Motor abnormalities
• Psychiatric symptoms
• Encephalopathy
• PRES

Current labeling specifically recognizes posterior reversible encephalopathy syndrome (PRES) as a cyclosporine complication.

Posterior Reversible Encephalopathy Syndrome

PRES should be suspected when a patient receiving cyclosporine develops:

Hypertension + headache + seizures + confusion/encephalopathy + visual disturbance

MRI typically demonstrates posterior-predominant vasogenic edema, although distribution can be more widespread.

Risk factors described with cyclosporine include hypertension, hypomagnesemia, high drug concentrations, high-dose corticosteroid therapy, and graft-versus-host disease.

Treatment consists of:

• Reducing or stopping cyclosporine
• Controlling blood pressure
• Correcting magnesium and other metabolic abnormalities
• Treating seizures
• MRI/neurocritical-care assessment when severe

Most cases improve after appropriate management, although severe complications can occur.

Seizures

Seizures may occur with cyclosporine neurotoxicity and have particularly been reported when cyclosporine is combined with high-dose methylprednisolone.

Treat seizures with standard benzodiazepine-based therapy while correcting hypertension, hypomagnesemia, and excessive cyclosporine exposure.

Routine use of phenytoin solely because the patient has cyclosporine toxicity is undesirable because phenytoin strongly induces CYP3A metabolism and can complicate subsequent immunosuppressant dosing.

Hepatic Toxicity

Cyclosporine can cause hyperbilirubinemia, cholestatic or hepatocellular injury, hepatitis, and rarely liver failure.

Current labeling notes that hepatotoxicity usually improves after dose reduction.

Serial bilirubin and liver enzymes should therefore be monitored after significant overdose or sustained supratherapeutic exposure.

Thrombotic Microangiopathy

Cyclosporine can rarely contribute to thrombotic microangiopathy, producing thrombocytopenia and microangiopathic hemolytic anemia with organ dysfunction.

Current labeling recognizes a syndrome of thrombocytopenia and microangiopathic hemolytic anemia associated with cyclosporine.

If anemia and thrombocytopenia develop, obtain a smear, LDH, bilirubin, haptoglobin, renal studies, and other appropriate TMA testing rather than assuming the abnormalities are simple marrow suppression.

Hematologic Effects

The old description suggesting that cyclosporine routinely causes a decreased WBC count, decreased platelets, and elevated hematocrit as a typical toxicity syndrome is misleading.

Cyclosporine does not characteristically produce the predictable bone-marrow suppression seen with cytotoxic chemotherapy. Cytopenias should prompt evaluation for:

• Infection
• Other immunosuppressants
• TMA
• Bone-marrow disease
• Graft-related complications

Gingival Hyperplasia

Gingival overgrowth is a classic chronic adverse effect, particularly when cyclosporine is combined with nifedipine.

This is not a sign of acute poisoning.

Hypertrichosis

Hypertrichosis is another classic chronic cyclosporine adverse effect and can help identify long-term therapy, but it does not indicate acute toxicity severity.

Infection Risk

Cyclosporine’s therapeutic immunosuppression increases susceptibility to opportunistic and serious infections.

Current labeling describes potentially serious viral complications such as JC-virus-associated progressive multifocal leukoencephalopathy and BK/polyomavirus-associated nephropathy in immunosuppressed patients.

In a chronically treated transplant patient presenting with confusion or renal deterioration, drug toxicity should therefore be considered alongside opportunistic infection and graft-related disease.

Malignancy Risk

Long-term immunosuppression increases the risk of lymphoma and other malignancies, particularly skin malignancies. The risk is related to the degree and duration of immunosuppression.

This is a chronic therapeutic complication rather than an acute-overdose problem.

Diagnosis

Acute cyclosporine toxicity is diagnosed from the combination of:

Exposure history + symptoms + blood concentration + renal/electrolyte abnormalities

In chronic therapy, diagnosis is more difficult because the same findings can result from infection, rejection, other nephrotoxins, hypertensive disease, or underlying transplant complications.

The exact medication formulation and recent interacting drugs are essential parts of the diagnostic history.

Laboratory Evaluation

For significant overdose or suspected chronic toxicity, obtain:

• Serum creatinine and BUN
• Sodium and potassium
• Magnesium
• Bicarbonate
• Glucose
• Liver enzymes and bilirubin
• CBC
• Cyclosporine whole-blood concentration
• Urinalysis

Additional tests should be guided by severity.

CK is appropriate when rhabdomyolysis is possible, particularly in a patient taking an interacting statin or colchicine.

Cyclosporine Concentration Timing

The timing of a cyclosporine concentration must be documented.

A “level” drawn:

• immediately after a dose,
• at random,
• at C0,
• or at C2

cannot be interpreted using the same target.

Therefore:

Never interpret a cyclosporine concentration without knowing when the last dose was given.

Neurologic Testing

MRI brain is preferred when PRES is suspected.

CT may be useful initially in an unstable patient or when hemorrhage must be excluded, but a normal CT does not exclude PRES.

Lumbar puncture should not be routine in cyclosporine toxicity; it is performed only when infection or another CNS diagnosis remains a concern after considering procedural safety.

Initial Treatment

There is no specific antidote.

For acute toxicity:

1. Stop cyclosporine temporarily
2. Assess airway, breathing, and circulation
3. Obtain ECG and vital signs
4. Check renal function, potassium, magnesium, liver function, and cyclosporine concentration
5. Identify formulation and interacting medications
6. Correct dehydration and metabolic abnormalities
7. Treat hypertension and neurologic complications

In transplant recipients, decisions about holding and restarting cyclosporine should involve the transplant team because excessive reduction in immunosuppression creates a competing risk of graft rejection.

Gastrointestinal Decontamination

Induced Emesis

Do not induce vomiting.

Although current product labeling still contains historical language stating that forced emesis may be useful after overdose, modern toxicology no longer recommends induced emesis as routine poisoning management.

The risks of aspiration and uncertain benefit outweigh its usefulness.

Gastric Lavage

Current Sandimmune labeling also retains historical language suggesting gastric lavage may be valuable within two hours because absorption is relatively slow.

This recommendation conflicts with modern general toxicology practice.

AACT/EAPCCT guidance states that gastric lavage should not be performed routinely, if at all, because outcome benefit has not been demonstrated and serious complications can occur.

Therefore:

Routine gastric lavage is obsolete for cyclosporine overdose.

Only an extraordinary, immediately life-threatening, very recent ingestion could justify consideration after expert toxicology consultation and airway protection.

Activated Charcoal

Single-dose activated charcoal may be considered after a recent substantial oral cyclosporine ingestion if the patient is alert with an intact airway or has a protected airway.

Activated charcoal has been reported in cyclosporine overdose, but there is no high-quality evidence that it improves clinical outcomes. General toxicology guidance states that charcoal is most likely to reduce absorption when given within approximately the first hour and should not be administered routinely.

Thus:

Activated charcoal is selective, not mandatory.

Multiple-dose charcoal is not an established cyclosporine elimination strategy.

IV Fluids

Patients with vomiting or volume depletion should receive appropriate isotonic crystalloid.

Avoid excessive fluid administration in transplant patients with impaired cardiac or renal function.

Correcting hypovolemia is important because dehydration can intensify calcineurin-inhibitor nephrotoxicity.

Treatment of AKI

Hold or reduce cyclosporine and discontinue avoidable nephrotoxins.

Correct volume depletion, electrolyte abnormalities, and hemodynamic disturbances.

Serially monitor:

• Creatinine
• Potassium
• Magnesium
• Urine output
• Acid-base status

Nephrology consultation is appropriate for severe or progressive AKI.

Hemodialysis

Cyclosporine is not effectively removed by hemodialysis.

Current prescribing information explicitly states that cyclosporine is not dialyzable to any significant extent and is also poorly cleared by charcoal hemoperfusion.

Hemodialysis should therefore not be initiated merely to eliminate cyclosporine.

It remains appropriate for standard indications such as:

• Refractory hyperkalemia
• Severe metabolic acidosis
• Pulmonary edema/volume overload
• Uremic complications
• Severe AKI requiring renal replacement

A published overdose case underwent hemodialysis because of acute renal failure, not because dialysis was expected to substantially clear cyclosporine.

Charcoal Hemoperfusion

Charcoal hemoperfusion does not reliably clear cyclosporine and is not recommended as routine enhanced elimination.

Plasma Exchange and Whole-Blood Exchange

There are case reports of whole-blood exchange and plasma exchange after exceptionally severe cyclosporine intoxication. One cardiac-transplant patient with severe nephrotoxicity, hepatotoxicity, and neurotoxicity recovered after erythrocytapheresis followed by plasma exchange.

However:

These procedures remain experimental rescue therapies, not standard care.

Evidence is limited to isolated cases.

CYP3A Enzyme Induction as Rescue Therapy

Because cyclosporine is metabolized by CYP3A, drugs such as phenobarbital, phenytoin, and rifampin have occasionally been deliberately used to accelerate elimination after severe supratherapeutic exposure.

A 2017 review found only a small number of case reports and concluded that routine use cannot be recommended.

A 2026 pediatric overdose report used rifampin and phenobarbital with rapid decline in cyclosporine concentration, but this remains case-level evidence.

The major danger is obvious:

CYP induction → cyclosporine concentration falls → prolonged under-immunosuppression → possible graft rejection

Rifampin induction can persist after the drug is stopped and has caused prolonged subtherapeutic cyclosporine concentrations.

Therefore:

Metabolic induction should be reserved for exceptional severe toxicity under transplant/toxicology/pharmacy guidance.

Hypertension Treatment

For mild-to-moderate cyclosporine-associated hypertension, reducing cyclosporine exposure may itself improve blood pressure.

When pharmacologic treatment is needed, choose antihypertensive agents based on the clinical situation while accounting for cyclosporine interactions.

Avoid automatically using:

• Potassium-sparing diuretics in hyperkalemia-prone patients
• Diltiazem or verapamil without recognizing that they may increase cyclosporine concentrations

Severe hypertension with neurologic symptoms should be treated as a hypertensive emergency.

Treatment of PRES

For suspected cyclosporine-associated PRES:

Hold/reduce cyclosporine → control severe hypertension → correct magnesium → treat seizures → obtain MRI → involve neurology/transplant specialists

PRES is often reversible when the cause is recognized early.

Hyperkalemia Treatment

Treat severe hyperkalemia using standard emergency measures:

• IV calcium for membrane stabilization when indicated
• Insulin plus glucose
• β₂-agonist therapy
• Bicarbonate when appropriate for significant metabolic acidosis
• Renal replacement for refractory cases

Simultaneously stop contributory potassium-retaining drugs when possible.

Hypomagnesemia Treatment

Replace magnesium when clinically significant, especially with:

• Seizures
• Ventricular dysrhythmias
• PRES/neurotoxicity
• Marked laboratory deficiency

Rhabdomyolysis

If rhabdomyolysis occurs, search for interacting drugs—especially statins or colchicine.

Stop implicated agents, provide appropriate crystalloid, and monitor CK, potassium, creatinine, calcium, and urine output.

Pregnancy

The old FDA Pregnancy Category C classification is obsolete.

Current Sandimmune labeling states that decades of human experience—including transplant registries, cohort studies, and case reports—have not identified a cyclosporine-associated increase in major congenital malformations or miscarriage. However, hypertension, preeclampsia, prematurity, and low birth weight are increased among cyclosporine-treated pregnant populations, although underlying disease and concomitant therapy make causality difficult to determine.

Therefore therapeutic cyclosporine may be continued during pregnancy when clinically necessary, particularly for transplant maintenance.

Acute maternal toxicity should be treated aggressively because maternal renal failure, severe hypertension, seizures, and hypoxia pose major fetal risks.

Breastfeeding

The historical implication that lactation should generally be avoided is outdated.

Current LactMed data indicate that a fully breastfed infant typically receives less than about 2% of the maternal weight-adjusted cyclosporine dose, often less than 1%. Most reported breastfed infants have undetectable blood cyclosporine concentrations, and published follow-up has not demonstrated adverse effects on growth, development, or renal function. Many professional guidelines consider cyclosporine compatible with breastfeeding with appropriate infant monitoring.

Current Sandimmune labeling likewise states that cyclosporine is present in human milk but that adverse effects in breastfed infants have not been reported.

Therapeutic breastfeeding data should not automatically be extrapolated to a mother with an acute massive overdose.

Ophthalmic Cyclosporine in Pregnancy/Lactation

Systemic absorption after ophthalmic cyclosporine is minimal. LactMed considers significant infant exposure unlikely, and punctal occlusion after eye-drop administration can further reduce systemic absorption.

Monitoring After Acute Overdose

Patients with a substantial ingestion should have serial assessment of:

• Mental status
• Blood pressure
• Heart rate
• Serum creatinine/BUN
• Potassium
• Magnesium
• Liver enzymes/bilirubin
• Cyclosporine concentration

The appropriate monitoring duration depends on formulation, amount, symptoms, concentration trend, renal function, and comorbidities.

The old rule simply to recheck “within a day or two” is inadequate for a symptomatic patient with marked overdose.

Monitoring During Chronic Therapy

Current systemic labeling emphasizes repeated monitoring of:

renal function, liver function, potassium, magnesium, lipids, and cyclosporine blood concentrations, especially in transplant patients.

Drug concentrations should also be reassessed whenever:

• An interacting medication is started or stopped
• Formulation is changed
• Graft dysfunction occurs
• Renal function deteriorates unexpectedly
• Neurotoxicity appears

Observation

A small isolated oral dosing error in an asymptomatic patient may require only clinical observation and follow-up testing after poison-center/transplant consultation.

Patients with:

• Significant intentional overdose
• Markedly elevated concentration
• AKI
• Hypertension
• Neurologic symptoms
• Significant electrolyte abnormalities
• IV overdose

require prolonged monitored evaluation.

There is no universally validated fixed “6-hour” discharge rule for cyclosporine overdose.

Admission

Hospital admission is appropriate for:

• Significant acute overdose with symptoms
• AKI
• Sustained hypertension
• Important hyperkalemia or hypomagnesemia
• Altered consciousness
• Tremor or progressive neurotoxicity
• Significant hepatotoxicity
• Substantial IV dosing error
• Inability to obtain reliable transplant follow-up

ICU admission is appropriate for:

• Seizures
• PRES
• Severe hypertensive emergency
• Coma
• Severe AKI with metabolic complications
• Hemodynamic instability
• Massive IV overdose

Discharge

Discharge requires:

• Stable mental status and vital signs
• Stable or improving renal function
• No significant electrolyte abnormality
• No progressive neurotoxicity
• A clearly declining/acceptable cyclosporine exposure pattern
• A safe plan for restarting or adjusting immunosuppression

For transplant recipients, discharge planning should include the transplant team because prolonged withholding of cyclosporine can create serious rejection risk.

Prognosis

Most isolated oral cyclosporine overdoses recover completely with drug withdrawal and supportive care.

Even doses approaching 10 g have produced relatively modest toxicity in many patients.

However, prognosis is worse when poisoning involves:

• Massive IV exposure
• Severe neurotoxicity/PRES
• Refractory hypertension
• Advanced AKI
• Significant hepatic dysfunction
• Prolonged repeated overdose
• Serious drug interactions

Chronic nephrotoxicity may leave persistent renal impairment even after cyclosporine is reduced or discontinued.

Important Pitfalls

A major pitfall is the historical concentration unit.

Cyclosporine levels are measured in ng/mL—not mg/mL.

A stated “500 mg/mL cyclosporine trough” would be physiologically implausible.

Another pitfall is assuming that a blood concentration above one arbitrary threshold proves toxicity. There is no universal toxic level, and therapeutic targets differ widely according to indication and timing.

Another major error is ignoring the exact formulation. Sandimmune and modified cyclosporine formulations such as Neoral are not bioequivalent or automatically interchangeable.

The most important modern source of toxicity is often drug interaction, particularly CYP3A4/P-gp inhibition.

Always ask about:

clarithromycin, erythromycin, azoles, diltiazem, verapamil, amiodarone, HIV antivirals, grapefruit, colchicine, statins, and additional nephrotoxins.

Another pitfall is interpreting rising creatinine in a transplant recipient as automatically due to rejection. Cyclosporine nephrotoxicity and rejection can look similar and may coexist.

Do not miss PRES in a cyclosporine-treated patient with hypertension, seizures, confusion, or visual symptoms.

The historical recommendation for gastric lavage and forced emesis should not be followed routinely. Modern toxicology discourages both; activated charcoal is selective rather than mandatory.

Another pitfall is ordering hemodialysis simply to clear cyclosporine.

Dialysis treats AKI complications—it does not effectively clear cyclosporine.

Finally, using rifampin, phenytoin, or phenobarbital to intentionally accelerate metabolism is not routine therapy. Evidence consists mainly of case reports, and prolonged enzyme induction may drive concentrations too low and endanger a transplanted organ.

High-Yield Toxicology Pearls

Cyclosporine toxicity is primarily a renal–vascular–neurologic syndrome.

Think:

AKI + hypertension + hyperkalemia/hypomagnesemia + tremor/encephalopathy

The mechanism is cyclophilin binding → calcineurin inhibition → reduced NFAT/IL-2 signaling, while toxicity reflects renal vasoconstriction, endothelial dysfunction, tubular effects, and CNS vascular injury.

A single oral overdose is often less toxic than expected. Current labeling reports oral doses up to 10 g (~150 mg/kg) producing mainly vomiting, drowsiness, headache, tachycardia, and reversible renal dysfunction in many patients.

However, IV overdose can be catastrophic and repeated excessive exposure can produce severe renal, hepatic, and neurologic toxicity.

Whole-blood concentrations are usually reported in ng/mL. Do not use the old mg/mL units.

There is no universal “toxic cyclosporine level.” Target concentrations vary by transplant type, time since transplantation, assay, and whether C0 or C2 monitoring is used.

Always establish the exact formulation:

Sandimmune and Neoral/modified cyclosporine are not automatically interchangeable.

Cyclosporine is a CYP3A4 and P-glycoprotein substrate. Clarithromycin, erythromycin, azole antifungals, diltiazem, verapamil, amiodarone, protease inhibitors, and grapefruit can raise concentrations.

Cyclosporine also raises concentrations of other drugs, notably colchicine and statins, increasing the risk of myopathy/rhabdomyolysis.

Acute nephrotoxicity is usually caused by renal vasoconstriction and reduced GFR and may improve after dose reduction. Chronic exposure can produce arteriolopathy and irreversible interstitial fibrosis.

Hypertension is common. Monitor potassium because hyperkalemia can occur, and monitor magnesium because hypomagnesemia may contribute to neurologic toxicity.

A patient receiving cyclosporine who develops:

Headache + hypertension + seizures + visual disturbance/confusion

should be evaluated urgently for PRES.

There is no antidote.

Activated charcoal can be considered after a recent substantial ingestion when the airway is safe, but routine lavage and induced emesis are obsolete.

Cyclosporine is not effectively removed by hemodialysis or charcoal hemoperfusion. Dialysis is reserved for conventional AKI/metabolic indications.

CYP enzyme induction with phenytoin, phenobarbital, or rifampin has been used in exceptional severe cases, but evidence is limited and routine use is not recommended because excessive reduction in immunosuppression can precipitate graft rejection.

Pregnancy Category C terminology is obsolete. Available human data have not demonstrated an increased rate of major congenital malformations or miscarriage, although prematurity, hypertension, preeclampsia, and low birth weight are more frequent in cyclosporine-treated transplant populations.

Therapeutic cyclosporine is increasingly regarded as compatible with breastfeeding with appropriate infant monitoring, with typical infant exposure well below the maternal weight-adjusted dose.

The most important clinical warning is:

In a patient taking cyclosporine, an unexplained rise in creatinine plus hypertension or tremor should trigger an immediate search for excessive drug exposure and a CYP3A4/P-gp interaction.

Toxicology – Cyclobenzaprine

Core Concept

Cyclobenzaprine is a centrally acting skeletal muscle relaxant with a tricyclic chemical structure closely related to amitriptyline. In overdose, its dominant effects are usually sedation and antimuscarinic toxicity, particularly drowsiness, sinus tachycardia, agitation, confusion, dry mucosae, mydriasis, and urinary retention.

A useful toxicologic sequence is:

Cyclobenzaprine → central sedation + muscarinic antagonism → drowsiness/confusion + tachycardia + dry skin/mouth + mydriasis + urinary retention

Severe poisoning can additionally produce coma, seizures, hypotension, respiratory depression, QRS widening, and ventricular dysrhythmias, but important modern poison-center series show that cyclobenzaprine is considerably less cardiotoxic than classic tricyclic antidepressants in most isolated overdoses.

The major bedside principle is:

Cyclobenzaprine looks chemically like a TCA, but most isolated overdoses behave primarily as sedative-antimuscarinic poisoning rather than classic severe TCA cardiotoxicity.

Nevertheless, an ECG is essential because the rare patient who develops QRS widening or ventricular dysrhythmia should be treated as having sodium-channel blockade.

Current Forms and Uses

Cyclobenzaprine is used as an adjunct to rest and physical therapy for short-term relief of muscle spasm associated with acute painful musculoskeletal conditions. It is not considered effective for spasticity caused by cerebral or spinal-cord disease. Current labeling recommends limiting treatment to approximately 2–3 weeks because evidence for prolonged use is inadequate.

Immediate-release tablets are currently available in strengths including 5 mg, 7.5 mg, and 10 mg. The usual adult immediate-release dose is:

5 mg orally three times daily

which may be increased to 7.5–10 mg three times daily according to response. The old statement that 10 mg three times daily is simply the “usual dose” therefore overstates current starting therapy.

Extended-release formulations are also available as 15-mg and 30-mg capsules, generally administered once daily.

Pharmacology

Cyclobenzaprine acts predominantly in the central nervous system, particularly at brainstem motor pathways, reducing tonic somatic motor activity. It does not act directly at the neuromuscular junction and is not a peripheral skeletal-muscle paralytic.

Its pharmacologic profile includes:

Central sedation + antimuscarinic activity + alpha-adrenergic effects + monoaminergic activity

These actions explain the mixture of somnolence, anticholinergic findings, sinus tachycardia, occasional hypotension, and serotonergic drug interactions.

Relationship to Tricyclic Antidepressants

Cyclobenzaprine is structurally related to amitriptyline and imipramine, and older toxicology texts therefore often approached overdose as if it were essentially TCA poisoning.

That comparison is useful—but incomplete.

Two large poison-center studies demonstrate an important difference. A multicenter review of 402 isolated cyclobenzaprine ingestions found no deaths, no seizures, and no life-threatening dysrhythmias; common effects were lethargy, sinus tachycardia, and agitation. Doses ranged up to 1000 mg.

A later review of 209 isolated acute overdoses similarly found no deaths, no wide-QRS cases, and no ventricular dysrhythmias attributable to cyclobenzaprine. Hypotension was uncommon.

Thus:

Do not assume that every cyclobenzaprine overdose will behave like amitriptyline.

However, rare severe cardiotoxic cases and fatalities have been reported, and current FDA labeling continues to regard QRS widening, dysrhythmia, severe hypotension, seizures, and cardiac arrest as possible critical manifestations.

Mechanism of Toxicity

The most common toxicity reflects central nervous system depression and muscarinic receptor antagonism.

Antimuscarinic effects produce:

Mydriasis + dry mouth + dry/flushed skin + tachycardia + decreased bowel motility + urinary retention + delirium

At very large concentrations, cyclobenzaprine may also interfere with cardiac sodium conduction in a TCA-like manner. Clinically significant sodium-channel blockade is uncommon in isolated poisoning but should be suspected when the ECG demonstrates QRS widening, terminal conduction abnormalities, ventricular dysrhythmia, or severe hypotension.

Pharmacokinetics

Cyclobenzaprine is relatively slowly eliminated. Current immediate-release labeling reports an effective half-life of approximately 18 hours, with a wide range of about 8–37 hours. It is highly protein bound and undergoes extensive hepatic metabolism, including metabolism through CYP3A4, CYP1A2, and to a lesser extent CYP2D6.

Repeated three-times-daily dosing results in accumulation, with steady state reached after several days. Plasma concentrations are higher in older adults and patients with hepatic impairment.

The long half-life helps explain why symptomatic patients may remain sedated or anticholinergic well beyond the initial emergency-department period.

Toxic Dose

There is no precisely defined toxic or fatal dose.

Older statements that “several hundred milligrams may cause death” are too simplistic. Fatal cases exist, but large isolated overdoses are often survivable with supportive care.

In the classic multicenter poison-center study, doses ranged from 5 to 1000 mg. No deaths occurred, and no patient developed life-threatening cardiovascular or neurologic toxicity. No effects requiring treatment beyond gastrointestinal decontamination were reported below 100 mg in that series.

This should not be converted into a rigid “safe dose” rule. Patient age, formulation, coingestants, cardiovascular disease, serotonergic drugs, and uncertainty in the reported amount all matter.

Therefore:

Dose helps with risk assessment, but the ECG and clinical syndrome determine management.

Risk Factors for Severe Toxicity

Risk is increased by large intentional ingestion, extended-release formulations, alcohol or sedative coingestion, serotonergic coingestants, advanced age, hepatic impairment, and underlying cardiac conduction disease.

Current labeling specifically recognizes higher cyclobenzaprine concentrations in elderly patients and patients with hepatic impairment.

Extended-release labeling advises against use in moderate-to-severe hepatic impairment and recommends caution regarding the drug’s anticholinergic and sedating properties.

Drug Interactions

Cyclobenzaprine potentiates the effects of alcohol, barbiturates, opioids, benzodiazepines, and other CNS depressants. Coingestion can convert an otherwise moderate cyclobenzaprine overdose into clinically important respiratory depression or coma.

An important modern addition is its interaction with serotonergic medications.

Serotonin Syndrome

Cyclobenzaprine has serotonergic pharmacology and has been associated with serotonin syndrome, particularly when combined with other serotonergic drugs.

Reported interacting agents include:

SSRIs, SNRIs, TCAs, tramadol, meperidine, bupropion, and MAO inhibitors, among others. Current labeling specifically warns about this potentially life-threatening interaction.

The clinical syndrome includes:

Agitation/confusion + diaphoresis + hyperthermia + autonomic instability + tremor + hyperreflexia + clonus ± rigidity

This differs from uncomplicated antimuscarinic delirium, in which the skin and mucosa are characteristically dry and clonus/hyperreflexia are not typical.

Monoamine Oxidase Inhibitors

Cyclobenzaprine is contraindicated during treatment with an MAO inhibitor and for 14 days after MAOI discontinuation. Hyperpyretic reactions, seizures, and deaths have been reported with cyclobenzaprine or closely related tricyclic drugs in this setting.

Therefore:

Cyclobenzaprine + MAOI is a major interaction, not merely additive sedation.

Clinical Features

The typical isolated overdose produces:

Drowsiness + sinus tachycardia ± antimuscarinic findings

Current labeling identifies drowsiness and tachycardia as the most common manifestations of overdose. Less frequent findings include tremor, agitation, ataxia, confusion, hallucinations, hypertension, vomiting, and coma. Rare severe manifestations include cardiac arrest, dysrhythmias, severe hypotension, seizures, and neuroleptic-malignant-syndrome-like presentations.

Central Nervous System

Sedation is common and may range from mild drowsiness to significant somnolence. Patients can also develop agitation, confusion, hallucinations, dysarthria, ataxia, or delirium.

This apparent mixture of sedation and agitation is typical of drugs with both central sedative and antimuscarinic activity.

Coma is unusual in uncomplicated moderate isolated overdose and should prompt careful consideration of:

opioids, ethanol, benzodiazepines, sedative-hypnotics, hypoglycemia, trauma, seizures, or another coingestant.

Antimuscarinic Syndrome

Characteristic findings include:

Mydriasis, blurred vision, dry mouth, warm/dry skin, sinus tachycardia, urinary retention, decreased bowel sounds, agitation, hallucinations, and delirium.

Severe ileus and urinary retention are possible but uncommon.

Hyperthermia can result when reduced sweating combines with severe agitation.

Cardiovascular Effects

Sinus tachycardia is by far the most frequent cardiovascular abnormality and usually reflects antimuscarinic activity.

Mild hypertension may occur. Hypotension is less frequent and can result from vasodilation, severe CNS depression, dehydration, or rare myocardial/conduction toxicity.

Life-threatening ventricular dysrhythmias are uncommon in isolated cyclobenzaprine overdose, which distinguishes it from classic TCA poisoning.

Nevertheless, current labeling considers changes in QRS width or axis clinically significant markers of severe toxicity.

Respiratory Toxicity

Respiratory depression can occur from severe CNS depression, particularly after large overdose or coingestion of alcohol, opioids, benzodiazepines, or other sedatives.

Patients with declining mental status require close airway assessment.

Respiratory failure in a presumed cyclobenzaprine overdose should trigger strong consideration of an opioid or other sedative coingestant.

Seizures

Seizures are rare after isolated cyclobenzaprine overdose. In one large series of 402 isolated ingestions, no seizures occurred; another poison-center study found reported seizure events were not attributable to cyclobenzaprine itself.

Nevertheless, seizures remain described in postmarketing overdose reports and are plausible in severe poisoning or mixed ingestion.

Treat seizures with benzodiazepines first-line.

Gastrointestinal Effects

Nausea and vomiting can occur. Antimuscarinic effects may slow gastrointestinal motility and produce constipation or ileus.

Delayed gastric emptying is theoretically relevant after very large ingestions, although routine prolonged gastrointestinal decontamination is not supported.

Genitourinary Effects

Urinary retention is a classic antimuscarinic effect and may require bladder assessment or temporary catheterization when severe.

Patients with prostatic obstruction or other baseline voiding problems may be more susceptible.

Rhabdomyolysis

Rhabdomyolysis is uncommon but may develop after prolonged agitation, seizures, hyperthermia, or prolonged immobilization.

Check CK, potassium, renal function, and urinalysis in patients with those risk factors.

Diagnosis

Diagnosis is primarily clinical and based on history, medication access, physical findings, and ECG.

A characteristic presentation is:

Cyclobenzaprine exposure → drowsiness/tachycardia → dry antimuscarinic findings ± delirium

Because overdose frequently occurs in deliberate self-poisoning, clinicians should actively search for coingestants.

Differential Diagnosis

Important toxicologic alternatives include:

Tricyclic antidepressants, diphenhydramine and other antihistamines, antipsychotics, ethanol, opioids, benzodiazepines, sedative-hypnotics, serotonin syndrome, and sympathomimetic poisoning.

TCA poisoning is particularly important because QRS widening and severe cardiotoxicity require immediate sodium bicarbonate treatment.

Serotonin syndrome can overlap with cyclobenzaprine toxicity but is suggested by clonus, hyperreflexia, diaphoresis, increased bowel activity, and serotonergic coexposure rather than a purely dry antimuscarinic syndrome.

Initial Assessment

Begin with airway, breathing, circulation, bedside glucose, temperature, neurologic examination, and a careful medication history.

In unexplained respiratory depression, naloxone should be given when opioid toxicity is plausible. Naloxone does not reverse cyclobenzaprine itself.

Routine “coma cocktail” administration of thiamine or glucose to every patient is obsolete; glucose should be measured and hypoglycemia treated when present, while thiamine is used when clinically indicated.

ECG

Obtain an ECG after a significant cyclobenzaprine overdose.

Current labeling identifies QRS abnormalities as important markers of severe toxicity.

Assess:

heart rate, rhythm, PR interval, QRS duration, QT/QTc, and evidence of sodium-channel blockade.

A normal ECG strongly reduces concern for major TCA-like cardiotoxicity but does not replace clinical observation.

QRS Widening

A QRS duration of approximately ≥100 ms is traditionally regarded as concerning in this setting, consistent with current product labeling.

However, the key concept is not the exact number in isolation:

Cyclobenzaprine overdose + new QRS widening, ventricular dysrhythmia, or conduction-related hypotension = treat for sodium-channel blockade.

Laboratory Testing

Asymptomatic low-risk patients generally do not require extensive laboratory testing.

In symptomatic or intentional overdose, useful studies include:

glucose, electrolytes, renal function, and an acetaminophen concentration when the ingestion history is uncertain.

Additional tests should be targeted to the clinical picture. CK is appropriate after seizures, prolonged agitation, hyperthermia, or prolonged unconsciousness.

Blood gas and lactate can help when severe hypotension, seizures, respiratory failure, or major conduction abnormalities are present.

Cyclobenzaprine Levels

Serum cyclobenzaprine concentrations do not guide acute management.

Current labeling specifically advises against using plasma drug levels to direct overdose care.

Clinical status and ECG findings are more useful.

Initial Treatment

Treatment is primarily supportive.

Provide airway support, oxygen when indicated, IV access, cardiac monitoring for significant exposures, treatment of agitation or seizures, management of hypotension, and correction of hyperthermia or metabolic abnormalities.

A poison center or medical toxicologist should be consulted for severe or unusual toxicity, especially QRS widening, dysrhythmia, seizures, refractory delirium, or significant extended-release overdose.

Airway Management

Patients with severe CNS depression should be positioned and monitored carefully for aspiration and hypoventilation.

Endotracheal intubation is appropriate for:

loss of airway reflexes, persistent hypoventilation, profound coma, recurrent seizures, or inability to manage secretions.

Current product labeling warns that severe CNS depression can deteriorate abruptly.

Activated Charcoal

A single dose of activated charcoal may be considered after a recent substantial ingestion if the airway is intact or protected.

Modern toxicology guidance does not recommend activated charcoal routinely for every poisoned patient. Its greatest potential benefit is during approximately the first hour after ingestion, and it is contraindicated when the airway is unprotected.

Because cyclobenzaprine has antimuscarinic effects that may delay gastric emptying, occasional later use might be considered after a very large ingestion in consultation with toxicology, but evidence for improved clinical outcomes is lacking.

Gastric Lavage

The current cyclobenzaprine package insert still contains old language recommending large-volume gastric lavage after overdose.

That recommendation is not consistent with modern general toxicology practice.

AACT/EAPCCT guidance concludes that gastric lavage should not be performed routinely, if at all, because evidence for clinical benefit is poor and complications can be serious.

Therefore:

Routine gastric lavage is obsolete for cyclobenzaprine overdose.

Only an extraordinary, immediately life-threatening ingestion presenting extremely early could justify considering it after expert toxicology consultation and airway protection.

Do Not Induce Vomiting

Ipecac or other induced emesis has no role.

Cyclobenzaprine can cause sedation abruptly, increasing aspiration risk.

Sodium Bicarbonate

Cyclobenzaprine ordinarily does not require sodium bicarbonate merely because it resembles a TCA.

However, if there is evidence of cardiac sodium-channel blockade—particularly:

QRS widening + ventricular dysrhythmia ± severe conduction-related hypotension

then treat with IV sodium bicarbonate.

A reasonable toxicology regimen is:

Sodium bicarbonate 1–2 mEq/kg IV bolus

repeated according to ECG and hemodynamic response, followed when necessary by an alkalinizing infusion.

Current labeling recommends alkalinization when dysrhythmia or QRS widening occurs and identifies a target blood pH around 7.45–7.55, while avoiding excessive alkalemia.

The therapeutic endpoint is improvement in QRS duration, rhythm, and blood pressure, not attainment of a bicarbonate concentration.

Dysrhythmias

Correct oxygenation, acidemia, and electrolyte abnormalities first.

Sodium bicarbonate is first-line when sodium-channel blockade is suspected.

If ventricular dysrhythmia persists despite adequate bicarbonate therapy, lidocaine can be considered after toxicology consultation.

The product label still mentions bretylium and phenytoin as possible therapies, but bretylium is essentially obsolete in contemporary practice, and phenytoin is not a preferred treatment for toxicologic sodium-channel cardiotoxicity or drug-induced seizures.

Avoid class IA and IC sodium-channel-blocking antiarrhythmics such as procainamide and flecainide because they may worsen conduction toxicity.

Hypotension

Give isotonic crystalloid when volume depletion is present.

If clinically important hypotension persists despite appropriate fluids:

Norepinephrine is a reasonable first-line vasopressor.

The historical dopamine-first strategy and routine Trendelenburg positioning are outdated.

Persistent hypotension associated with QRS widening should also prompt immediate sodium bicarbonate therapy because myocardial sodium-channel blockade may be contributing.

Agitation

Mild antimuscarinic agitation can often be managed with environmental control and observation.

For significant agitation, benzodiazepines are reasonable, particularly when the diagnosis is uncertain, seizures are a concern, or serotonin syndrome cannot be excluded.

Excessive benzodiazepine administration should be avoided because cyclobenzaprine already produces sedation and may increase the likelihood of respiratory compromise.

Physostigmine – Important Modern Nuance

The old chapter recommends physostigmine 1–2 mg IV diagnostically for cyclobenzaprine-associated anticholinergic syndrome.

That is too liberal.

Physostigmine can be highly effective for severe pure antimuscarinic delirium, and modern evidence suggests it is safer than its historical reputation when appropriately selected. However, significant adverse effects are more concerning in patients with QRS prolongation or exposure to drugs capable of sodium-channel blockade. A large literature review concluded that physostigmine should be avoided when the ECG demonstrates QRS prolongation.

Cyclobenzaprine is structurally TCA-like and has at least theoretical and label-recognized potential for sodium-channel toxicity.

Therefore:

Physostigmine is not routine treatment for cyclobenzaprine overdose.

It may be considered only for severe, clearly antimuscarinic delirium when:

• the ECG is reassuring,
• QRS is not widened,
• no important TCA or other sodium-channel blocker is suspected,
• there is no significant bradycardia or conduction disease,
• and a medical toxicologist or poison center supports its use.

Current cyclobenzaprine labeling itself recommends against physostigmine except in exceptional severe cases after consultation with a poison center.

Serotonin Syndrome Treatment

If serotonin syndrome develops, stop cyclobenzaprine and other serotonergic drugs.

Treatment is primarily:

sedation with benzodiazepines + IV fluids + active cooling for significant hyperthermia + management of autonomic instability.

Severe hyperthermia from muscle activity requires aggressive sedation and external cooling. Antipyretics do not treat the mechanism.

Cyproheptadine may be considered in persistent moderate-to-severe serotonin toxicity when enteral administration is possible, but supportive care remains the priority.

Seizure Treatment

Use benzodiazepines first-line.

Refractory seizures can be treated with additional GABAergic therapy such as phenobarbital or propofol according to severity.

Phenytoin is generally a poor choice for toxin-induced seizures and is not preferred despite its appearance in older cyclobenzaprine labeling.

Hyperthermia

Hyperthermia can arise from antimuscarinic impairment of sweating, agitation, seizures, or serotonin toxicity.

Treatment is:

sedation + removal of excess clothing + active external cooling + IV fluids as appropriate.

Severe hyperthermia requires rapid control because rhabdomyolysis, AKI, coagulopathy, and neurologic injury can develop.

Rhabdomyolysis

Treat with appropriate IV crystalloid and management of the precipitating cause, especially seizures, agitation, or hyperthermia.

Follow CK, potassium, creatinine, and urine output.

Routine bicarbonate alkalinization of the urine is not required solely because rhabdomyolysis is present.

Enhanced Elimination

Hemodialysis does not have a meaningful role in cyclobenzaprine clearance.

Cyclobenzaprine is highly protein bound, extensively distributed, and present at relatively low plasma concentrations. Current labeling states dialysis is probably of no value.

Hemoperfusion, forced diuresis, and urinary manipulation are likewise not established therapies.

Antidote

There is no specific antidote for cyclobenzaprine poisoning.

Physostigmine is an antidote to selected antimuscarinic delirium, not a specific cyclobenzaprine antidote and not a treatment for sodium-channel toxicity.

Monitoring

Symptomatic patients should receive serial neurologic examinations and appropriate respiratory monitoring.

Significant overdose warrants continuous ECG monitoring until:

mental status is improving, vital signs are stable, and there is no evolving conduction abnormality.

Repeat the ECG if tachycardia worsens, hypotension develops, seizures occur, or mental status deteriorates.

Observation Period

The older fixed 6-hour rule is useful only as a rough minimum for immediate-release exposures.

In the classic multicenter poison-center series, all patients with a known ingestion time who eventually became symptomatic did so within approximately 4 hours.

Thus, an asymptomatic patient after an uncomplicated immediate-release ingestion who has a normal ECG and remains completely well through an adequate observation interval—commonly around 6 hours—may often be medically cleared.

However, observation should be longer for:

extended-release formulations, very large or uncertain ingestions, significant coingestants, abnormal ECG, evolving anticholinergic findings, older adults, or hepatic impairment.

Admission

Hospital admission is appropriate for patients with:

persistent altered mental status, significant agitation, recurrent vomiting with aspiration risk, hypotension, seizures, respiratory depression, urinary retention requiring treatment, significant serotonin toxicity, or ECG abnormalities.

ICU-level care is appropriate for:

coma requiring ventilation, seizures, severe hyperthermia, QRS widening, ventricular dysrhythmia, severe hypotension, or multiorgan complications.

Discharge

A patient may be discharged when:

mental status has returned to baseline, vital signs are stable, the ECG is reassuring, ambulation is safe, oral intake is adequate, and no delayed toxicity is expected from the formulation or coingestants.

Intentional ingestion requires appropriate psychiatric and safety assessment after medical stabilization.

Prognosis

Most isolated cyclobenzaprine overdoses have a favorable prognosis with supportive care.

In the major multicenter study of 402 isolated exposures, no deaths occurred, no seizures were observed, and life-threatening dysrhythmias were absent even at reported doses up to 1000 mg.

The later Texas poison-center analysis similarly found no deaths, ventricular dysrhythmias, or wide-QRS cases among 209 isolated acute overdoses.

Fatal cyclobenzaprine overdoses have nevertheless been reported, including cases with substantial postmortem cyclobenzaprine concentrations.

Thus the correct interpretation is:

Severe cardiotoxicity is rare—not impossible.

Pregnancy

The old FDA Pregnancy Category B terminology is obsolete.

Current extended-release labeling states that available human case-report data have not identified an increased risk of major birth defects, miscarriage, or adverse maternal/fetal outcomes, although the human evidence remains limited. Animal studies have shown reduced pup weight and survival at sufficiently high maternal exposures.

In acute overdose, maternal stabilization takes priority. Hypoxia, hypotension, seizures, and hyperthermia pose greater immediate fetal risks than most necessary resuscitative treatments.

Breastfeeding

Modern lactation data are more reassuring than the older statement that milk transfer was unknown.

The 2026 LactMed review reports that cyclobenzaprine concentrations in breast milk appear to be very low, with an estimated relative infant dose of approximately 0.5% in two studied mothers. Breastfeeding generally does not need to be stopped solely because therapeutic cyclobenzaprine is required.

The infant should nevertheless be monitored for excessive drowsiness, feeding problems, adequate weight gain, and respiratory depression, especially in neonates, preterm infants, or when the mother also receives opioids or other sedatives.

These therapeutic data should not automatically be extrapolated to a mother with a major acute overdose.

Older Adults

Cyclobenzaprine deserves particular caution in older adults because of sedation, antimuscarinic effects, confusion, urinary retention, and fall risk.

Current pharmacokinetic data show substantially increased drug exposure in elderly individuals.

A relatively modest overdose may therefore cause disproportionate delirium or sedation in an older patient.

Hepatic Impairment

Because cyclobenzaprine is extensively hepatically metabolized, plasma concentrations rise in hepatic dysfunction. Immediate-release labeling recommends cautious low-dose use in mild impairment and states that use in moderate-to-severe hepatic impairment is not recommended because adequate data are lacking.

This can prolong toxicity after overdose.

Important Pitfalls

A major pitfall is assuming that cyclobenzaprine is simply “amitriptyline without the antidepressant indication.” Its structure is similar, but poison-center data show that life-threatening sodium-channel cardiotoxicity is substantially less common in isolated cyclobenzaprine overdose.

The opposite error is equally dangerous: because cardiotoxicity is uncommon, clinicians should not ignore the ECG. New QRS widening or ventricular dysrhythmia requires immediate sodium bicarbonate treatment.

Another pitfall is treating simple sinus tachycardia with antiarrhythmics. Most tachycardia reflects antimuscarinic activity and does not need rhythm-specific therapy.

Do not use physostigmine reflexively simply because the patient is delirious and dry. Cyclobenzaprine has potential sodium-channel effects, and physostigmine is best reserved for carefully selected patients with a reassuring ECG after toxicology consultation.

The package insert’s routine recommendation for gastric lavage is outdated. Modern AACT/EAPCCT guidance states that lavage should not be performed routinely, if at all.

Another important modern pitfall is missing serotonin syndrome. Agitation, hyperthermia, diaphoresis, clonus, and hyperreflexia in a patient taking cyclobenzaprine with an SSRI, SNRI, tramadol, MAOI, or another serotonergic drug should not simply be labeled anticholinergic delirium.

Profound respiratory depression should trigger a search for opioids, ethanol, benzodiazepines, or other sedative coingestants rather than being automatically attributed to cyclobenzaprine.

Finally, do not use a serum cyclobenzaprine concentration to guide treatment. Current labeling specifically advises that plasma drug levels should not determine overdose management.

High-Yield Toxicology Pearls

Cyclobenzaprine overdose most commonly causes drowsiness + sinus tachycardia + antimuscarinic findings.

Its structure resembles a TCA, but large poison-center studies show that isolated cyclobenzaprine overdose much less commonly produces seizures, wide-QRS dysrhythmia, or fatal cardiotoxicity than amitriptyline overdose.

Current immediate-release dosing usually starts at 5 mg three times daily, with escalation to 7.5–10 mg three times daily if needed. Extended-release formulations contain 15 or 30 mg once daily. Therapy is generally limited to 2–3 weeks.

The main toxidrome is:

Sedation + tachycardia + dry mouth/skin + mydriasis + urinary retention ± antimuscarinic delirium

Always obtain an ECG after a significant overdose.

If there is QRS widening, ventricular dysrhythmia, or conduction-related hypotension, treat with:

Sodium bicarbonate 1–2 mEq/kg IV

and repeat according to ECG and hemodynamic response.

Sinus tachycardia alone does not require sodium bicarbonate.

Seizures are rare but should be treated with benzodiazepines. Phenytoin is not preferred for toxin-induced seizures.

Routine gastric lavage is obsolete despite language that persists in some current package inserts. Activated charcoal is selective rather than routine, with greatest potential benefit after a recent substantial ingestion when the airway is safe.

There is no specific antidote.

Physostigmine can reverse severe pure antimuscarinic delirium, but in cyclobenzaprine poisoning it should be highly selective, with a reassuring ECG and toxicology consultation; avoid it when QRS prolongation or another sodium-channel blocker is suspected.

Cyclobenzaprine can contribute to serotonin syndrome, especially with SSRIs, SNRIs, TCAs, tramadol, or MAO inhibitors. MAOI use is contraindicated during cyclobenzaprine treatment and for 14 days after MAOI discontinuation.

Hemodialysis does not meaningfully enhance elimination.

Most toxicity becomes evident within several hours after an immediate-release ingestion; a classic poison-center series found all eventually symptomatic patients with known timing had developed symptoms within 4 hours. Extended-release preparations and large or mixed ingestions require longer observation.

The most important clinical distinction is:

Cyclobenzaprine overdose usually behaves like an antimuscarinic sedative—but if the QRS widens, treat the patient like sodium-channel-blocker poisoning.

Toxicology – Cyanide

Core Concept

Cyanide is a rapidly acting cellular asphyxiant that prevents tissues from using oxygen despite adequate oxygen delivery. Severe poisoning can progress within minutes from headache, confusion, and dyspnea to seizures, profound lactic acidosis, cardiovascular collapse, coma, and death.

The key mechanism is:

Cyanide exposure → inhibition of mitochondrial cytochrome c oxidase → oxidative phosphorylation stops → cellular ATP failure → anaerobic metabolism → massive lactate production → cardiovascular/CNS collapse

The most important modern treatment principle is:

Suspected severe cyanide poisoning → give 100% oxygen + aggressive supportive care + hydroxocobalamin early; do not wait for a cyanide level.

Hydroxocobalamin is FDA-approved for known or suspected cyanide poisoning and can be administered immediately when clinical suspicion is high.

Forms and Sources

Important cyanide exposures include hydrogen cyanide (HCN) gas, sodium cyanide, potassium cyanide, calcium cyanide, cyanogen compounds, cyanogenic plants, nitriles, sodium nitroprusside, and combustion products from structural fires.

Hydrogen cyanide is a volatile liquid/gas that can be rapidly lethal by inhalation. Cyanide salts can generate HCN when exposed to acid, including gastric acid after ingestion.

Industrial exposures occur in mining and metal extraction, electroplating, metallurgy, jewelry manufacture, plastics and synthetic-fiber production, chemical manufacturing, fumigation, and laboratory processes.

Smoke Inhalation

Modern toxicology places particular emphasis on enclosed-space structural fires.

Combustion of nitrogen-containing synthetic materials can generate hydrogen cyanide. A fire victim may therefore have simultaneous:

thermal injury + airway injury + carbon monoxide poisoning + cyanide poisoning

Cyanide should be particularly suspected after an enclosed-space fire when the patient has altered consciousness, seizures, cardiovascular instability, severe metabolic/lactic acidosis, or cardiac arrest.

Not every smoke-inhalation victim has clinically significant cyanide poisoning, however. Empiric hydroxocobalamin use in smoke inhalation remains an area of imperfect evidence; recent systematic reviews emphasize that outcome data are largely observational and that indiscriminate administration to every smoke-exposed patient is not supported.

Cyanogenic Plants and Foods

Cyanogenic glycosides can release cyanide after enzymatic hydrolysis. Important sources include bitter cassava, apricot kernels, bitter almonds, peach and cherry pits, and certain other seeds and plants.

Proper processing of cassava substantially reduces cyanogenic compounds. Poisoning is more likely after consumption of inadequately processed bitter cassava or concentrated cyanogenic products than after ordinary consumption of fruit flesh.

Amygdalin/laetrile is particularly important because it can release cyanide and has caused serious poisoning.

Nitroprusside

Sodium nitroprusside metabolism releases cyanide. Toxicity becomes more likely with high-dose or prolonged infusions, particularly when detoxification pathways are overwhelmed.

Cyanide generated from nitroprusside is normally converted to thiocyanate, which is predominantly eliminated by the kidneys. Prolonged exposure may therefore also produce thiocyanate accumulation, especially in renal dysfunction.

Toxic Dose

There is no single clinically reliable toxic dose because toxicity depends on the cyanide compound, route, concentration, duration, gastrointestinal conditions, and speed of treatment.

Hydrogen cyanide inhalation can cause extremely rapid poisoning because pulmonary absorption is nearly immediate. The historical statement that approximately 90 ppm for 30 minutes may be lethal should not be treated as a clinical threshold.

NIOSH lists hydrogen cyanide as having a REL of 4.7 ppm (5 mg/m³) as a short-term exposure limit with skin notation; the current OSHA PEL listed by NIOSH is 10 ppm (11 mg/m³) as an 8-hour TWA with skin notation. NIOSH historically designated 50 ppm as immediately dangerous to life or health.

Reported lethal oral doses of cyanide salts vary widely, and a quoted value such as “200 mg” should therefore not be used as a reliable bedside cutoff.

Pathophysiology

Cyanide has a high affinity for the ferric iron within cytochrome c oxidase (Complex IV) of the mitochondrial electron transport chain.

Normally:

O₂ → final electron acceptor → oxidative phosphorylation → ATP

With cyanide:

Cytochrome oxidase inhibited → O₂ cannot be effectively utilized → oxidative phosphorylation stops → ATP depletion → anaerobic glycolysis → lactate accumulation

This produces histotoxic hypoxia: oxygen may reach the tissues, but cells cannot use it normally.

The brain and heart are particularly vulnerable because of their high metabolic requirements.

Venous Hyperoxia

Because tissues cannot adequately extract oxygen, venous blood may remain unusually oxygenated. This explains the classic description of unusually bright venous blood or reduced arterial–venous oxygen difference.

However, this finding is neither sufficiently sensitive nor specific to diagnose cyanide poisoning and should not delay treatment.

Clinical Features

Cyanide poisoning is primarily a neurologic, cardiovascular, and metabolic catastrophe.

Early manifestations may include headache, dizziness, anxiety, agitation, confusion, nausea, vomiting, dyspnea, tachypnea, tachycardia, and hypertension.

As toxicity progresses:

agitation/confusion → seizures → coma → hypotension → bradycardia → apnea → cardiovascular collapse

Large inhalational exposures can produce this sequence within minutes. CDC describes rapid development of respiratory abnormalities, altered mental status, seizures, loss of consciousness, blood-pressure abnormalities, coma, and death after substantial exposure.

Cardiovascular Toxicity

Early sympathetic activation can produce tachycardia and hypertension.

Severe cellular hypoxia then produces myocardial dysfunction, dysrhythmias, hypotension, bradycardia, and ultimately cardiovascular collapse.

Profound hypotension after a credible cyanide exposure is therefore a major indication for immediate antidotal therapy.

Neurologic Toxicity

Early neurologic manifestations include headache, dizziness, restlessness, anxiety, and confusion.

Severe poisoning causes altered consciousness, generalized seizures, coma, and respiratory arrest.

Patients who survive profound poisoning may develop hypoxic-ischemic brain injury or delayed neurologic syndromes including movement disorders and parkinsonian features.

Respiratory Findings

Tachypnea is common initially because of metabolic acidosis and CNS stimulation.

Severe poisoning may progress to central respiratory depression, apnea, and respiratory arrest.

Smoke inhalation may simultaneously produce upper-airway thermal injury, bronchospasm, chemical pneumonitis, and pulmonary edema, so respiratory failure in a fire victim is frequently multifactorial.

Gastrointestinal Findings

Ingested cyanide salts commonly produce nausea, vomiting, abdominal pain, and rapidly developing systemic toxicity.

Onset may be slower than with inhaled hydrogen cyanide, but substantial salt ingestion remains a medical emergency.

Certain cyanogenic glycosides and nitriles can produce more delayed toxicity because cyanide must first be liberated metabolically.

Skin Exposure

Hydrogen cyanide and some cyanide compounds can be absorbed through skin, particularly when liquid contamination is present.

Contaminated clothing should therefore be removed promptly and exposed skin irrigated thoroughly.

Some cyanide salts can additionally cause local irritation or chemical injury.

“Bitter Almond” Odor

The classic bitter-almond odor associated with cyanide is unreliable.

Many people cannot genetically perceive the odor, concentrations may be insufficient to smell, and deliberately smelling a suspected cyanide source is dangerous.

Therefore:

Absence of a bitter-almond odor does not exclude cyanide poisoning.

Cyanosis

Cyanosis is not a reliable early finding. Because the primary problem is failure of cellular oxygen utilization rather than failure of oxygen delivery, severe poisoning may occur without prominent cyanosis.

Diagnosis

Cyanide poisoning is primarily a clinical diagnosis.

The combination of:

credible exposure + neurologic deterioration + cardiovascular instability + severe unexplained lactic acidosis

should trigger immediate consideration of cyanide.

Treatment should never be delayed while waiting for confirmatory testing when severe poisoning is clinically suspected. Both hydroxocobalamin and nitrite/thiosulfate labeling emphasize prompt antidotal treatment when suspicion is high.

Serum Lactate

Lactate is one of the most useful rapidly available laboratory clues.

Cyanide-induced inhibition of oxidative phosphorylation causes dramatic anaerobic lactate production. A markedly elevated lactate following an appropriate exposure strongly supports the diagnosis.

In smoke-inhalation literature, an arterial lactate >8 mmol/L increases concern for cyanide exposure, while approximately ≥10 mmol/L has historically been used as a stronger indicator of significant cyanide toxicity.

These are decision-support thresholds, not absolute diagnostic cutoffs. Lactate can also rise from burns, seizures, shock, carbon monoxide poisoning, catecholamines, trauma, or cardiac arrest.

Thus:

High lactate + compatible exposure + neurologic/cardiovascular collapse is much more important than lactate alone.

Acid–Base Findings

Severe poisoning typically causes a high-anion-gap metabolic acidosis with elevated lactate.

Obtain blood gas, electrolytes, bicarbonate, lactate, glucose, and renal function in significantly symptomatic patients.

Profound acidosis supports severe cellular poisoning but is not specific for cyanide.

Cyanide Concentrations

Whole-blood cyanide concentrations can confirm exposure but are usually not useful for acute treatment decisions because results are often unavailable quickly enough.

Cyanide is also unstable in biologic specimens, making proper collection and handling important. Published reviews note that cyanide measurements may require hours while critically poisoned patients can die within minutes.

Therefore:

Never wait for a cyanide concentration before treating a critically ill patient.

The old tables correlating individual cyanide concentrations with tachycardia, obtundation, coma, or death are too rigid for modern bedside use.

Additional Investigations

Obtain continuous ECG monitoring in significant poisoning. Troponin may be useful when myocardial injury is suspected.

In smoke-inhalation patients, measure carboxyhemoglobin by co-oximetry because concomitant carbon monoxide poisoning is common.

Other testing should be guided by the circumstances and may include CBC, renal and liver function, CK, toxicology testing, chest imaging, and evaluation for trauma or burns.

An intentional ingestion should prompt testing for relevant occult coingestants such as acetaminophen according to standard overdose practice.

Differential Diagnosis

The most important toxicologic mimics include carbon monoxide, hydrogen sulfide, methemoglobinemia, sodium azide, toxic alcohols, salicylates, iron, isoniazid, and other cellular or chemical asphyxiants.

Nontoxicologic causes include sepsis, cardiogenic shock, status epilepticus, severe hypoxemia, diabetic or alcoholic ketoacidosis, mesenteric ischemia, and other causes of profound lactic acidosis.

In an enclosed-space fire, cyanide and carbon monoxide should not be considered mutually exclusive:

CO poisoning + cyanide poisoning can coexist.

Immediate Treatment

Management begins simultaneously with diagnosis.

Remove the patient from exposure while protecting rescuers. Give 100% oxygen immediately, establish airway and ventilatory support as required, obtain IV/IO access, treat seizures, support circulation, correct life-threatening metabolic disturbances, and administer an antidote promptly when severe cyanide poisoning is suspected.

FDA labeling specifically emphasizes that antidote administration must occur together with airway, ventilation, circulatory support, oxygen, and seizure management.

Oxygen

Give 100% oxygen, even if pulse oximetry appears normal.

Cyanide prevents normal oxygen utilization rather than necessarily lowering arterial oxygen content. Supplemental oxygen therefore does not correct the fundamental biochemical lesion, but it maximizes available oxygen and is particularly important because pulmonary injury and carbon monoxide poisoning may coexist.

Pulse oximetry cannot rule out either cyanide or carbon monoxide poisoning.

Airway and Ventilation

Early intubation is appropriate for progressive coma, recurrent seizures, inadequate ventilation, severe hypoxemia, respiratory failure, or anticipated airway edema after smoke inhalation.

Mechanical ventilation should use a high inspired oxygen concentration initially.

Seizures

Treat seizures promptly with benzodiazepines.

Persistent seizures can dramatically increase lactate production and oxygen demand and should be treated aggressively using standard status-epilepticus escalation if necessary.

Hypotension and Shock

Give appropriate isotonic crystalloid while avoiding unnecessary volume overload.

Persistent shock should be treated with a titratable vasopressor. Norepinephrine is generally the preferred first-line vasopressor for undifferentiated distributive or vasoplegic shock rather than the historical dopamine-first strategy.

Severe cyanide-induced shock may improve rapidly after effective antidotal therapy.

The Trendelenburg position is obsolete as a treatment for shock.

Antidote – Hydroxocobalamin

Hydroxocobalamin is the preferred modern antidote for most suspected severe cyanide poisoning.

Hydroxocobalamin binds cyanide to form cyanocobalamin, which is substantially less toxic and eliminated in the urine.

Its major advantage is that it does not intentionally induce methemoglobinemia, making it especially attractive when carbon monoxide poisoning or smoke-induced hypoxemia may coexist.

CYANOKIT is FDA-approved for known or suspected cyanide poisoning.

Hydroxocobalamin Dose

For adults:

Hydroxocobalamin 5 g IV over 15 minutes

If severe toxicity persists or recurs, a second 5-g IV dose may be given, for a maximum total dose of 10 g according to current U.S. labeling. The second dose may be infused over approximately 15 minutes to 2 hours depending on clinical severity.

Pediatric hydroxocobalamin dosing is generally 70 mg/kg IV, maximum 5 g for the initial dose, with repeat dosing considered in severe poisoning according to toxicology protocols and specialist guidance.

Antidotal treatment should not be delayed for laboratory confirmation.

Hydroxocobalamin Adverse Effects

Hydroxocobalamin commonly causes dramatic but usually benign red discoloration of the skin and urine (chromaturia).

Other effects include transient hypertension, nausea, headache, rash, infusion reactions, and occasional hypersensitivity.

Current labeling also warns of acute kidney injury and urinary calcium oxalate crystals, and recommends renal-function monitoring after treatment.

Recent observational literature has raised concern about an association between hydroxocobalamin and AKI in smoke-inhalation patients, although causality is difficult to establish because these patients are often critically ill.

Laboratory Interference After Hydroxocobalamin

The intense red coloration of hydroxocobalamin can interfere with colorimetric laboratory assays and some bedside or dialysis equipment.

The laboratory should therefore be informed immediately that hydroxocobalamin has been administered.

This interference can affect interpretation of several chemistry, hematology, and co-oximetry measurements depending on the analyzer.

Hemodialysis After Hydroxocobalamin

The red pigment can trigger false blood-leak alarms on some hemodialysis machines, potentially complicating renal replacement therapy.

This is clinically important in severely ill fire victims who develop AKI.

Sodium Nitrite and Sodium Thiosulfate

The traditional cyanide antidote kit used:

Sodium nitrite → methemoglobin formation → cyanide binding

followed by:

Sodium thiosulfate → sulfur donor → conversion of cyanide to thiocyanate

The combination remains FDA-approved as NITHIODOTE for serious or life-threatening acute cyanide poisoning.

However, it is no longer the preferred empiric strategy for many smoke-inhalation patients when hydroxocobalamin is available.

Why Sodium Nitrite Can Be Dangerous

Sodium nitrite deliberately oxidizes hemoglobin to methemoglobin, which binds cyanide.

The problem is that methemoglobin cannot carry oxygen normally.

In an enclosed-space fire victim who may already have:

carbon monoxide → reduced functional hemoglobin

plus

smoke/airway injury → impaired oxygenation

creating additional methemoglobinemia can further compromise oxygen delivery.

Sodium nitrite can also cause hypotension, which is particularly undesirable in cyanide-induced cardiovascular collapse. Current NITHIODOTE labeling specifically warns about hypotension and methemoglobin formation.

Therefore:

Avoid routine nitrite administration in smoke-inhalation patients when significant CO poisoning or impaired oxygen delivery is possible and hydroxocobalamin is available.

NITHIODOTE Dosing

If the nitrite/thiosulfate regimen is selected for serious confirmed or strongly suspected cyanide poisoning, current U.S. labeling recommends in adults:

Sodium nitrite 300 mg IV — supplied as 10 mL — administered slowly, followed immediately by sodium thiosulfate 12.5 g IV — supplied as 50 mL.

For children, sodium nitrite is 6 mg/kg IV, maximum 300 mg, followed by sodium thiosulfate 250 mg/kg IV, maximum 12.5 g. If toxicity recurs, one-half of the original doses may be repeated.

Blood pressure must be monitored during nitrite administration.

Hydroxocobalamin Plus Thiosulfate

Sodium thiosulfate has historically been used as an adjunct because it enhances conversion of cyanide to thiocyanate.

However, modern management usually prioritizes hydroxocobalamin when rapid empiric therapy is needed.

If hydroxocobalamin and nitrite/thiosulfate products are used in the same patient, compatibility matters: current product labeling states that NITHIODOTE components are chemically incompatible with hydroxocobalamin and should not be administered through the same IV line.

Decontamination – Inhalation

Rescuers must not enter a contaminated atmosphere without appropriate respiratory protection.

Remove the patient to fresh air and administer 100% oxygen.

A patient exposed only to cyanide gas who has no liquid or particulate contamination generally does not require extensive skin decontamination once removed from the source.

Decontamination – Dermal Exposure

Remove contaminated clothing and jewelry promptly.

Wash contaminated skin thoroughly with water and soap as appropriate while preventing secondary contamination of staff.

Liquid hydrogen cyanide and soluble cyanide compounds can be absorbed through skin, making rapid removal important.

Decontamination – Ingestion

Do not induce vomiting.

Ipecac is obsolete.

Routine gastric lavage is also not recommended because of aspiration risk, rapid cyanide absorption, and potential danger to staff from released hydrogen cyanide.

Activated charcoal may be considered after a very recent significant oral exposure when the airway is intact or protected, but it must never delay airway stabilization or antidote administration.

Because severe cyanide poisoning can progress extremely rapidly, antidote and resuscitation take priority over gastrointestinal decontamination.

Sodium Bicarbonate

Metabolic acidosis usually improves when cyanide toxicity, shock, seizures, and hypoxia are corrected.

Sodium bicarbonate is not an antidote to cyanide.

It may be used selectively for severe life-threatening acidemia according to ordinary critical-care principles, but routine administration based solely on cyanide exposure is not indicated.

Hyperbaric Oxygen

Hyperbaric oxygen is not a standard antidotal treatment for isolated cyanide poisoning.

The historical suggestion that HBO prevents delayed neurologic injury from cyanide is not supported sufficiently to justify routine use.

In smoke-inhalation patients, hyperbaric oxygen may be considered independently for significant carbon monoxide poisoning according to CO-specific indications, but transport to an HBO facility must never delay hydroxocobalamin, airway management, seizure control, or hemodynamic resuscitation.

Extracorporeal Elimination

Hemodialysis is not routinely used to remove cyanide itself because poisoning evolves too rapidly and effective antidotes are available.

Renal replacement therapy may nevertheless be required for conventional indications such as severe AKI, refractory electrolyte disturbance, or acid-base abnormalities.

Thiocyanate generated during cyanide detoxification is renally eliminated and can accumulate in renal failure, particularly during prolonged sodium nitroprusside exposure.

Smoke-Inhalation Decision Making

In an enclosed-space fire victim, empiric hydroxocobalamin is most compelling when there is a combination such as:

altered consciousness or coma + severe lactic acidosis + hypotension/cardiovascular collapse ± seizures/cardiac arrest

Soot around the mouth or nose, carbonaceous sputum, burns, and enclosed-space exposure strengthen the history but do not by themselves prove cyanide poisoning.

An unexplained lactate around 8–10 mmol/L or higher substantially increases suspicion in the correct clinical context.

Because recent evidence remains observational and heterogeneous, hydroxocobalamin should not be viewed as mandatory for every patient who merely inhaled smoke.

Cardiac Arrest

Cyanide should be considered in otherwise unexplained cardiovascular collapse or cardiac arrest immediately following a credible high-concentration exposure or enclosed-space fire.

Standard high-quality resuscitation should continue while 100% oxygen and hydroxocobalamin are administered when severe cyanide poisoning is suspected.

Successful resuscitation is possible even after profound poisoning when antidotal therapy and cardiovascular support are delivered rapidly.

Pregnancy

Pregnancy should not delay life-saving antidotal treatment.

Severe maternal cyanide poisoning threatens both mother and fetus through profound cellular hypoxia. Maternal stabilization and rapid antidotal treatment therefore take priority.

Specialist toxicology and obstetric involvement is appropriate after stabilization.

Monitoring

Severely poisoned patients require continuous ECG, blood pressure, oxygenation, respiratory, temperature, and neurologic monitoring.

Serial lactate, blood gas/pH, electrolytes, glucose, renal function, and markers of end-organ injury help determine response to treatment.

After hydroxocobalamin, monitor renal function and recognize that several laboratory measurements may be analytically distorted by the drug’s intense red pigmentation. Current labeling recommends monitoring renal function for 7 days following treatment.

Admission and Disposition

Any patient with significant neurologic symptoms, severe lactic acidosis, cardiovascular instability, respiratory compromise, substantial intentional ingestion, or requirement for antidotal treatment should be admitted, usually to an ICU.

Minor exposures with no symptoms and reassuring serial assessment may eventually be discharged after an exposure-specific observation period. A rigid historical 8-hour observation rule should not be applied to every cyanide exposure.

Delayed toxicity is more relevant after cyanogenic glycosides, certain nitriles, or potentially ongoing gastrointestinal absorption than after a brief low-level HCN inhalation.

Intentional exposure requires appropriate psychiatric assessment after medical stabilization.

Prognosis

Outcome is strongly dependent on dose, route, duration of exposure, and speed of resuscitation and antidotal therapy.

Massive HCN inhalation may cause death within minutes.

Patients who regain cardiovascular and neurologic function rapidly may recover completely. Patients who experience prolonged coma, seizures, severe hypotension, or cardiac arrest are at risk for hypoxic-ischemic brain injury.

Delayed neurologic sequelae have been described after severe poisoning, including cognitive impairment, movement disorders, and parkinsonism.

Important Pitfalls

The first major pitfall is waiting for a cyanide concentration. Cyanide poisoning is treated clinically; laboratory confirmation is generally too slow to guide emergency antidotal therapy.

The second is assuming normal pulse oximetry excludes poisoning. Cyanide is a cellular oxygen-utilization poison, so SpO₂ may appear reassuring despite profound mitochondrial hypoxia.

The third is relying on the smell of bitter almonds. Odor perception is unreliable and should never determine diagnosis.

The fourth is overlooking cyanide in an enclosed-space fire victim with coma, hypotension, seizures, or marked lactic acidosis.

The fifth is treating every smoke-inhalation patient automatically with hydroxocobalamin. Empiric treatment is most defensible when clinical findings suggest significant cyanide toxicity; recent evidence for indiscriminate use remains uncertain.

The sixth is using sodium nitrite indiscriminately in a smoke-inhalation victim. Nitrite-induced methemoglobinemia can further compromise oxygen delivery when carbon monoxide poisoning and pulmonary injury already coexist.

The seventh is allowing decontamination, imaging, laboratory testing, or hyperbaric transfer to delay antidotal therapy in a critically ill patient.

Finally, after hydroxocobalamin, remember the striking red skin and urine discoloration, laboratory interference, possible AKI, and interference with some hemodialysis blood-leak detectors.

High-Yield Toxicology Pearls

Cyanide = histotoxic hypoxia.

The core mechanism is:

Cyanide → cytochrome c oxidase inhibition → oxidative phosphorylation failure → ATP depletion → anaerobic metabolism → severe lactic acidosis

The classic severe syndrome is:

Rapid altered mental status/seizures + profound lactic acidosis + hypotension/cardiovascular collapse

Think particularly about cyanide after an enclosed-space structural fire, industrial exposure, cyanide-salt ingestion, cyanogenic plant ingestion, or problematic nitroprusside exposure.

A markedly elevated lactate—particularly around 8–10 mmol/L or greater in a compatible smoke-inhalation presentation—strongly increases suspicion but is not diagnostic by itself.

Blood cyanide levels can confirm exposure but are usually too slow to guide emergency treatment.

Give 100% oxygen even when SpO₂ is normal.

For severe known or suspected poisoning:

Hydroxocobalamin 5 g IV over 15 minutes

A second 5 g may be administered if severe toxicity persists or recurs, for an adult total of 10 g.

Hydroxocobalamin is particularly advantageous in smoke inhalation because it does not induce methemoglobinemia.

Expect red skin and urine, laboratory interference, transient hypertension, and possible renal injury after hydroxocobalamin.

The traditional sodium nitrite + sodium thiosulfate antidote regimen remains FDA-approved, but nitrite produces methemoglobinemia and hypotension and is therefore problematic when carbon monoxide poisoning or impaired oxygen delivery coexists.

Do not induce vomiting. Routine gastric lavage is obsolete. Activated charcoal has only a selective role after very recent oral exposure and must never delay resuscitation or antidote.

Hyperbaric oxygen is not routine treatment for isolated cyanide poisoning; in a fire victim it may be considered separately for significant concomitant carbon monoxide poisoning.

Most importantly:

If severe cyanide poisoning is clinically likely, treat first—the patient can die long before the cyanide level returns.

Toxicology – Cone Snail Envenomation

Core Concept

Cone snails are venomous marine gastropods whose sting can produce a rapidly progressive neuroparalytic syndrome. Most human stings cause only local symptoms, but envenomation by large fish-hunting species—particularly Conus geographus, the geography cone—can progress from localized numbness to cranial neuropathies, generalized flaccid paralysis, respiratory failure, cardiac arrest, and death.

A useful toxicologic sequence is:

Cone-snail sting → conopeptide neurotoxins → ion-channel/receptor blockade → neuromuscular paralysis → respiratory failure

The most important modern treatment is not hot-water immersion. It is:

Pressure immobilization + complete physical rest + early respiratory monitoring/support

There is no antivenom. Survival from severe envenomation depends primarily on maintaining ventilation until the venom effects wear off. Current Australian emergency guidance treats cone-shell envenomation as potentially fatal and specifically recommends pressure immobilization, splinting, close neurologic and respiratory observation, and assisted ventilation when necessary.

Species and Distribution

The old estimate of 300–500 species is outdated. More than 900 cone-snail species are now recognized, occurring predominantly in tropical and subtropical marine environments. They are especially diverse in the Indo-Pacific and commonly inhabit coral reefs, rocky areas, sand, and shallow coastal habitats.

Cone snails are predatory. Different species specialize in eating marine worms, other mollusks, or fish. The fish-hunting species are generally the most dangerous to humans because their venoms evolved to rapidly immobilize vertebrate prey.

Conus geographus – The Most Dangerous Species

The geography cone, Conus geographus, is overwhelmingly the species of greatest human toxicologic importance. A comprehensive review of documented cases through 2017 identified 141 reported human envenomations with 36 deaths. Approximately 57% of all known stings were attributed to C. geographus, and the authors concluded that most or possibly all reliably documented human fatalities were caused by this species.

The historical statement that Conus tulipa has “the most toxic venom” should not be used clinically. Venom potency varies substantially according to species, toxin composition, prey type, defensive versus predatory venom, and the amount injected. In real-world human envenomation, C. geographus has by far the strongest association with fatality.

How the Sting Occurs

Cone snails possess specialized hollow radular teeth that function like miniature disposable harpoons. A tooth is connected through the proboscis to the venom apparatus, allowing the snail to inject a complex venom mixture into prey—or into a person’s hand when the animal is handled.

Human stings most often occur when someone picks up a live cone shell while:

• Collecting shells
• Walking or diving on reefs
• Handling snails in aquaria
• Fishing or beachcombing

The shell itself may appear empty while the living snail remains retracted deeply within it. A person should therefore never assume that an attractive cone shell is safe to handle.

Predatory and Defensive Venom

Modern research has shown that cone snails can deploy different venom mixtures for prey capture and defense. Defensive venom, which is particularly relevant to human stings, may contain paralytic toxins different from those preferentially released while hunting prey.

This helps explain why simple descriptions of “the conotoxin” are misleading. Cone-snail venom is not a single toxin but an extremely complex mixture of biologically active peptides, with individual species producing hundreds to potentially thousands of different components.

Conotoxins

Cone-snail venom contains numerous conopeptides, many of which act with extraordinary selectivity on ion channels and neurotransmitter receptors.

Important toxin families include α-conotoxins, which inhibit nicotinic acetylcholine receptors; ω-conotoxins, which inhibit voltage-gated calcium channels; μ-conotoxins, which block voltage-gated sodium channels in skeletal muscle; and κ-conotoxins, which affect potassium channels.

The combined effect is disruption of neural and neuromuscular transmission, resulting in sensory abnormalities, cranial nerve dysfunction, weakness, and potentially complete flaccid paralysis.

The older description of one specific “virgotoxin” as a major clinically important cardiotoxic protein is not central to contemporary understanding of human cone-snail envenomation. Modern toxicology emphasizes the combined neurophysiologic actions of numerous conopeptides, rather than attributing the syndrome to a single cardiac toxin.

α-Conotoxins

α-Conotoxins act principally on nicotinic acetylcholine receptors at neuromuscular junctions and neuronal synapses. By interfering with acetylcholine-mediated transmission, they can contribute to progressive weakness and paralysis.

The clinical effect resembles a pharmacologic neuromuscular block:

Motor nerve signal → blocked nicotinic transmission → muscle weakness/paralysis

Respiratory muscles can be affected, making ventilatory failure the principal life-threatening complication.

ω-Conotoxins

ω-Conotoxins inhibit selected voltage-gated calcium channels, reducing neurotransmitter release from nerve terminals.

One synthetic conopeptide derived from Conus magus, ziconotide, is used medically as an intrathecal analgesic. This illustrates the highly specific pharmacologic actions of cone-snail toxins, although ziconotide therapy is separate from management of natural envenomation.

μ-Conotoxins

μ-Conotoxins inhibit voltage-gated sodium channels in skeletal muscle and thereby impair muscle action-potential propagation. This contributes to rapid paralysis in vertebrate prey and potentially to generalized weakness after severe human envenomation.

Toxic Dose

There is no measurable human “toxic dose” after a natural sting. Severity depends on the species, size of the snail, amount of venom injected, sting location, victim size, and possibly whether the snail delivered a predatory or defensive venom mixture.

A single sting from a large C. geographus can be fatal. Fatal cases have historically occurred after one sting, emphasizing that the absence of multiple punctures does not imply a low-risk exposure.

Clinical Onset

Symptoms usually begin rapidly after clinically important envenomation. Local pain or numbness may be immediate, while systemic neurologic symptoms can evolve over minutes to several hours.

Severe envenomation may progress to respiratory or cardiac arrest within approximately 40 minutes to several hours. Current Queensland emergency guidance describes severe paralysis and arrest within this early period.

Therefore:

Do not wait for respiratory distress before treating a potentially serious cone-snail sting as dangerous.

Local Effects

The sting may initially cause sharp pain, burning, tingling, numbness, swelling, or localized weakness. Surprisingly, some stings may be only mildly painful, particularly relative to the severity of later paralysis.

Localized numbness can spread proximally from the sting site. Older reports also describe local pallor, discoloration, or cyanosis, but ischemic skin injury is not the defining toxic effect.

A puncture wound may be extremely small and difficult to identify.

Early Neurologic Symptoms

The hallmark of systemic envenomation is progressive neurologic dysfunction. Early manifestations can include perioral tingling, numbness of the lips and tongue, spreading paresthesias, weakness, dizziness, blurred or double vision, ptosis, speech difficulty, and dysphagia.

Perioral symptoms are especially important because they may herald evolving cranial and bulbar dysfunction.

Progressive Paralysis

Severe envenomation can progress to muscle incoordination, generalized weakness, flaccid paralysis, loss of effective swallowing, and respiratory-muscle paralysis.

An extremely important clinical feature is that the patient may remain:

Conscious and aware despite profound paralysis

Current Queensland guidance specifically warns clinicians to reassure patients because a severely paralyzed victim may remain fully aware.

A motionless patient should therefore not automatically be assumed unconscious.

Respiratory Failure

The older statement that respiratory paralysis had not been reported in humans is incorrect.

Respiratory paralysis is the major life-threatening manifestation of severe human cone-snail envenomation.

Current Australian clinical guidance explicitly recognizes progressive swallowing and breathing difficulty followed by respiratory paralysis, and reviews of human envenomation document paralysis progressing to respiratory or cardiac arrest.

Because the respiratory muscles may progressively fail while consciousness is preserved, respiratory rate alone can be misleading. Serial assessment of:

• Work of breathing
• Tidal volume
• Speech
• Swallowing
• Oxygenation
• Ventilation
• Respiratory muscle strength

is essential.

Cardiovascular Effects

Cardiovascular abnormalities are less consistent than neurologic paralysis but may include tachycardia, bradycardia, hypotension, rhythm disturbance, or cardiovascular arrest in catastrophic envenomation.

Some observed tachycardia may reflect anxiety and stress rather than direct cardiotoxicity. The principal mechanism of death remains paralysis with respiratory failure, although severe hypoxia can ultimately produce cardiac arrest.

Diagnosis

Diagnosis is primarily clinical and rests on a compatible marine exposure together with rapidly developing local neurologic symptoms or paralysis.

A particularly suggestive history is:

Handling a cone-shaped marine shell → puncture/sting → local numbness → spreading paresthesias/cranial symptoms → weakness

Whenever possible, identification of the shell can help assess risk. However, treatment must not be delayed while attempting to identify the exact species.

Do not handle or bring a live snail into the treatment area.

Differential Diagnosis

The differential includes blue-ringed octopus envenomation, sea-snake envenomation, tetrodotoxin poisoning, paralytic shellfish poisoning, botulism, acute stroke, Guillain-Barré syndrome, myasthenic crisis, and other causes of rapidly evolving neuromuscular paralysis.

Blue-ringed octopus toxicity is particularly similar because it also produces rapid flaccid paralysis with potentially preserved consciousness and minimal local injury.

A history of handling a cone shell is therefore extremely valuable.

Laboratory Testing

There is no clinically available conotoxin blood test. Laboratory testing should be guided by severity rather than ordered routinely after every minor sting.

In symptomatic systemic envenomation, useful assessments may include:

• Glucose
• Electrolytes
• Renal function
• Blood gas if ventilation is impaired
• Lactate in severe illness

These tests assess physiologic consequences rather than quantify venom.

Respiratory Monitoring

Pulse oximetry should be used in symptomatic patients, but a normal oxygen saturation does not prove that ventilation is adequate, particularly if supplemental oxygen is being administered.

Capnography or blood-gas assessment can help identify evolving hypoventilation and hypercapnia.

Serial respiratory muscle assessment is particularly important when dysphagia, dysarthria, ptosis, or generalized weakness develops.

ECG and Cardiac Monitoring

Patients with systemic envenomation should receive continuous cardiac monitoring. An ECG is appropriate when there is significant weakness, hypoxia, hypotension, palpitations, or other systemic toxicity.

Cardiac monitoring should not distract from the primary danger, which is progressive neuromuscular respiratory failure.

Immediate First Aid

The historical chapter recommended treating the sting like a snakebite but also emphasized hot-water immersion. Modern first aid is clearer.

For a suspected cone-snail sting:

Keep the patient still, call emergency medical services, and apply pressure immobilization to the affected limb.

Pressure immobilization is recommended by current Australian national/state guidance for cone-shell stings because limiting lymphatic movement can slow systemic venom spread.

A broad pressure bandage should cover the sting area and the involved limb, and the limb should be immobilized with a splint. The patient should remain as motionless as possible.

Pressure Immobilization

The purpose of pressure immobilization is not to stop arterial flow. Instead it reduces lymphatic transport of venom.

The bandage should therefore be firm but not a tourniquet. The limb should be splinted, and walking or unnecessary movement should be avoided.

If an effective pressure-immobilization bandage has already been applied:

Do not repeatedly remove it for inspection during transport.

Current Queensland protocols specifically advise leaving it in place while the patient remains immobilized and is transferred for definitive care.

Hot-Water Immersion – Important Modern Correction

The older text states that the wound should be immersed in water around 105°F to “inactivate” the toxin.

This is not current first-line treatment for cone-snail envenomation.

Modern Australian first-aid recommendations use pressure immobilization, not hot-water immersion, for cone shells. Hot water is recommended for painful envenomations from animals such as stonefish and some other marine creatures, but cone-shell stings are treated differently because the major danger is systemic neurotoxin spread.

There is no good clinical evidence that hot water reliably denatures injected conotoxins in human tissue or prevents systemic paralysis.

Therefore:

Do not delay pressure immobilization, emergency transport, or respiratory support in order to perform hot-water immersion.

Do Not Use a Tourniquet

A tourniquet should not be applied. Complete arterial occlusion creates ischemic injury and is not the goal of venom first aid.

Likewise:

• Do not cut the wound
• Do not suck out venom
• Do not apply caustic chemicals
• Do not attempt to capture the live snail

Airway and Ventilation

The definitive lifesaving treatment for severe cone-snail envenomation is:

Effective ventilation until paralysis resolves.

If respiratory muscle weakness progresses, provide bag-mask ventilation immediately when needed and prepare for early endotracheal intubation.

Intubation should be strongly considered with:

• Progressive respiratory weakness
• Bulbar dysfunction
• Dysphagia
• Inability to handle secretions
• Declining tidal volume
• Hypercapnia
• Respiratory arrest

Current Queensland guidance emphasizes that bag-valve-mask ventilation can be lifesaving and that intubation may be required before transfer in patients developing respiratory failure.

Prolonged Ventilation

If the circulation is maintained, even profound neuroparalysis can be survivable because venom effects eventually wear off.

Current Queensland emergency protocols caution that severe paralytic marine envenomation may require prolonged mechanical ventilation, potentially for days, until neuromuscular function returns.

This makes early recognition and high-quality supportive care extraordinarily important.

Analgesia

Local pain should be treated according to severity. Many victims require only simple analgesia, while some may need stronger medication.

Opioids can be used when clinically necessary, but in a patient with evolving neuromuscular respiratory weakness they must be titrated carefully because additional respiratory depression can complicate assessment.

Pain control is secondary to airway and respiratory monitoring.

Wound Care

After the immediate envenomation risk has been managed, the puncture wound should be assessed for:

• Retained foreign material
• Local infection
• Tissue injury

Standard wound hygiene is appropriate.

Tetanus immunization should be updated according to routine wound-management guidelines.

Routine prophylactic antibiotics are not required for every uncomplicated cone-snail sting unless there is:

• Significant contamination
• Established infection
• Another specific indication

Antidote

There is no cone-snail antivenom or clinically available specific antidote.

Modern reviews and current emergency guidance continue to emphasize supportive treatment.

Because the toxins impair neurotransmission rather than causing irreversible destruction in most survivors, patients can recover fully if oxygenation and ventilation are maintained during the paralytic period.

Role of Anticholinesterases

Because some α-conotoxins interfere with nicotinic acetylcholine receptors, anticholinesterase therapy has occasionally been proposed theoretically. However, there is no established evidence supporting routine use of neostigmine, pyridostigmine, or related agents for cone-snail envenomation.

They should not be considered substitutes for respiratory support.

Enhanced Elimination

There is no established role for:

• Hemodialysis
• Hemoperfusion
• Plasma exchange
• Forced diuresis

in removing injected conopeptides after cone-snail envenomation.

Treatment remains supportive.

Observation

There is no rigorously validated universal observation period because severe envenomation is rare. Historically, systemic symptoms tend to evolve during the first several hours.

A patient with a credible sting from a potentially dangerous cone snail should therefore undergo observation with serial neurologic and respiratory examinations even if initially well.

The old 4–6 hour observation concept may be reasonable as a minimum for a clearly asymptomatic minor exposure, but it should not function as an automatic discharge rule when:

• Species is high risk or unknown
• The snail was large
• Neurologic symptoms occurred
• The patient has respiratory complaints
• Access to emergency care is limited

Admission

Hospital admission is appropriate for any patient with systemic neurologic symptoms, including spreading numbness, ptosis, visual disturbance, dysarthria, dysphagia, generalized weakness, or respiratory symptoms.

Patients with progressive weakness or respiratory impairment require high-acuity monitoring, usually in an ICU or equivalent setting.

Current Queensland guidance recommends urgent consultation and retrieval for suspected clinically important cone-shell envenomation with ongoing neurologic and respiratory monitoring.

Discharge

A patient may be considered for discharge only when:

• No systemic neurologic features have developed during an adequate period of observation
• Respiratory function is normal
• Local symptoms are mild or improving
• The patient can ambulate safely
• Reliable return precautions and access to care are available

A patient who developed systemic paralysis should remain hospitalized until neuromuscular and respiratory function have clearly recovered.

Prognosis

Most reported cone-snail stings are nonfatal, particularly those caused by worm- or mollusk-eating species. However, C. geographus can cause rapidly fatal paralysis, and historical case compilations contain more than 30 deaths.

Modern emergency care substantially improves survival because even profound paralysis can be supported with mechanical ventilation until venom effects resolve.

Local numbness or discomfort may persist longer than the systemic illness, while severe survivors can require prolonged recovery of strength.

Prevention

The most effective preventive advice is:

Never handle a live cone snail with bare hands.

Colorful or patterned cone shells should be treated as potentially venomous, particularly in tropical Indo-Pacific waters. Gloves do not guarantee protection because the harpoon-like radular tooth may penetrate some materials.

Do not place a live cone shell in:

• A pocket
• Clothing
• A bag held against the body

and do not handle one simply because the animal appears withdrawn into its shell.

A shell collector should use tools rather than fingers when identification is uncertain.

Important Pitfalls

A major historical error is assuming that human respiratory paralysis is unreported. In fact, progressive respiratory-muscle paralysis is the principal lethal complication of severe cone-snail envenomation.

Another pitfall is relying on local pain severity. A potentially dangerous envenomation may begin with relatively little pain, so the absence of dramatic local injury does not exclude severe systemic poisoning.

Hot-water immersion should not replace modern first aid. Current Australian guidance specifically recommends pressure immobilization for cone-shell envenomation, while hot-water immersion is used for different marine envenomations such as stonefish.

Do not wait for hypoxemia before recognizing respiratory paralysis. A patient can initially maintain oxygen saturation while ventilation and respiratory muscle strength are progressively deteriorating.

Do not assume a motionless patient is unconscious. Severe neuroparalysis may occur with preserved awareness, and communication/reassurance should continue.

The historical claim that C. tulipa is categorically the most toxic cone snail is also misleading. In human clinical experience, C. geographus is overwhelmingly the species associated with fatal envenomation.

Finally, there is no antivenom. Searching for an antidote should never delay the intervention that saves lives:

Ventilation.

High-Yield Toxicology Pearls

Cone-snail envenomation is a neuroparalytic marine emergency. More than 900 cone-snail species are now recognized, but the greatest human danger comes from large fish-hunting species, especially Conus geographus. Historical reviews document more than 30 fatalities, probably almost entirely from the geography cone.

Cone snails inject venom using a disposable harpoon-like radular tooth. Their venom is a complex mixture of conopeptides rather than a single toxin. Important families include α-conotoxins affecting nicotinic receptors, ω-conotoxins blocking calcium channels, μ-conotoxins blocking sodium channels, and κ-conotoxins affecting potassium channels.

The clinical progression is typically sting → local pain/numbness → spreading paresthesias → cranial/bulbar symptoms → generalized weakness → flaccid paralysis → respiratory failure. Perioral tingling, ptosis, blurred vision, dysarthria, and dysphagia are important warning signs.

Human respiratory paralysis is well documented and represents the major lethal mechanism. The patient may remain completely conscious while unable to move or breathe.

First aid is pressure immobilization and complete immobilization of the patient, not routine hot-water immersion. The limb should be bandaged firmly and splinted, and unnecessary movement should be avoided.

There is no antivenom and no proven pharmacologic antidote. Severe paralysis is treated with bag-mask ventilation followed by intubation and mechanical ventilation when necessary. Patients can recover if ventilation is sustained until toxin effects resolve.

Systemic neurologic symptoms require hospital admission and close respiratory monitoring. Asymptomatic minor stings may be observed and discharged if no systemic manifestations develop, but a rigid 4–6-hour discharge rule should not override species, exposure, or clinical-risk considerations.

The single most important clinical pearl is:

Cone snail + progressive weakness = anticipate respiratory paralysis before the patient becomes hypoxic.

Toxicology – Colchicine

Core Concept

Colchicine is a potent microtubule-disrupting alkaloid with a narrow therapeutic index. Severe poisoning is characterized by an initially gastrointestinal illness followed by rapidly progressive multiorgan failure, cardiovascular collapse, bone-marrow suppression, respiratory failure, coagulopathy, and sepsis.

A useful toxicologic sequence is:

Colchicine → tubulin binding → failure of microtubule polymerization → impaired mitosis and intracellular transport → GI mucosal injury + myocardial dysfunction + bone-marrow suppression + multiorgan failure

The typical clinical progression is triphasic: severe gastroenteritis during the first day, systemic organ failure over the next several days, and—if the patient survives—marrow recovery, rebound leukocytosis, and alopecia after approximately one week.

There is currently no commercially available specific antidote. Treatment requires early recognition, gastrointestinal decontamination when appropriate, aggressive intensive supportive care, and serial surveillance for delayed marrow failure.

Current Forms and Uses

Modern colchicine is principally administered orally. U.S. formulations include 0.6-mg tablets and capsules, while the cardiovascular product LODOCO contains 0.5 mg. Current indications include treatment and prophylaxis of gout flares and familial Mediterranean fever. Colchicine also has specialist uses in inflammatory diseases and pericarditis, while low-dose colchicine 0.5 mg daily is now approved in the United States to reduce cardiovascular events in adults with established atherosclerotic disease or multiple cardiovascular risk factors.

The historical practice of treating acute gout with 0.6 mg every hour until diarrhea or a cumulative 6 mg is obsolete and dangerous. The current FDA-labeled regimen for an acute gout flare is 1.2 mg initially followed by 0.6 mg one hour later, for a total of 1.8 mg, because higher doses provide no additional efficacy and substantially increase adverse effects.

Intravenous colchicine should also be regarded as historical in the United States. FDA took enforcement action in February 2008 to remove unapproved injectable colchicine products from the market because of the drug’s narrow therapeutic margin and the danger of fatal dosing errors with intravenous administration.

Plant Sources

Colchicine occurs naturally in Colchicum autumnale, commonly called autumn crocus or meadow saffron, and in Gloriosa superba, commonly called glory lily or flame lily. All portions of these plants can be toxic. Gloriosa tubers and seeds contain substantial amounts of colchicine and related alkaloids, while accidental Colchicum autumnale poisoning has occurred when leaves are mistaken for edible wild plants such as wild garlic.

Plant poisoning can be every bit as severe as pharmaceutical colchicine poisoning. A large Sri Lankan series of Gloriosa superba self-poisoning reported approximately 10% mortality, demonstrating that the older claim that plant intoxication is usually less severe is incorrect.

Mechanism of Toxicity

Colchicine binds to tubulin and prevents normal polymerization of microtubules. Because microtubules are necessary for mitosis, vesicular transport, maintenance of cellular structure, leukocyte movement, and many other cellular processes, colchicine toxicity affects far more than simply cell division.

Rapidly proliferating tissues are particularly vulnerable, including the gastrointestinal epithelium, bone marrow, and hair follicles, explaining the characteristic progression from gastroenteritis to pancytopenia and later alopecia. Myocardial and neuromuscular tissues can also be severely affected because microtubule disruption interferes with cellular transport, electrophysiology, contractility, and energy metabolism.

Pharmacokinetics

Colchicine is absorbed relatively rapidly after oral ingestion, with peak concentrations after ordinary therapeutic doses occurring at approximately one hour. It undergoes significant hepatic metabolism and biliary excretion, as well as renal elimination. It is a substrate for both CYP3A4 and P-glycoprotein (P-gp) and undergoes enterohepatic recirculation.

These characteristics help explain why toxicity may be prolonged and why drug interactions are so important. Colchicine also has extensive tissue distribution, which is one reason extracorporeal removal is ineffective once systemic absorption has occurred.

Drug Interactions

Modern understanding of colchicine interactions is substantially different from the older emphasis on cimetidine and tolbutamide. The most important interactions involve inhibitors of:

CYP3A4 and P-glycoprotein

Important examples include clarithromycin, erythromycin, azole antifungals, cyclosporine, several HIV protease inhibitors, and other strong CYP3A4/P-gp inhibitors. These drugs can markedly increase colchicine exposure and have produced life-threatening or fatal toxicity even when colchicine itself was prescribed at therapeutic doses.

The combination is particularly dangerous in patients with renal or hepatic impairment. Current colchicine labeling contraindicates coadministration of strong CYP3A4 or P-gp inhibitors with colchicine in patients with renal or hepatic impairment because fatal interactions have occurred.

FDA’s review of historical colchicine deaths found that a substantial proportion of non-overdose fatalities involved drug interactions, with clarithromycin especially prominent.

Statins and Myotoxicity

Colchicine can itself cause neuromyopathy and rhabdomyolysis, particularly when accumulation occurs. Concomitant statins, fibrates, cyclosporine, and other myotoxic medications can increase this risk. Current labeling reports myopathy and rhabdomyolysis—including fatal cases—with colchicine and HMG-CoA reductase inhibitors.

Therefore, weakness or muscle pain in a patient receiving colchicine should not automatically be attributed to gout, age, or deconditioning.

Renal and Hepatic Impairment

Renal and hepatic dysfunction both increase the risk of colchicine accumulation and toxicity. Current dosing must be modified according to renal function, hepatic function, indication, and concomitant interacting medications. Severe renal impairment requires markedly reduced prophylactic dosing and prolonged intervals between treatment courses.

The important toxicology principle is that:

Therapeutic dosing can become toxic when clearance is impaired.

Therefore a patient can have severe colchicine poisoning without a deliberate overdose.

Toxic Dose

Colchicine has a notoriously narrow therapeutic margin. Historically, oral exposures have been divided into approximate risk categories of <0.5 mg/kg, 0.5–0.8 mg/kg, and >0.8 mg/kg. Early reports suggested little mortality below 0.5 mg/kg, significant toxicity between 0.5 and 0.8 mg/kg, and near-universal mortality above 0.8 mg/kg.

These categories remain useful as rough risk markers but should not be treated as reliable outcome thresholds. Modern case reports document critical illness after doses well below 0.5 mg/kg, including severe multiorgan poisoning after approximately 0.2 mg/kg, while survival has occurred after doses historically classified as lethal.

Thus:

There is no absolute “safe” or inevitably fatal colchicine dose.

Any substantial overdose deserves aggressive assessment, and symptoms matter more than a historical dose cutoff.

Clinical Course

Colchicine poisoning is classically divided into three overlapping phases. This triphasic description is useful clinically but should not be interpreted as an exact timetable.

Phase 1 – Gastrointestinal Toxicity

The first phase usually develops within the first several hours and predominates during approximately the first 24 hours. Patients develop nausea, profuse vomiting, severe abdominal pain, and watery diarrhea, sometimes with gastrointestinal bleeding.

The syndrome can resemble severe gastroenteritis or cholera and may cause profound volume depletion, electrolyte abnormalities, metabolic acidosis, and early hypotension. Leukocytosis is common during this stage.

Importantly, the gastrointestinal symptoms are not simply benign adverse effects. In a significant overdose they represent direct gastrointestinal cellular injury and can be the first warning of impending systemic toxicity.

Phase 2 – Multiorgan Failure

The second phase typically becomes apparent after approximately 24 hours and may continue for several days. This is the life-threatening phase, characterized by progressive dysfunction of the cardiovascular, hematologic, respiratory, hepatic, renal, neurologic, and muscular systems.

Patients may develop shock, myocardial depression, ventricular dysrhythmias, ARDS, renal and hepatic injury, disseminated intravascular coagulation, encephalopathy, seizures, rhabdomyolysis, and profound bone-marrow suppression. Death during this phase is commonly caused by cardiovascular collapse, respiratory failure, or progressive multiorgan failure.

Phase 3 – Recovery

Patients who survive the period of multiorgan dysfunction generally enter a recovery phase beginning around day 7 or later. Bone marrow activity returns, often producing rebound leukocytosis, and alopecia may appear as damaged hair follicles enter recovery.

Weakness, neuropathy, and myopathy may persist for weeks, but survivors can eventually make a substantial or complete recovery if irreversible hypoxic or organ injury has not occurred.

Gastrointestinal Toxicity

Nausea, vomiting, abdominal cramping, and diarrhea are usually the earliest symptoms. Severe fluid losses can produce hypovolemic shock, renal hypoperfusion, metabolic acidosis, and major electrolyte abnormalities.

The onset of diarrhea after therapeutic colchicine is also an important warning sign. Because gastrointestinal effects are dose-related, new significant diarrhea in a patient receiving colchicine—particularly with renal disease or interacting medications—should trigger immediate review of dosing and toxicity risk.

Cardiovascular Toxicity

Cardiovascular failure is one of the most important causes of early death. Colchicine can produce myocardial dysfunction, reduced contractility, conduction abnormalities, dysrhythmias, and refractory shock. Patients may initially be tachycardic from dehydration and physiologic stress but later develop severe pump failure and vasoplegia.

ECG abnormalities can include conduction disturbances and nonspecific ST-T changes. Troponin elevation may occur with myocardial injury. Bedside echocardiography is particularly useful in severe poisoning to distinguish hypovolemia, vasodilatory shock, and cardiogenic myocardial depression.

Pulmonary Toxicity

Severe poisoning may progress to acute respiratory failure and ARDS. Respiratory failure can reflect pulmonary edema, systemic inflammation, neuromuscular weakness, aspiration, cardiovascular collapse, or a combination of these processes.

Patients with increasing oxygen requirements, altered consciousness, or progressive shock require early critical-care involvement and may need lung-protective mechanical ventilation.

Hematologic Toxicity

A characteristic feature of significant colchicine poisoning is delayed bone-marrow suppression. Early leukocytosis may be followed by leukopenia, neutropenia, thrombocytopenia, anemia, and potentially pancytopenia or aplastic marrow failure.

The nadir commonly occurs around days 3–7, although the exact timing varies. Current labeling recognizes leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia as manifestations of colchicine toxicity.

Severe poisoning may also produce disseminated intravascular coagulation and bleeding.

Neutropenic Sepsis

Once severe neutropenia develops, secondary bacterial or fungal infection can become life-threatening. Fever during this stage must never simply be attributed to colchicine toxicity.

Fever + severe neutropenia = treat as febrile neutropenia/sepsis until proven otherwise.

Broad-spectrum antimicrobial therapy should be initiated promptly according to contemporary febrile-neutropenia protocols after appropriate cultures, without delaying treatment for microbiologic confirmation.

G-CSF

Granulocyte colony-stimulating factor, such as filgrastim, has been used in severe colchicine-induced neutropenia and marrow suppression. Published case series report accelerated recovery of neutrophil counts, but controlled outcome evidence is limited.

Therefore G-CSF is reasonable to consider in severe poisoning with substantial neutropenia, particularly febrile neutropenia, after hematology/toxicology consultation. It should be considered an adjunct rather than a colchicine antidote.

Hepatic Toxicity

Significant colchicine poisoning can produce hepatocellular injury with rising aminotransferases, bilirubin abnormalities, and impaired synthetic function. Prolonged INR may reflect both hepatic injury and disseminated intravascular coagulation.

Severe hepatic dysfunction generally occurs in the setting of broader multiorgan poisoning rather than isolated liver toxicity.

Renal Toxicity

Acute kidney injury may result from several mechanisms including severe dehydration, shock, rhabdomyolysis, multiorgan failure, and direct cellular toxicity. Urinalysis may reveal hematuria, proteinuria, or myoglobinuria.

Renal failure is particularly important because impaired colchicine clearance can further prolong systemic exposure.

Muscular and Neurologic Toxicity

Colchicine can produce myopathy, rhabdomyolysis, peripheral neuropathy, weakness, and hyporeflexia. Neuromuscular toxicity is particularly recognized during chronic therapeutic accumulation in patients with renal impairment or interacting medications, but it can also occur during major acute poisoning.

Severe acute poisoning may produce confusion, delirium, seizures, coma, and profound weakness. Neurologic abnormalities should also trigger evaluation for hypoxia, electrolyte disturbances, hypoglycemia, sepsis, and other causes.

Alopecia

Hair loss is a classic delayed finding and usually becomes apparent about one to several weeks after substantial poisoning. It reflects interruption of mitosis in rapidly dividing hair-follicle cells and is typically reversible in survivors.

Alopecia appearing during recovery can therefore retrospectively strengthen the diagnosis of significant colchicine exposure.

Diagnosis

Diagnosis is usually clinical and is based on known or suspected exposure combined with the characteristic progression from gastroenteritis to multiorgan dysfunction and marrow suppression.

Important clues include access to colchicine medication, treatment for gout or FMF, recent prescription of a CYP3A4/P-gp inhibitor, renal impairment, or ingestion of Colchicum autumnale or Gloriosa superba.

The differential includes iron poisoning, salicylate poisoning, arsenic, organophosphate or carbamate poisoning, toxic mushrooms or plants, severe infectious gastroenteritis, sepsis, and other cytotoxic or antimitotic agents.

Laboratory Evaluation

All significant exposures require serial laboratory testing rather than a single reassuring initial panel. Appropriate studies include CBC with differential and platelets, electrolytes, bicarbonate, glucose, BUN, creatinine, magnesium, calcium, liver enzymes, bilirubin, PT/INR, aPTT, fibrinogen, CK, lactate, and urinalysis.

Severe poisoning warrants blood-gas analysis, type and crossmatch, serial coagulation studies, and frequent assessment for hypoglycemia, acidosis, rhabdomyolysis, hepatic failure, and evolving marrow suppression.

The CBC is especially important because the initial leukocytosis can create false reassurance before a later precipitous decline in leukocytes and platelets.

ECG and Cardiac Assessment

An ECG and continuous cardiac monitoring are appropriate for significant poisoning. Serial ECGs should be obtained when hemodynamic instability or conduction abnormalities develop.

In severe shock, cardiac biomarkers and bedside echocardiography can help identify myocardial dysfunction. Persistent or worsening cardiogenic shock despite conventional treatment should prompt early discussion with a center capable of advanced mechanical circulatory support.

Colchicine Concentrations

The old statement that colchicine concentrations are completely useless requires nuance. Specialized quantitative colchicine testing is not routinely available rapidly enough to guide emergency management and there is no widely validated therapeutic decision threshold, so initial treatment should never wait for a level.

However, research involving Gloriosa superba poisoning found that admission plasma colchicine concentrations correlated strongly with mortality. Thus, concentrations can have toxicokinetic or prognostic value in specialized settings even though they remain impractical for routine bedside management.

Initial Treatment

Any significant colchicine overdose should be discussed early with a poison center or medical toxicologist. Patients with substantial intentional ingestion, severe gastrointestinal symptoms, hemodynamic abnormalities, laboratory abnormalities, or uncertain high-risk doses require hospital admission, usually to a high-acuity monitored setting.

The patient can initially look relatively well while irreversible intracellular toxicity is developing. Early aggressive care is therefore preferable to waiting for overt multiorgan failure.

Airway and Breathing

Airway management should follow standard critical-care principles. Intubation is appropriate for coma, respiratory failure, severe aspiration risk, or progressive shock with inability to maintain adequate ventilation.

ARDS should be managed with lung-protective ventilation and appropriate PEEP.

Circulation and Shock

Early shock may reflect profound gastrointestinal fluid loss, and isotonic crystalloid should be administered when hypovolemia is present. Severe cases often progress to mixed distributive and cardiogenic shock, so further fluids should be guided by examination, ultrasound, hemodynamics, and response rather than indiscriminate large-volume administration.

Persistent shock generally requires norepinephrine, with additional vasoactive or inotropic support individualized to cardiac function. Echocardiography can help identify severe myocardial depression.

Rare patients with otherwise refractory cardiogenic or mixed shock have been managed with extracorporeal life support. This remains rescue therapy for selected catastrophic cases rather than routine treatment.

Gastrointestinal Decontamination

Induced Emesis

Do not induce vomiting and do not use ipecac.

The old recommendation to induce emesis within 30 minutes is obsolete. These patients frequently vomit spontaneously, can deteriorate rapidly, and are at risk for aspiration.

Activated Charcoal

Colchicine is adsorbed by activated charcoal, so single-dose activated charcoal should be considered after a recent potentially serious oral ingestion when the airway is intact or protected. The greatest expected benefit is early after ingestion. Routine charcoal in every patient is not supported, and it is contraindicated when the airway is unprotected.

Because colchicine undergoes enterohepatic recirculation, multiple-dose activated charcoal (MDAC) has a plausible pharmacokinetic rationale and is sometimes used after severe poisoning. However, controlled evidence that MDAC reduces mortality is lacking, and general toxicology guidelines have not established colchicine as one of the classic evidence-supported MDAC indications.

Thus MDAC should be viewed as a specialist-directed adjunct in major poisoning, provided bowel function and airway safety permit it.

Gastric Lavage

Several older colchicine reviews and even some current product labels continue to recommend gastric lavage after severe recent ingestion. However, modern toxicology position statements conclude that gastric lavage should not be performed routinely, if at all, because clinical benefit is unproven and serious complications can occur.

Only an extraordinary, immediately life-threatening, very recent ingestion could justify lavage after airway protection and consultation with an experienced medical toxicologist. It should not be a routine response to colchicine overdose.

Antidote

There is currently no commercially available specific antidote for colchicine poisoning.

Supportive critical care remains the standard treatment.

Colchicine-Specific Fab Fragments

Colchicine-specific antibody Fab fragments represent a genuine potential antidotal strategy. A landmark human case described dramatic improvement after administration of colchicine-specific Fab in a patient with otherwise extremely severe poisoning.

Animal models also demonstrate effective binding and redistribution of colchicine. However:

Colchicine-specific Fab fragments are not commercially available for routine clinical use.

They should therefore be regarded as an experimental antidote rather than something an emergency department can ordinarily obtain. Contemporary reviews continue to identify Fab development as an important future therapeutic strategy.

Hemodialysis

Hemodialysis does not effectively remove colchicine.

Colchicine has extensive tissue distribution and rapidly leaves the vascular compartment. Current prescribing information specifically states that colchicine is not effectively removed by dialysis.

Therefore dialysis should not be initiated simply to enhance colchicine elimination.

It remains appropriate for conventional indications such as refractory hyperkalemia, severe metabolic acidosis, volume overload, or severe kidney failure. In such situations dialysis is treating the complications of poisoning rather than substantially clearing colchicine.

Hemoperfusion, Plasma Exchange, and Other Extracorporeal Techniques

Hemoperfusion, plasma exchange, hemofiltration, and related extracorporeal approaches have been reported in severe cases, but evidence is limited to case reports and small series. Because colchicine rapidly distributes into tissues, these methods are not established antidotal treatments.

They may sometimes be used as part of multiorgan supportive care or experimental rescue strategies, but clinicians should not expect reliable toxin clearance.

Rhabdomyolysis

Rhabdomyolysis should be treated with adequate IV crystalloid, correction of electrolyte abnormalities, and management of the underlying shock or hyperthermia. Serial CK, potassium, calcium, creatinine, and urine output should be monitored.

Routine urine alkalinization is not an established colchicine treatment.

Coagulopathy and Bleeding

Severe disseminated intravascular coagulation may require blood-product support according to bleeding, fibrinogen concentration, platelet count, and coagulation status. Packed red blood cells, platelets, cryoprecipitate, and plasma should be used according to standard critical-care/transfusion indications rather than prophylactically solely because colchicine was ingested.

Infection Management

The risk of infection rises substantially when neutropenia develops. Cultures should be obtained when infection is suspected, but broad-spectrum antibiotics should not be delayed in a hemodynamically unstable or febrile neutropenic patient.

Routine prophylactic antibiotics for every early colchicine ingestion are not established. Therapy should be driven by neutropenia, fever, documented infection, or standard ICU infectious indications.

Plant Poisoning Management

Poisoning from Colchicum autumnale or Gloriosa superba should be managed according to the same principles as pharmaceutical colchicine poisoning. Do not assume a natural product is milder.

When plant material is available, preserve it for botanical identification. Accidental Colchicum autumnale ingestion can occur when leaves are mistaken for wild garlic or other edible plants, while Gloriosa superba tuber ingestion may be intentional in regions where the plant is readily available.

Pregnancy

The old FDA Pregnancy Category D system is obsolete, and the statement that therapeutic colchicine is associated with Down syndrome or “trisomy 23” should not be carried forward.

Current labeling states that decades of published human experience with therapeutic colchicine during pregnancy have not identified an increased risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes, although colchicine crosses the placenta and animal studies demonstrate developmental toxicity at sufficient exposures.

In acute overdose, maternal resuscitation and treatment of shock, hypoxemia, multiorgan failure, and electrolyte abnormalities take priority.

Breastfeeding

The old implication that breastfeeding should generally be avoided is also outdated for therapeutic colchicine use. Colchicine enters breast milk, but LactMed reports that maternal doses up to approximately 1.5 mg/day result in an infant exposure below 10% of the maternal weight-adjusted dose, and published studies have not identified adverse effects in breastfed infants. Many expert guidelines consider therapeutic colchicine compatible with breastfeeding.

This therapeutic evidence should not be extrapolated to a mother with acute colchicine overdose. Breastfeeding decisions during significant maternal poisoning require individualized toxicology and pediatric assessment.

Observation

A known significant overdose should not be discharged after a short symptom-free interval simply because the patient initially appears well. Gastrointestinal manifestations may be delayed for several hours and systemic deterioration can become evident during the following day.

The older 24-hour asymptomatic observation rule is safer than a short ED observation period but should still be individualized. Because of the potentially catastrophic delayed course, deliberate or uncertain substantial ingestions generally warrant prolonged observation with serial laboratory testing and toxicology consultation.

Admission

Hospital admission is appropriate for any patient with significant intentional overdose, substantial plant ingestion, gastrointestinal symptoms, metabolic abnormalities, cardiovascular abnormalities, renal or hepatic dysfunction, or an uncertain potentially serious dose.

ICU admission is appropriate for severe vomiting/diarrhea with major fluid loss, hypotension, metabolic acidosis, myocardial dysfunction, dysrhythmia, respiratory failure, significant coagulopathy, evolving multiorgan failure, or severe neurologic toxicity.

Monitoring

Patients with serious poisoning require continuous cardiac and respiratory monitoring together with frequent assessment of hemodynamics and urine output. Serial CBC with differential, platelet count, electrolytes, renal function, liver function, coagulation studies, lactate, CK, and acid-base status are essential.

Importantly, monitoring must continue after the gastrointestinal symptoms improve because marrow suppression often worsens after the patient appears to be recovering from the initial GI illness.

Prognosis

Prognosis depends on dose, timing of treatment, age, renal and hepatic function, drug interactions, and the severity of early systemic abnormalities. Severe acidosis, cardiovascular collapse, coagulopathy, progressive organ failure, and major marrow suppression are concerning findings.

Historical dose-response estimates are useful only for broad risk assessment. A patient who has ingested less than 0.8 mg/kg can still become critically ill, while survival above this traditional “lethal” dose is possible with intensive care.

Patients who survive the first several days and demonstrate marrow and cardiovascular recovery often ultimately recover, although prolonged weakness, neuropathy, myopathy, renal dysfunction, or complications of hypoxia and sepsis may persist.

Important Pitfalls

A major pitfall is using the historical gout regimen of repeated hourly colchicine until diarrhea develops. Diarrhea is a sign of toxicity, not a therapeutic endpoint. Current acute-gout treatment is only 1.8 mg total over one hour.

Another important error is believing that only deliberate massive overdoses cause fatal colchicine toxicity. Therapeutic doses can become life-threatening when combined with CYP3A4 or P-gp inhibitors, particularly in renal or hepatic impairment. Clarithromycin is a classic example.

The historical 0.5- and 0.8-mg/kg thresholds should not be interpreted as guarantees of survival or death. Severe poisoning has occurred below these ranges.

An early leukocytosis should not reassure the clinician. Colchicine poisoning can subsequently produce profound leukopenia and pancytopenia several days later.

Improvement in vomiting and diarrhea does not necessarily mean the poisoning is resolving. The patient may be transitioning from gastrointestinal toxicity into the multiorgan-failure phase.

Routine ipecac and gastric lavage are obsolete. Activated charcoal is the more reasonable decontamination strategy after a recent substantial exposure when the airway is safe, with MDAC considered selectively rather than automatically.

Another major pitfall is starting hemodialysis simply to remove colchicine. Dialysis does not meaningfully clear the drug after tissue distribution.

Finally, colchicine-specific Fab fragments are a promising genuine antidotal concept, but they remain experimental and unavailable for routine clinical treatment.

High-Yield Toxicology Pearls

Colchicine poisoning should be remembered as “GI catastrophe first, multiorgan failure second, marrow recovery and alopecia later.” The drug binds tubulin and disrupts microtubules, damaging rapidly dividing tissues as well as myocardium, muscle, and other organs.

Current acute gout therapy is 1.2 mg followed by 0.6 mg one hour later, not repeated hourly dosing until diarrhea. Oral colchicine has a very narrow therapeutic margin, and CYP3A4/P-gp inhibitors—especially clarithromycin and cyclosporine—can cause fatal accumulation even during therapeutic dosing.

Historical dose categories of <0.5 mg/kg, 0.5–0.8 mg/kg, and >0.8 mg/kg are only rough prognostic markers. Severe toxicity can occur below 0.5 mg/kg, and no dose guarantees a particular outcome.

The early phase produces vomiting, abdominal pain, profuse diarrhea, dehydration, and leukocytosis. The dangerous second phase produces cardiovascular collapse, ARDS, hepatic and renal injury, DIC, rhabdomyolysis, neurologic toxicity, and bone-marrow suppression. Neutrophils and platelets may reach their nadir around days 3–7.

Serial CBC and multiorgan laboratory monitoring are therefore essential even after gastrointestinal symptoms improve. Fever during severe neutropenia should be treated as febrile neutropenia/sepsis, and G-CSF may be considered for severe marrow suppression.

There is no commercially available antidote. Colchicine-specific Fab fragments have produced dramatic benefit experimentally and in a rare human case but remain unavailable for routine clinical use.

Activated charcoal should be considered early after a significant ingestion when the airway is safe. Ipecac is obsolete, routine gastric lavage is not recommended, and multiple-dose charcoal remains a specialist-directed option with limited outcome evidence.

Colchicine is not effectively removed by hemodialysis because of extensive tissue distribution. Dialysis should be used for standard renal/metabolic indications rather than as a toxin-removal strategy.

Plant poisoning from Colchicum autumnale and Gloriosa superba can be severe or fatal and should be treated exactly as pharmaceutical colchicine poisoning.

The old Pregnancy Category D classification is obsolete. Therapeutic human pregnancy data do not demonstrate an increased major congenital-malformation or miscarriage risk, and therapeutic colchicine is generally considered compatible with breastfeeding.

The most important clinical warning is:

Severe gastroenteritis after colchicine exposure may be the beginning—not the peak—of the poisoning.

Toxicology – Cocaine “Washed-Out” Syndrome

Core Concept

The historical term “cocaine washed-out syndrome” describes marked somnolence or depressed mental status following prolonged or binge cocaine use. In modern terminology, this presentation is better considered part of the acute stimulant crash/withdrawal spectrum rather than a distinct toxicologic syndrome.

A typical stimulant crash consists of exhaustion, hypersomnolence, fatigue, dysphoria, increased appetite, and psychomotor slowing after prolonged stimulant use and sleep deprivation. Current ASAM/AAAP guidance notes that many patients experience approximately 12–24 hours of somnolence and irritability after abrupt reduction or cessation of stimulant use, probably reflecting both catecholaminergic adaptation and accumulated sleep deprivation.

The crucial modern point is:

Profound coma should never automatically be attributed to a cocaine “crash.”

True unresponsiveness requires exclusion of opioid or sedative coexposure, hypoglycemia, hypoxia, hypercapnia, stroke, intracranial hemorrhage, trauma, seizure/postictal state, infection, metabolic abnormalities, and other causes.

Terminology

“Washed-out syndrome” is largely a historical emergency-medicine term and is not commonly used as a formal contemporary diagnostic category. Current guidelines instead describe stimulant withdrawal, whose acute manifestations include hypersomnolence, fatigue, irritability, depression, altered appetite, and psychomotor changes.

Classic cocaine-withdrawal symptoms include dysphoric mood, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor retardation or agitation.

Thus, a better conceptual sequence is:

Repeated cocaine/stimulant use + prolonged wakefulness → stimulant cessation → crash → hypersomnolence + exhaustion + dysphoria

rather than assuming that cocaine directly produces a delayed pharmacologic coma.

Pathophysiology

The older explanation attributed the syndrome simply to catecholamine depletion after repeated cocaine exposure. That concept remains plausible but is incomplete. Modern understanding emphasizes a combination of neuroadaptation to repeated dopaminergic and adrenergic stimulation, changes in reward circuitry, acute withdrawal, and profound sleep debt accumulated during stimulant binges.

ASAM/AAAP specifically notes that early somnolence after stimulant cessation is likely related to both catecholamine depletion and sleep deprivation.

The depressed mental state is therefore often physiologically different from the respiratory and CNS depression produced by opioids, benzodiazepines, or barbiturates.

Typical Time Course

After cessation of a binge, many patients enter an early “crash” characterized by overwhelming tiredness and increased sleep. Current guidance describes 12–24 hours of prominent somnolence and irritability in many patients, although the broader withdrawal syndrome can continue for days.

Subsequent symptoms may include depression, anxiety, insomnia, paranoia, and other psychiatric complaints that can persist for weeks to months in some patients. Sleep may initially increase and later become disrupted.

The older statement that mental status should always normalize within several hours or at most 24 hours is therefore too rigid. Profound coma lasting many hours, however, remains atypical and should trigger renewed diagnostic evaluation.

Clinical Features

The most typical patient is profoundly tired after repeated stimulant use and may sleep for prolonged periods. Mental status may range from lethargy to marked somnolence, but the patient should generally maintain stable ventilation, oxygenation, and hemodynamics unless another complication or coexposure exists.

Vital signs may be normal or may show residual effects of recent stimulant use, such as mild tachycardia or hypertension. Later withdrawal can occasionally be associated with relative bradycardia. Pupils are not reliably diagnostic and may be normal or mid-position.

There should be no persistent focal neurologic deficit attributable simply to stimulant withdrawal. Hemiparesis, aphasia, gaze deviation, severe headache, meningismus, or asymmetric examination findings require evaluation for an alternative neurologic diagnosis.

Why Deep Coma Is a Red Flag

Contemporary stimulant-withdrawal guidance describes somnolence, not unexplained deep coma, as the characteristic acute neurologic finding.

Therefore, a patient who cannot be awakened, does not protect the airway, has significant hypoventilation, or has a Glasgow Coma Scale markedly below normal should not simply be labeled “washed out.”

The differential should remain broad until serious causes have been excluded.

Opioid Coexposure – Major Modern Pitfall

This is perhaps the most important change from the original chapter.

Modern illicit cocaine is often used with or contaminated by other substances, particularly illegally manufactured fentanyl and other opioids. CDC notes that polysubstance exposure involving cocaine and opioids is common, and in 2021 approximately 78.6% of U.S. cocaine-involved overdose deaths also involved an opioid.

Therefore:

Cocaine history + coma or respiratory depression ≠ cocaine crash until opioid toxicity has been considered.

Findings such as bradypnea, apnea, marked miosis, low oxygen saturation, or rising CO₂ should prompt immediate treatment as possible opioid poisoning.

Naloxone

Naloxone does not reverse cocaine withdrawal itself. However, because opioid coexposure is common and may be unintentional:

Give naloxone promptly when opioid toxicity cannot be excluded and respiratory depression is present.

Naloxone is safe and effective for opioid overdose, including fentanyl, but it will not reverse isolated cocaine effects.

Airway support and ventilation should never be delayed while waiting to see whether naloxone works.

Other Important Differential Diagnoses

Other toxicologic causes of depressed consciousness include opioids, alcohol, benzodiazepines, barbiturates, GHB, clonidine, antipsychotics, sedating anticonvulsants, baclofen, and mixed drug overdose.

Medical causes include hypoglycemia, hypoxia, hypercapnia, severe electrolyte abnormalities, renal or hepatic failure, sepsis, meningitis or encephalitis, hypothyroidism, adrenal crisis, stroke, intracranial hemorrhage, head trauma, and postictal states.

Cocaine itself can cause ischemic stroke, intracranial hemorrhage, seizures, myocardial infarction, and hyperthermic multiorgan injury, so a recent cocaine binge does not make these alternative diagnoses less likely.

Cardiac Disease Can Be Hidden by Somnolence

An important historical case described myocardial infarction in a patient initially considered to have cocaine “washed-out syndrome.” Her marked hypersomnolence made assessment of ongoing chest pain difficult.

This remains clinically important. A sleepy patient following a cocaine binge can still have:

Acute coronary syndrome, myocarditis, dysrhythmia, or other cardiovascular injury.

Do not allow a benign-appearing sleeping patient to obscure evidence of serious cocaine-associated disease.

Initial Assessment

The first priorities are airway, breathing, circulation, bedside glucose, temperature, and neurologic examination.

Assess respiratory rate and depth rather than relying solely on oxygen saturation. A patient receiving supplemental oxygen can remain well saturated while developing severe hypercapnia. Capnography is useful when ventilation is uncertain.

Examine for trauma, injection marks, focal neurologic findings, meningismus, hyperthermia, muscle rigidity, and evidence of prolonged immobilization.

Laboratory Evaluation

Testing should be guided by the presentation rather than performed automatically in every mildly sleepy patient. Current ASAM/AAAP guidance recommends symptom-directed testing and identifies CBC, metabolic testing, liver tests, CK/lactate when muscle injury or acidosis is suspected, and cardiac biomarkers when myocardial injury is a concern.

At minimum, significant unexplained depressed consciousness generally warrants bedside glucose, electrolytes, renal function, and an ECG. Additional testing may include liver enzymes, CK, lactate, blood gas, troponin, CBC, urinalysis, and pregnancy testing according to the clinical setting.

In an intentional or uncertain overdose, acetaminophen and salicylate concentrations remain appropriate when occult coingestion is possible.

Blood Gas and Capnography

The old recommendation for routine arterial blood gas analysis in every case is unnecessary. A venous or arterial blood gas is useful when there is:

Hypoventilation, unexplained acidosis, significant hypoxemia, severe systemic illness, or uncertain respiratory status.

Capnography is particularly valuable when respiratory depression from a possible opioid or sedative coexposure is suspected.

Routine methemoglobin measurement is unnecessary unless the clinical presentation specifically suggests methemoglobinemia.

Urine Drug Screening

A positive cocaine urine test generally reflects detection of the metabolite benzoylecgonine and proves only recent exposure. It does not show that cocaine is responsible for the patient’s current coma.

Similarly, standard opioid immunoassays may fail to detect fentanyl, depending on the assay used. Therefore a negative routine “opiate” screen must not be used to rule out fentanyl exposure.

Clinical treatment—including naloxone when appropriate—should not wait for toxicology results.

Neuroimaging

Head CT is indicated when there is concern for:

Head trauma, focal neurologic deficit, severe sudden headache, persistent unexplained coma, intracranial hemorrhage, or stroke.

Cocaine is itself a risk factor for cerebrovascular disease, so clinicians should maintain a low threshold for neuroimaging when the neurologic examination is abnormal.

Routine CT is not required for a patient with a classic, improving stimulant crash and normal neurologic examination.

Lumbar Puncture

Lumbar puncture is not routine for stimulant withdrawal. It should be performed only when there is a specific concern for meningitis, encephalitis, subarachnoid hemorrhage not adequately evaluated by imaging, or another appropriate neurologic indication.

The old approach of automatically obtaining CT, lumbar puncture, and cultures for every deeply sleepy cocaine user is unnecessarily broad; evaluation should be guided by the history and examination.

Treatment

There is no specific pharmacologic antidote for stimulant withdrawal or the cocaine crash. Current care focuses on maintaining physiologic safety, excluding dangerous alternative diagnoses, providing a calm environment, allowing restorative sleep, hydration and nutrition, and treating specific symptoms. ASAM/AAAP states that the modern standard of care for stimulant withdrawal is symptom relief and risk reduction, with environmental and behavioral measures forming an important component.

Airway and Ventilation

A genuinely somnolent withdrawal patient should ordinarily continue to breathe adequately. If ventilation or airway protection is impaired:

Support the airway rather than attributing respiratory failure to “washout.”

Provide oxygen for hypoxemia and bag-mask ventilation when needed. Intubate for persistent apnea, inadequate ventilation, inability to protect the airway, or other standard indications.

At the same time, give naloxone when opioid coexposure is plausible.

Fluids and Nutrition

Many patients have eaten, slept, and hydrated poorly during a stimulant binge. Oral fluids and nutrition are appropriate once the patient is awake and can swallow safely. IV isotonic fluid is appropriate for clinically significant dehydration or associated rhabdomyolysis.

There is no benefit to routine forced diuresis.

Stimulant Withdrawal Medication

No medication is established as a specific treatment for the acute cocaine crash. ASAM/AAAP notes that pharmacotherapies studied for general stimulant withdrawal have limited and generally low-quality evidence.

Medication should therefore target specific clinically significant problems such as persistent depression, psychosis, agitation, or insomnia rather than attempting to “reverse” withdrawal pharmacologically.

Stimulants should not simply be administered to awaken a sleeping patient who has not yet been adequately evaluated.

Psychiatric Symptoms

Withdrawal may include depressed mood, anxiety, irritability, paranoia, and sleep disturbance, and some symptoms can persist for weeks or months.

Patients presenting after stimulant intoxication or withdrawal should be assessed for suicide and self-harm risk. ASAM/AAAP specifically recommends routine assessment of suicidality because people using stimulants have an elevated risk of self-harm.

This is particularly important during the crash when euphoria abruptly gives way to exhaustion, dysphoria, anhedonia, and depression.

Gastrointestinal Decontamination

GI decontamination has no role in the ordinary cocaine “washed-out” syndrome.

The syndrome follows cessation after a binge; there is generally no relevant drug remaining in the stomach that can be removed.

Therefore:

Do not induce vomiting. Do not perform gastric lavage. Do not routinely administer activated charcoal.

Activated charcoal would only be considered if there were a separate, recent, clinically significant oral ingestion for which charcoal is otherwise indicated and the airway is intact or protected.

The old recommendation to administer charcoal merely because a patient presents after cocaine binge use should not be carried forward.

Enhanced Elimination

There is no role for:

Hemodialysis, hemoperfusion, urinary alkalinization, or forced diuresis

for stimulant withdrawal or cocaine elimination.

Management remains supportive.

Prolonged Immobilization

A very somnolent patient may remain in one position for many hours and can develop pressure injury, peripheral nerve compression, or compartment syndrome.

Patients with prolonged unresponsiveness should be examined for:

Limb swelling, tense compartments, severe pain when awake, pressure injuries, and rhabdomyolysis.

Check CK, potassium, and renal function when prolonged immobilization is substantial.

Monitoring

Patients with significant depressed consciousness should have serial assessment of:

Mental status, respiratory rate, oxygenation, ventilation, blood pressure, pulse, temperature, and glucose.

Continuous cardiac monitoring is appropriate when there is:

• Significant altered consciousness
• Chest pain
• Dysrhythmia
• Severe recent cocaine toxicity
• Important coingestion

Monitoring can be reduced once a benign stimulant crash has been established and the patient is clearly recovering.

Admission

The old recommendation that every patient must be admitted is unnecessarily rigid.

Patients with genuine coma, airway compromise, respiratory depression, persistent unexplained altered consciousness, significant cardiovascular abnormalities, serious metabolic abnormalities, stroke/trauma concerns, rhabdomyolysis, or significant coingestion require admission and sometimes ICU care.

A patient with uncomplicated stimulant withdrawal who is sleepy but readily arousable, maintains normal ventilation and hemodynamics, has no concerning alternative diagnosis, and progressively improves may be managed in an appropriate observation setting without mandatory inpatient admission.

Discharge

Discharge is appropriate when the patient is awake enough to function safely, has returned toward neurologic baseline, has stable vital signs and adequate ventilation, can maintain hydration, and has no untreated acute medical complication.

Before discharge, evaluate psychiatric status, particularly depression and suicidality. Persistent severe depression, psychosis, suicidal thoughts, or inability to care for oneself requires further mental-health assessment rather than simple discharge after waking.

Stimulant Use Disorder Treatment

The emergency visit should also be used to identify stimulant use disorder and offer treatment rather than simply allowing the patient to “sleep it off.”

ASAM/AAAP identifies contingency management as the behavioral intervention with the strongest evidence for stimulant use disorder and describes it as the current standard of care, often combined with approaches such as cognitive behavioral therapy or community reinforcement.

There is no single FDA-approved medication specifically for cocaine use disorder, although specialist-directed off-label pharmacotherapies may be considered in selected patients.

Prognosis

Uncomplicated stimulant crash generally has a good prognosis. Prominent sleepiness often improves over approximately 12–24 hours, although fatigue, depression, anxiety, craving, sleep disturbance, and other withdrawal symptoms may continue much longer.

Persistent deep coma or failure to improve should not simply be attributed to cocaine withdrawal. The differential diagnosis must be reopened and additional toxicologic, neurologic, infectious, or metabolic investigation performed.

Important Pitfalls

The most important pitfall is using “washed-out syndrome” as a premature explanation for coma. Modern stimulant withdrawal commonly produces hypersomnolence, but profound unresponsiveness should remain a diagnosis of exclusion.

Another major error is failing to consider fentanyl or another opioid in a patient believed to have used only cocaine. Modern polysubstance exposure is common, and opioid-associated respiratory depression requires naloxone and ventilatory support.

A positive cocaine urine test should not end the diagnostic investigation. Cocaine metabolites remain detectable beyond the period of intoxication and can coexist with stroke, infection, metabolic disease, trauma, or another overdose.

Do not assume that normal vital signs exclude serious disease. A sleeping post-binge patient may still have occult myocardial infarction, as demonstrated in historical cases of so-called washed-out syndrome.

Routine activated charcoal, gastric lavage, lumbar puncture, and broad laboratory testing are not automatically indicated simply because cocaine withdrawal is suspected. Testing and interventions should be guided by the clinical presentation.

Finally, do not overlook depression and suicide risk during the crash and withdrawal period. Modern stimulant guidelines explicitly recommend assessment for suicidality during intoxication and withdrawal.

High-Yield Toxicology Pearls

“Cocaine washed-out syndrome” is best viewed today as an acute stimulant crash/withdrawal state rather than a distinct poisoning syndrome. The expected picture is exhaustion, hypersomnolence, fatigue, dysphoria, increased appetite, and psychomotor slowing after prolonged cocaine or other stimulant use.

Many patients have marked sleepiness for approximately 12–24 hours, reflecting stimulant withdrawal and accumulated sleep deprivation. However, deep coma is not a diagnosis to accept casually.

In a cocaine user with profound depressed consciousness, always consider opioid/fentanyl coexposure, alcohol or sedatives, hypoglycemia, hypoxia/hypercapnia, stroke or intracranial hemorrhage, head injury, seizure/postictal state, infection, and metabolic disease.

Respiratory depression should prompt immediate airway assessment and naloxone when opioid exposure cannot be excluded. A positive cocaine urine screen proves recent exposure but does not prove that cocaine caused the coma.

There is no antidote for the stimulant crash and no role for routine activated charcoal, gastric lavage, dialysis, or forced elimination. Treatment is supportive: protect the airway when necessary, provide hydration and nutrition, allow restorative sleep, monitor for complications, and investigate atypical findings.

Patients should also be screened for depression, suicidality, and stimulant use disorder. Persistent psychiatric symptoms require treatment, and contingency management currently has the strongest evidence among behavioral treatments for stimulant use disorder.

The single most important modern pearl is:

Cocaine binge + sleepiness may be withdrawal; cocaine binge + coma must be proven safe before calling it “washed out.”

Toxicology – Cocaine

Core Concept

Cocaine is a potent sympathomimetic stimulant, local anesthetic, and vasoconstrictor. Severe toxicity results from a combination of excessive catecholaminergic activity and direct cardiac ion-channel blockade. The classic acute syndrome is agitation, diaphoresis, mydriasis, tachycardia, hypertension, hyperthermia, and seizures, with severe cases progressing to myocardial ischemia, ventricular dysrhythmias, stroke, rhabdomyolysis, shock, or death.

A useful toxicologic sequence is:

Cocaine → monoamine reuptake blockade → sympathetic excess → hypertension/tachycardia/agitation/hyperthermia

while at sufficiently high concentrations:

Cocaine → cardiac Na⁺-channel blockade → QRS widening + impaired contractility → ventricular dysrhythmia/cardiovascular collapse

The immediate management priorities are rapid control of agitation and seizures with benzodiazepines, aggressive treatment of hyperthermia, cardiovascular monitoring, and recognition of cocaine-associated myocardial ischemia and sodium-channel cardiotoxicity. There is no specific antidote.

Current Medical Cocaine

Cocaine remains a legitimate prescription medication despite its widespread illicit use. Current U.S. products include 4% cocaine hydrochloride nasal solutions, including NUMBRINO and GOPRELTO, which are Schedule II controlled substances used to produce local anesthesia of nasal mucous membranes during diagnostic procedures or surgery.

Current NUMBRINO labeling recommends approximately 40–160 mg applied intranasally by pledgets, with a maximum total dose of 3 mg/kg cocaine hydrochloride for a procedure. The approved solution contains 40 mg/mL. These formulations are for topical intranasal use only and should not be injected or applied ophthalmically.

The older use of combinations such as tetracaine-adrenaline-cocaine (TAC) is now largely historical in many settings because alternative topical anesthetics are available and cocaine creates avoidable cardiovascular and abuse-related risks.

Illicit Forms and Routes

Cocaine is derived from leaves of plants in the genus Erythroxylum. Illicit cocaine hydrochloride is commonly insufflated intranasally or injected after dissolution. Crack cocaine is a cocaine base formulation that can be heated and smoked, producing extremely rapid pulmonary absorption and a correspondingly rapid rise in brain cocaine concentrations.

Cocaine may also be taken orally or applied to mucosal surfaces. Particularly dangerous exposures occur in body stuffers, who hurriedly swallow poorly wrapped packets to conceal drugs, and body packers, who intentionally swallow larger numbers of carefully prepared packets for smuggling. Packet rupture can release an enormous dose and produce fulminant poisoning.

Epidemiology

Cocaine remains an important cause of drug-related morbidity and death. Final U.S. mortality data for 2024 showed a cocaine-involved overdose death rate of 6.3 per 100,000 population, down from 8.6 in 2023 but still representing a major public-health burden.

Modern cocaine toxicity also frequently occurs in the context of polysubstance exposure. Opioids, particularly illegally manufactured fentanyl, are commonly involved in stimulant-related deaths. CDC data showed that 78.6% of U.S. cocaine-involved overdose deaths in 2021 also involved an opioid. Consequently, unexpected respiratory depression in a presumed cocaine exposure should immediately raise concern for opioid coexposure, and naloxone should not be withheld while waiting for toxicology results.

Toxic Dose

There is no reliable toxic or lethal dose of cocaine. The older observation that death has followed as little as 25 mg should not be used as a clinical threshold. Individual response varies dramatically according to route, rate of administration, underlying cardiovascular disease, tolerance, adulterants, coingestants, genetic/metabolic factors, and the presence of hyperthermia or acidosis.

Current prescription labeling likewise notes that cocaine toxicity can occur idiosyncratically at relatively low doses. Therapeutic intranasal dosing therefore does not define a “safe” dose for illicit use.

Pathophysiology – Monoamine Reuptake Blockade

The older description that cocaine mainly increases release of norepinephrine is incomplete. Cocaine principally blocks presynaptic reuptake of norepinephrine, dopamine, and serotonin. Accumulation of norepinephrine at peripheral sympathetic synapses drives tachycardia, hypertension, vasoconstriction, diaphoresis, and hyperthermia, while enhanced dopamine signaling contributes to euphoria, reinforcement, agitation, psychosis, and addiction.

The overall cardiovascular result is particularly dangerous because cocaine simultaneously increases myocardial oxygen demand through tachycardia, hypertension, and increased contractility while decreasing oxygen supply through coronary vasoconstriction. It also promotes platelet activation and thrombosis, allowing myocardial infarction to occur even in young people without conventional atherosclerotic disease.

Sodium-Channel Blockade

Cocaine is also an ester-type local anesthetic. It reversibly blocks voltage-gated sodium channels, preventing normal action-potential conduction. This explains both its therapeutic local anesthetic action and an important component of severe cardiotoxicity.

In massive poisoning, particularly after rapidly absorbed large doses or rupture of an internal packet, sodium-channel blockade may produce QRS widening, impaired myocardial contractility, hypotension, ventricular dysrhythmias, and cardiac arrest. The 2024 ASAM/AAAP stimulant guideline specifically recognizes cocaine-induced QRS widening as a sodium-channel-blocking complication requiring sodium bicarbonate therapy.

Potassium Channels and QT

Cocaine can also interfere with cardiac potassium currents and prolong ventricular repolarization. Current prescription pharmacology demonstrates concentration-dependent QTc prolongation, although the effect at approved 4% topical dosing is generally modest.

Thus severe cocaine poisoning can produce both QRS widening from sodium-channel blockade and QT prolongation from repolarization abnormalities, and management should be guided by the actual ECG pattern.

Cocaine Plus Alcohol – Cocaethylene

When cocaine and ethanol are present simultaneously, hepatic metabolism produces the active metabolite:

Cocaethylene

Cocaethylene has psychoactive and cardiovascular effects and generally persists longer than cocaine itself. Human data suggest that combined cocaine and alcohol exposure carries greater cardiovascular risk than cocaine alone, including increased cardiac-arrest and sudden-death risk.

Therefore a history of alcohol use should always be obtained in cocaine intoxication. A patient may remain at cardiovascular risk longer than expected from cocaine alone.

Clinical Features – Sympathomimetic Toxidrome

Typical acute findings include agitation, anxiety, restlessness, paranoia, mydriasis, diaphoresis, tachycardia, hypertension, and hyperthermia. Tremor, hyperreflexia, increased motor activity, and repetitive stereotyped behavior may occur.

Severe toxicity can progress rapidly to delirium, seizures, extreme hyperthermia, profound metabolic acidosis, ventricular dysrhythmia, hypotension, coma, or cardiac arrest. Severe hyperthermia is particularly ominous because it accelerates rhabdomyolysis, acidosis, hepatic injury, coagulopathy, renal failure, and multiorgan dysfunction.

Neuropsychiatric Effects

Cocaine can cause anxiety, panic, severe agitation, insomnia, paranoia, hallucinations, mania-like behavior, and stimulant-induced psychosis. Tactile hallucinations such as formication may occur during heavy or prolonged use.

Benzodiazepines remain first-line pharmacologic treatment for stimulant-induced agitation. Modern guidance no longer supports the older absolute prohibition against antipsychotics. Antipsychotics may be used when prominent stimulant-associated psychosis or refractory agitation persists, although agent-specific risks such as QT prolongation, seizure threshold, and thermoregulation must be considered.

Neurologic Complications

Seizures are a major manifestation of severe cocaine toxicity and may be followed by lactic acidosis, hyperthermia, rhabdomyolysis, and cerebral injury. Cocaine can also cause ischemic stroke, intracranial hemorrhage, subarachnoid hemorrhage, and hypertensive encephalopathy.

A focal neurologic deficit, persistent altered consciousness, severe headache, or atypical presentation should not simply be attributed to intoxication. Neuroimaging should be performed when stroke or intracranial hemorrhage is clinically suspected.

Cardiovascular Toxicity

Cocaine can produce a broad range of cardiovascular complications, including myocardial ischemia, acute myocardial infarction, coronary vasospasm, thrombosis, myocarditis, acute cardiomyopathy, malignant dysrhythmias, aortic dissection, and sudden cardiac death. These complications reflect the combined effects of catecholamine excess, coronary vasoconstriction, thrombosis, sodium- and potassium-channel blockade, oxidative injury, and increased myocardial oxygen demand.

Chronic use can also contribute to left ventricular hypertrophy, dilated cardiomyopathy, accelerated coronary disease, and heart failure.

Cocaine-Associated Chest Pain

Any patient with cocaine-associated chest pain should be evaluated for acute coronary syndrome, regardless of age. Initial evaluation should include ECG and serial cardiac troponin measurements when clinically indicated. Other life-threatening cocaine-associated diagnoses such as aortic dissection, pneumothorax, pneumomediastinum, myocarditis, pulmonary embolism, and esophageal rupture should be considered according to the presentation.

Modern stimulant guidelines recommend simultaneously treating the underlying hyperadrenergic state with a GABAergic agent such as a benzodiazepine while evaluating persistent chest pain according to standard ACS pathways.

Pulmonary Complications

Smoking crack cocaine can cause cough, bronchospasm, pneumothorax, pneumomediastinum, alveolar hemorrhage, pulmonary edema, and an inflammatory lung injury sometimes termed “crack lung.” Patients may develop hypoxemia, hemoptysis, diffuse infiltrates, and respiratory distress.

Chest radiography is appropriate when respiratory symptoms, hypoxemia, significant chest pain, or suspected pneumothorax/pneumomediastinum is present. CT may be required when serious thoracic pathology remains suspected despite a nondiagnostic radiograph.

Gastrointestinal and Mesenteric Ischemia

Profound splanchnic vasoconstriction can cause mesenteric ischemia and bowel infarction, even in young patients without vascular disease. Severe or persistent abdominal pain after cocaine exposure should therefore not automatically be attributed to benign gastrointestinal upset.

Possible manifestations include severe abdominal pain, vomiting, gastrointestinal bleeding, bowel necrosis, perforation, and peritonitis. Lactate and CT angiographic imaging may be appropriate when intestinal ischemia is suspected.

Renal and Musculoskeletal Toxicity

Rhabdomyolysis can result from agitation, prolonged exertion, seizures, hyperthermia, ischemia, or prolonged immobilization. Complications include hyperkalemia, metabolic acidosis, acute kidney injury, and compartment syndrome.

Patients with severe agitation, hyperthermia, seizures, or substantial muscle pain should have CK, potassium, creatinine, and urinalysis monitored. Management focuses on controlling the driving agitation/hyperthermia and providing appropriate IV crystalloid. Routine urinary alkalinization is not required. The current ASAM/AAAP guideline emphasizes fluids and treatment of agitation and hyperthermia rather than routine urine alkalinization.

Hepatic and Hematologic Effects

Severe hyperthermic cocaine poisoning may cause acute hepatocellular injury or hepatic necrosis. Disseminated intravascular coagulation and thrombocytopenia may occur as part of catastrophic hyperthermia and multiorgan failure rather than as routine manifestations of cocaine exposure.

CBC, coagulation testing, liver enzymes, CK, renal function, lactate, and blood gas analysis are appropriate in critically ill or markedly hyperthermic patients.

Adulterants

Illicit cocaine frequently contains pharmacologically active adulterants. Levamisole has historically been associated with cocaine and can cause neutropenia/agranulocytosis, retiform purpura, vasculitis-like skin lesions, and other immune complications.

A more immediately lethal modern concern is polysubstance exposure to fentanyl or other opioids. Respiratory depression, apnea, profound miosis, or unexpectedly reduced consciousness in a presumed cocaine exposure should prompt opioid management, including naloxone when indicated.

Diagnosis

Cocaine poisoning is primarily a clinical diagnosis. The typical combination of agitation, diaphoresis, mydriasis, hypertension, tachycardia, hyperthermia, and compatible exposure strongly supports stimulant toxicity.

Laboratory testing should be tailored to severity. Mild, rapidly resolving intoxication may require little testing, whereas severe toxicity warrants ECG, glucose, electrolytes, renal function, CK, lactate, acid-base assessment, and additional tests directed by organ injury.

Urine Cocaine Testing

Routine urine drug testing usually detects benzoylecgonine, a cocaine metabolite, rather than active cocaine. A positive test confirms recent exposure but does not establish the timing, route, dose, clinical severity, or whether the patient’s current symptoms are actually caused by cocaine.

Because metabolites can remain detectable after the acute pharmacologic effects have resolved:

Treat the patient, not the urine screen.

Serum cocaine concentrations are not routinely useful for clinical management.

Initial Treatment

The first priorities are airway, breathing, circulation, temperature, glucose, and rapid control of dangerous agitation or seizure activity. Cardiac monitoring and IV access should be established in moderate or severe poisoning.

A quiet environment and verbal de-escalation can help in mild agitation, but medication should not be delayed in patients with severe agitation, delirium, hyperthermia, or imminent risk of injury.

Benzodiazepines

Benzodiazepines are first-line therapy for acute cocaine toxicity.

They treat several components simultaneously by reducing central sympathetic activation and muscle activity. Benefits include improvement in agitation, anxiety, seizures, tachycardia, hypertension, hyperthermia, and catecholamine-mediated myocardial oxygen demand.

Modern ASAM/AAAP guidance recommends GABAergic agents for the stimulant-induced hyperadrenergic state, with benzodiazepines considered first-line. Phenobarbital or propofol can be considered in severe or refractory cases at an appropriate level of care.

Repeated doses may be required. Fear of sedation should not lead to undertreatment of a severely hyperadrenergic patient, although airway and ventilation must be monitored.

Seizures

Cocaine-induced seizures should be treated first with benzodiazepines. Recurrent or refractory seizures may require additional GABAergic therapy such as phenobarbital or, in an intubated patient, propofol.

Phenytoin is generally a poor choice for primary toxin-induced seizures because it does not address the underlying catecholaminergic mechanism and sodium-channel blockade may already be present.

Hyperthermia

Severe cocaine hyperthermia is a medical emergency.

Treatment requires immediate control of agitation and muscle activity together with active external cooling. Antipyretic drugs such as acetaminophen are ineffective because this is not hypothalamic fever.

The ASAM/AAAP guideline notes that severe stimulant hyperthermia, generally above approximately 40.5°C, may require rapid cooling such as cold-water immersion together with pharmacologic sedation and, when necessary, neuromuscular paralysis. Less severe hyperthermia may respond to evaporative cooling with mist and fans.

Do not wait for laboratory abnormalities before aggressively treating extreme hyperthermia.

Hypertension

Cocaine-associated hypertension often improves substantially after adequate benzodiazepine sedation. If severe hypertension persists despite control of agitation, a short-acting, titratable agent should be used.

Current stimulant guidance recommends agents such as phentolamine, sodium nitroprusside, or a dihydropyridine calcium-channel blocker for hypertensive emergency and recommends nitroglycerin when myocardial ischemia is present. Long-acting antihypertensive drugs should be avoided because rapid disappearance of stimulant activity can produce abrupt hypotension.

Cocaine-Associated Myocardial Ischemia

Initial management of cocaine-associated ischemic chest pain should include benzodiazepines and coronary vasodilation, commonly with nitroglycerin when clinically appropriate. Aspirin and other ACS therapies should be used according to the clinical diagnosis and contraindications.

Persistent ST elevation, elevated troponin, or other evidence of ACS should be managed using contemporary cardiology standards, including urgent reperfusion or PCI when indicated. Cocaine use should not be used as a reason to undertreat a true myocardial infarction.

The β-Blocker Controversy

The older teaching that all β-blockers are absolutely contraindicated whenever cocaine is involved is now too simplistic. The concern arose from the possibility that pure β blockade during intense cocaine intoxication could leave α-mediated vasoconstriction relatively unopposed and worsen coronary or systemic vasoconstriction.

Current ASAM/AAAP guidance still generally prefers vasodilators and calcium-channel blockers for cardiac ischemia during active stimulant intoxication. However, when a β-blocker is considered necessary, it recommends favoring an agent with concurrent α₁ antagonism, such as labetalol or carvedilol. If a pure β-blocker has already been given during acute intoxication, a coronary vasodilator such as nitroglycerin or a calcium-channel blocker can be considered.

Thus, “never give a β-blocker to anyone who uses cocaine” is not modern practice. The greatest caution applies to acute hyperadrenergic intoxication, while longer-term β-blocker use for established cardiac indications should be individualized rather than reflexively withheld.

QRS Widening and Sodium-Channel Toxicity

A widened QRS in severe cocaine poisoning indicates significant fast sodium-channel blockade and is a major warning sign.

Sodium bicarbonate is first-line therapy.

The contemporary ASAM/AAAP guideline strongly recommends sodium bicarbonate when cocaine causes QRS widening or impaired cardiac contractility.

A practical toxicology approach is an IV sodium bicarbonate bolus with repeated dosing guided by improvement in QRS duration, hemodynamics, and acid-base status. Excessive alkalemia, hypernatremia, hypokalemia, and volume loading should be avoided.

If bicarbonate is unavailable, hypertonic sodium may provide sodium loading, although it does not correct acidosis.

Ventricular Dysrhythmias

Treatment depends on the electrical mechanism. Wide-complex ventricular dysrhythmia associated with QRS prolongation should prompt sodium bicarbonate because sodium-channel blockade is likely.

If polymorphic VT occurs in the setting of substantial QT prolongation, manage as torsades with IV magnesium, correction of potassium and magnesium, and defibrillation if unstable or pulseless.

The historical routine use of bretylium is obsolete. Lidocaine may occasionally be considered for refractory ventricular dysrhythmia with toxicology/cardiology guidance, but it is not a substitute for sodium bicarbonate when sodium-channel blockade is present.

In refractory severe cocaine sodium-channel cardiotoxicity or arrest despite standard treatment, the ASAM/AAAP guideline notes that 20% lipid emulsion may be considered as rescue therapy in an acute-care setting, although clinical evidence is limited.

Hypotension and Shock

Hypotension in severe cocaine poisoning can result from myocardial sodium-channel blockade, dysrhythmia, myocardial infarction, hyperthermia, volume depletion, or terminal catecholamine depletion.

Treatment should address the mechanism. Give isotonic crystalloid when hypovolemia is present and correct QRS widening/acidosis promptly. Persistent shock generally warrants a titratable vasopressor such as norepinephrine, with cardiac ultrasound and hemodynamic assessment useful when cardiogenic shock is suspected. The older routine preference for dopamine and Trendelenburg positioning is outdated.

Rhabdomyolysis

Rhabdomyolysis should be treated with appropriate crystalloid resuscitation and serial monitoring of CK, potassium, creatinine, calcium, and urine output. The most important upstream treatments are rapid sedation, seizure control, and correction of hyperthermia.

Routine urinary alkalinization has not been shown to improve outcomes and is not required. Dialysis is reserved for standard renal indications such as refractory hyperkalemia, severe acidosis, volume overload, or uremic complications.

Gastrointestinal Decontamination

Induced vomiting and ipecac have no role. Cocaine can cause sudden seizures and deterioration, making induced emesis particularly dangerous.

Routine gastric lavage is also not indicated. A single dose of activated charcoal may be considered after a substantial recent oral ingestion if the airway is intact or protected and aspiration risk is acceptable. Decontamination must never delay benzodiazepines, cooling, ECG management, or resuscitation.

Body Stuffers

A body stuffer usually swallows a relatively small number of hastily wrapped drug packets to avoid detection. The packaging is often fragile, so leakage or rupture is more likely than in professional body packing.

Because even one poorly wrapped packet can release a major cocaine dose, body stuffers require careful observation for sudden hyperadrenergic toxicity. Imaging may miss small or poorly prepared packets, so a negative abdominal radiograph does not reliably exclude stuffing.

Management is individualized and should involve medical toxicology or a poison center when possible.

Body Packers

A body packer intentionally swallows numerous well-prepared packets for smuggling. The immediate risks are intestinal obstruction and catastrophic drug poisoning from packet rupture.

CT is substantially more reliable than plain radiography for packet detection and is now regarded as the most sensitive imaging method when body packing must be assessed. A 2025 systematic review found CT to outperform plain radiography and ultrasound.

Stable, asymptomatic body packers can often be managed conservatively. Whole-bowel irrigation with polyethylene glycol electrolyte solution may be considered to facilitate packet passage, although controlled evidence that WBI improves outcomes is lacking. WBI is contraindicated in obstruction, perforation, ileus, hemodynamic instability, or an unprotected airway.

Evidence of packet rupture with cocaine toxicity or mechanical obstruction requires urgent surgical consultation. A ruptured cocaine packet can release an immediately lethal dose, so systemic treatment and surgical source control may need to occur simultaneously.

Antidote

There is no specific antidote for cocaine.

Treatment is directed at the physiologic consequences of sympathetic excess, hyperthermia, sodium-channel blockade, ischemia, seizures, and organ injury.

However, naloxone should be given when opioid coexposure is possible and respiratory depression is present. The modern illicit drug supply makes cocaine-opioid coexposure clinically important.

Enhanced Elimination

Hemodialysis and hemoperfusion do not meaningfully enhance cocaine elimination because cocaine is rapidly distributed into tissues and extensively metabolized. Current prescription labeling specifically states that dialysis and hemoperfusion are ineffective for cocaine overdose.

Urinary acidification is also ineffective and potentially harmful. There is no role for forced diuresis.

Pregnancy

The old FDA Pregnancy Category X classification is obsolete; FDA no longer uses the pregnancy letter system. Cocaine crosses the placenta and fetal exposure occurs after maternal use. Current pregnancy information does not support a simple statement that cocaine produces one specific pattern of congenital malformations, but exposure is associated with major obstetric risks including placental abruption, impaired fetal growth, preterm birth, and pregnancy loss, with risk influenced by dose, frequency, timing, and associated tobacco, alcohol, or other drug use.

During acute maternal cocaine poisoning, maternal stabilization is the priority. Severe hypertension, hyperthermia, hypoxemia, seizures, and placental abruption can all threaten both mother and fetus.

Breastfeeding

Breastfeeding during active cocaine use is not recommended because cocaine passes into breast milk and can cause serious infant toxicity, including irritability, hypertension, vomiting, respiratory abnormalities, and seizures.

For medically administered topical cocaine, individual product instructions should be followed. Current GOPRELTO labeling advises avoiding breastfeeding and pumping/discarding milk for 48 hours after administration.

Monitoring

Moderate or severe cocaine toxicity requires continuous ECG, blood-pressure, respiratory, and temperature monitoring. Serial neurologic examinations are important, particularly after seizures or severe hypertension.

Chest-pain patients require serial ECG and troponin evaluation according to their risk and clinical findings. Hyperthermic, severely agitated, or convulsing patients require serial CK, renal function, electrolytes, lactate, acid-base assessment, liver tests, and coagulation studies as clinically indicated.

Observation and Disposition

Mild uncomplicated intoxication often resolves over several hours because cocaine itself has a relatively short pharmacologic duration. However, there is no universal fixed observation period because risk depends on the route, dose, formulation, coingestants, ECG findings, chest pain, temperature, organ injury, and whether body stuffing or packing occurred.

Discharge is reasonable only after the patient has returned to baseline mental status, temperature and vital signs are stable, significant ischemia or dysrhythmia has been excluded when relevant, and there is no evolving end-organ injury. Persistent chest pain, neurologic abnormality, hyperthermia, rhabdomyolysis, significant hypertension, QRS/QT abnormality, or major body-packet exposure requires longer monitoring or admission.

Prognosis

Most mild or moderate cocaine intoxication resolves completely with prompt supportive treatment. Poor outcomes are associated particularly with severe hyperthermia, prolonged seizures, major acidosis, sodium-channel cardiotoxicity, myocardial infarction, stroke, aortic catastrophe, rhabdomyolysis, packet rupture, and polysubstance overdose.

After acute stabilization, patients with problematic cocaine use should be offered evidence-based treatment for stimulant use disorder and harm-reduction support. Current ASAM/AAAP guidance emphasizes structured addiction treatment rather than treating the emergency episode as an isolated event.

Important Pitfalls

A major diagnostic pitfall is assuming that every cocaine-positive urine sample explains the patient’s current illness. Benzoylecgonine can remain detectable after acute intoxication has resolved, so alternative diagnoses must still be considered.

Another important error is regarding cocaine only as a sympathomimetic. Severe poisoning also produces direct sodium-channel blockade, and QRS widening requires sodium bicarbonate rather than simply more antihypertensive therapy.

The old absolute statement that haloperidol must never be given is also outdated. Benzodiazepines remain first-line for agitation, but antipsychotics can be used selectively for stimulant-induced psychosis or refractory agitation when their individual risks are considered.

Similarly, the traditional statement that all β-blockers are absolutely forbidden after any cocaine exposure is too broad. During acute hyperadrenergic intoxication, benzodiazepines and vasodilators remain preferred; if β-blockade is required, contemporary stimulant guidance favors an agent with α₁-blocking properties such as labetalol or carvedilol.

Hyperthermia should never be managed as ordinary fever. Sedation plus rapid physical cooling is required, and extreme hyperthermia is an immediate resuscitation priority.

Finally, apparent cocaine intoxication with marked respiratory depression should raise immediate concern for fentanyl or another opioid, and naloxone should be given when indicated rather than assuming cocaine alone explains the presentation.

High-Yield Toxicology Pearls

• Cocaine = sympathomimetic + local anesthetic sodium-channel blocker.
• Main mechanism of stimulation is dopamine/norepinephrine/serotonin reuptake inhibition, not simply increased norepinephrine release.
• Classic syndrome: agitation + diaphoresis + mydriasis + tachycardia + hypertension + hyperthermia.
• Severe toxicity causes seizures, MI, stroke, rhabdomyolysis, QRS widening, ventricular dysrhythmias, and hyperthermic multiorgan failure.
• Benzodiazepines are first-line for agitation, seizures, and the hyperadrenergic state.
• Severe hyperthermia requires immediate active cooling; antipyretics do not work.
• Cocaine chest pain requires evaluation for ACS, aortic dissection, pneumothorax/pneumomediastinum, and other serious causes.
• Ischemia: benzodiazepines + nitroglycerin/vasodilator therapy, then standard ACS care when indicated.
• β-blockers are not an absolute lifelong contraindication; during acute intoxication, alternatives are generally preferred, and labetalol/carvedilol are favored if β-blockade is needed.
• Wide QRS = sodium-channel blockade → sodium bicarbonate.
• QT prolongation/torsades → magnesium, electrolyte correction, and defibrillation when required.
• Bretylium is obsolete.
• Cocaine + alcohol produces cocaethylene, which prolongs toxicity and increases cardiovascular risk.
• Rhabdomyolysis treatment centers on fluids + cooling + control of agitation/seizures, not routine urinary alkalinization.
• Do not induce vomiting.
• Activated charcoal is only for selected recent oral exposures with a safe airway.
• Body stuffer = few poorly wrapped packets → higher leakage risk.
• Body packer = many prepared packets → obstruction or catastrophic rupture risk.
• CT is the most reliable imaging method for suspected body packing.
• WBI may be considered for stable body packers, but evidence of outcome benefit is limited.
• Packet rupture or obstruction requires urgent surgical evaluation.
• No specific antidote exists.
• Naloxone should be given when opioid coexposure is suspected, especially with respiratory depression.
• Hemodialysis and hemoperfusion do not meaningfully remove cocaine.
• Pregnancy letter categories are obsolete; maternal cocaine exposure is strongly associated with placental abruption, preterm birth, and fetal-growth problems.
• Breastfeeding during active cocaine use is not recommended.
• A positive urine cocaine metabolite test proves recent exposure but does not prove current intoxication.

Toxicology – Cobalt

Core Concept

Cobalt toxicity depends heavily on the route, dose, chemical form, and duration of exposure. The two major modern clinical patterns are occupational inhalational disease, which can cause occupational asthma and hard-metal lung disease, and chronic systemic cobalt excess, which can produce cardiomyopathy, neurologic and sensory toxicity, thyroid dysfunction, and polycythemia. An important modern source of systemic cobalt toxicity is the release of cobalt from failing cobalt-containing orthopedic implants, particularly mechanically failing or metal-on-metal hip prostheses.

There is no universally accepted blood cobalt concentration that by itself establishes systemic poisoning, and there is no proven specific antidote. Management therefore centers on identifying and removing the source of cobalt exposure, providing supportive care, treating organ-specific complications, and considering chelation only in selected severe cases with medical-toxicology input.

Cobalt and Vitamin B12

Cobalt is present naturally in vitamin B12 (cobalamin), where it forms the central metal atom of the vitamin molecule. Humans therefore require cobalt indirectly through vitamin B12. However, the nutritional requirement is for cobalamin, not for free cobalt ions or inorganic cobalt salts. Cyanocobalamin and other vitamin B12 preparations do not behave toxicologically like soluble cobalt salts because the cobalt atom remains tightly bound within the cobalamin molecule. Routine vitamin B12 use should therefore not be confused with cobalt poisoning.

Forms and Uses

Cobalt is encountered in metallic form, soluble cobalt salts, cobalt oxides, cobalt-containing alloys, pigments, battery materials, catalysts, and medical-device alloys. Important industries include rechargeable battery manufacture and recycling, hard-metal tool production, aerospace superalloys, jet engines, magnets, electroplating, pigments and ceramics, metal refining, welding, diamond-tool manufacture, and chemical processing.

Modern exposure patterns have changed substantially because cobalt is increasingly important in lithium-ion and other rechargeable batteries, making battery manufacture and recycling significant occupational settings.

Hard Metal

“Hard metal” usually consists of tungsten carbide particles held together by cobalt as a binder. Typical formulations contain large amounts of tungsten carbide with smaller percentages of cobalt. Workers involved in manufacturing, grinding, sharpening, polishing, or recycling hard-metal tools can inhale cobalt- and tungsten-containing dust. This exposure is strongly associated with hard-metal lung disease, a distinctive form of occupational interstitial lung disease.

Orthopedic Implant Exposure

A major modern source of systemic cobalt exposure is wear or corrosion from cobalt-chromium orthopedic implants, particularly metal-on-metal hip systems or mechanically failing modular prostheses. Wear and corrosion can release cobalt and chromium particles and ions into surrounding tissues and the circulation.

Systemic cobalt toxicity from an implant should be considered in a patient with a relevant prosthesis who develops unexplained cardiomyopathy, hearing or visual impairment, neurologic changes, thyroid dysfunction, or polycythemia. Assessment must include the implant itself because blood cobalt measurement alone cannot determine whether revision is required.

Radioactive Cobalt

Radioactive cobalt, particularly cobalt-60, is used in industrial radiation sources and radiotherapy. Exposure to radioactive cobalt creates a radiation and internal-contamination problem in addition to ordinary chemical cobalt toxicity. Such exposures require radiation-medicine expertise and should not be managed as simple heavy-metal poisoning.

Toxic Dose

There is no reliable universal toxic dose for cobalt. Older descriptions suggested that airborne concentrations around 20 mg/m³ were potentially lethal and that chronic exposure around 1–2 mg/m³ could cause fatal pulmonary disease. These figures should not be interpreted as direct human lethality thresholds.

The current NIOSH IDLH of 20 mg/m³ is an emergency occupational-exposure benchmark designed to protect workers from conditions immediately dangerous to life or health. It is not an experimentally established human lethal concentration. Toxicity depends on the chemical form of cobalt, particle size, solubility, route, dose, and duration of exposure.

Pathophysiology

Cobalt toxicity is largely related to biologically available Co²⁺ ions. Soluble salts release cobalt ions directly, while poorly soluble particles may be engulfed by cells and subsequently release cobalt intracellularly. Proposed mechanisms include reactive oxygen species formation, oxidative stress, DNA injury, interference with DNA repair, disruption of calcium- and magnesium-dependent processes, and altered mitochondrial and enzymatic function.

One particularly important mechanism is stabilization of hypoxia-inducible factor-1α (HIF-1α). Cobalt can mimic cellular hypoxia and activate hypoxia-response pathways. This contributes to altered erythropoietin signaling and helps explain cobalt-induced polycythemia.

Cardiovascular Toxicity

Severe chronic systemic cobalt exposure may cause cobalt cardiomyopathy. Patients can develop reduced left ventricular function, dilated cardiomyopathy, heart failure, dysrhythmias, and, in extreme cases, cardiogenic shock. Historically, cobalt cardiomyopathy was described in people exposed to cobalt salts added to beer, but contemporary cases are more often associated with excessive cobalt release from orthopedic implants.

Patients with suspected cobalt cardiotoxicity should undergo ECG evaluation and assessment for structural myocardial injury, including echocardiography and, when appropriate, biomarkers such as troponin and BNP or NT-proBNP.

Hematologic Effects

Cobalt can stimulate red-cell production through effects on hypoxia-responsive pathways and erythropoietin signaling. Chronic systemic exposure may therefore produce polycythemia, with increases in hemoglobin, hematocrit, and red-cell count.

An elevated hematocrit in a cobalt-exposed patient should not automatically be attributed to cobalt. Other causes such as chronic hypoxia, smoking, obstructive sleep apnea, and myeloproliferative disease should also be considered.

Thyroid Toxicity

High systemic cobalt exposure can interfere with thyroid function and may produce hypothyroidism or goiter. Symptoms can include fatigue, cold intolerance, weight gain, and other typical manifestations of hypothyroidism. Thyroid dysfunction is an important clue in systemic cobaltism, especially when accompanied by cardiomyopathy or neurologic symptoms, but it is not present in every patient.

Evaluation should include TSH and free T4 when chronic systemic cobalt toxicity is suspected.

Pulmonary Toxicity

The respiratory tract is a major target of occupational cobalt exposure. Inhalation can cause upper-airway irritation, occupational asthma, hypersensitivity-type reactions, and hard-metal interstitial lung disease. Rarely, very high exposures can produce acute pneumonitis or significant hypoxemia.

Workers with chronic exposure may initially complain of nonproductive cough, exertional dyspnea, wheezing, or chest tightness. Persistent symptoms should prompt pulmonary-function testing and high-resolution CT.

Occupational Asthma

Cobalt is a recognized respiratory sensitizer. Sensitized workers may develop cough, wheezing, chest tightness, and reversible airflow obstruction. Once sensitization has occurred, relatively low subsequent exposure may trigger symptoms.

The most important long-term treatment is elimination or substantial reduction of cobalt exposure, because continued workplace exposure can perpetuate airway inflammation even when bronchodilators are effective.

Hard-Metal Lung Disease

Hard-metal lung disease is an occupational interstitial lung disease associated particularly with exposure to cobalt and tungsten carbide. The interaction between cobalt and tungsten carbide appears to enhance oxidative pulmonary toxicity, so the disease should not be viewed as a simple dose-dependent effect of cobalt alone.

Patients often present with progressive dry cough, exertional dyspnea, fatigue, and later hypoxemia. High-resolution CT may show ground-glass opacities, small nodules, reticulation, consolidation, fibrosis, or honeycombing. Pulmonary-function testing may demonstrate restrictive, obstructive, or mixed abnormalities, with reduced diffusion capacity commonly seen.

Giant Cell Interstitial Pneumonia

The classic histopathologic pattern of hard-metal lung disease is giant cell interstitial pneumonia (GIP). Multinucleated giant cells may be found on bronchoalveolar lavage or lung biopsy and are highly characteristic of hard-metal exposure when the occupational history is compatible.

Not every patient with hard-metal lung disease develops the classic GIP pattern. Other histologic appearances can resemble nonspecific interstitial pneumonia, hypersensitivity pneumonitis, usual interstitial pneumonia, or desquamative interstitial pneumonia.

Acute Inhalational Exposure

Acute exposure to high concentrations of cobalt-containing dust or fumes can cause mucous-membrane irritation, cough, dyspnea, bronchospasm, and rarely acute chemical pneumonitis. Patients should be removed immediately from the source and assessed for hypoxemia and respiratory distress.

Supplemental oxygen should be given when indicated, and inhaled β₂-agonists such as albuterol or salbutamol can be used for bronchospasm. Severe respiratory failure may require ventilatory support.

Dermatologic Toxicity

Cobalt is an important contact sensitizer. Dermal exposure may cause irritant dermatitis, allergic contact dermatitis, or a pruritic papular eruption sometimes called “cobalt itch.” Sensitization can become persistent, and later exposure to small quantities of cobalt may provoke recurrent eczema.

Workers exposed to cement, metal dust, pigments, or tools may also be exposed simultaneously to chromium or nickel. Therefore “cement worker’s eczema” should not automatically be attributed only to cobalt. Formal patch testing can help identify clinically important metal allergy.

Gastrointestinal Effects

Acute ingestion of soluble cobalt salts can cause nausea, vomiting, abdominal pain, and diarrhea. Human data describing severe acute gastrointestinal cobalt poisoning are limited compared with the extensive literature on respiratory and chronic systemic toxicity.

The main priorities after significant ingestion are supportive care, assessment for coingestants, and consultation with a poison center or medical toxicologist when the exposure is substantial.

Neurologic and Sensory Toxicity

High systemic cobalt exposure has been associated with neurologic and sensory abnormalities. Patients may experience paresthesias, cognitive changes, fatigue, mood disturbances, peripheral sensory symptoms, and in severe cases hearing impairment and visual or optic-nerve dysfunction.

This combination of auditory and visual abnormalities is particularly important in patients with suspected prosthetic cobaltism. Appropriate assessment may require neurology, audiology, ENT, ophthalmology, or neuro-ophthalmology consultation.

Renal Effects

The kidneys contribute importantly to cobalt elimination, so impaired renal function may reduce clearance and increase systemic cobalt burden. Renal dysfunction has also been reported among patients with systemic metal-ion exposure.

Older descriptions gave substantial emphasis to cobalt-associated glomerulonephritis, but this is not one of the most characteristic modern clinical manifestations of cobalt toxicity.

Carcinogenicity

Modern carcinogenicity classifications differ from older descriptions. Cobalt metal and soluble cobalt(II) salts are classified by IARC as Group 2A, probably carcinogenic to humans. Cobalt(II) oxide is classified as Group 2B, possibly carcinogenic to humans, while some other cobalt compounds remain Group 3, meaning not classifiable regarding carcinogenicity in humans.

It is therefore inaccurate to assign one carcinogenic classification to every cobalt compound. Occupational exposure reduction remains important, particularly for metal and soluble cobalt compounds.

Diagnosis

The diagnosis of cobalt toxicity requires correlation between exposure history, route, cobalt concentration when appropriate, and organ-specific findings. A detailed history should address hard-metal work, tool grinding, welding, battery manufacturing or recycling, pigment production, metal refining, cement exposure, cobalt-containing supplements, and orthopedic implants.

In any patient with otherwise unexplained cardiomyopathy, polycythemia, hypothyroidism, hearing or visual impairment, and a cobalt-containing prosthesis, systemic cobaltism should be considered.

Laboratory Evaluation

For acute significant exposure, testing may include CBC, electrolytes, bicarbonate, glucose, renal function, and liver enzymes according to the clinical picture. Significant respiratory disease may require pulse oximetry, blood gases, and chest imaging.

For chronic or systemic cobaltism, evaluation should include CBC and hematocrit, renal function, electrolytes, TSH and free T4, ECG, and organ-specific testing. Suspected cardiomyopathy may require troponin, BNP or NT-proBNP, echocardiography, and occasionally cardiac MRI.

Patients with neurologic symptoms may need detailed neurologic evaluation, while visual or auditory complaints warrant ophthalmologic and audiologic testing.

Blood Cobalt Measurement

For suspected metal-on-metal or cobalt-containing implant exposure, EDTA-anticoagulated whole blood measured by a validated ICP-MS method is preferred. Specimen type matters, and serum, plasma, and whole-blood cobalt values should not be compared interchangeably.

There is no universally accepted blood cobalt concentration at which systemic toxicity definitely begins. Many severe prosthetic cobaltism cases have involved concentrations above 100 μg/L, but this is not an absolute diagnostic threshold.

Likewise, the widely discussed level of 7 μg/L in implant surveillance is not a universal toxicity threshold. Patients may be asymptomatic above this concentration, while clinically important local implant problems can occur below it. Clinical assessment and implant evaluation remain essential.

Urinary Cobalt

Urinary cobalt can help document recent systemic or occupational exposure and is commonly used in occupational biomonitoring. However, the concentration depends on timing, renal function, and exposure pattern and should not be interpreted as a stand-alone measure of toxicity.

The old statement that “normal urinary cobalt is 0.1–0.2 μg/L” should not be used as a universal modern reference range. Laboratory-specific and occupational reference values should be used instead.

Evaluation of Hard-Metal Lung Disease

Patients with suspected hard-metal lung disease should undergo a detailed occupational history, pulmonary-function testing, and high-resolution CT of the chest. Bronchoscopy with bronchoalveolar lavage or lung biopsy may be required when diagnosis remains uncertain or when giant-cell interstitial pneumonia needs to be confirmed.

Treatment – Remove the Source

The single most important intervention in chronic cobalt toxicity is:

Identify and eliminate the cobalt source.

Workers with suspected cobalt-induced asthma, dermatitis, or lung disease should be removed from continued exposure until proper occupational evaluation is completed.

In prosthetic cobaltism, source control often means evaluation for orthopedic revision or removal of the failing cobalt-containing implant. Chelation alone is unlikely to provide durable benefit if cobalt continues to be released from the prosthesis.

Treatment of Acute Inhalation

After acute inhalation, the patient should be moved to fresh air. Supplemental oxygen is given for hypoxemia, and inhaled β₂-agonists are appropriate for bronchospasm. Severe respiratory failure should be treated with standard ventilatory support.

Systemic corticosteroids may be appropriate when the presentation resembles a significant asthma exacerbation or inflammatory interstitial lung disease, but they are not a cobalt-specific antidote.

Treatment of Hard-Metal Lung Disease

The cornerstone of hard-metal lung disease treatment is complete cessation of exposure. Systemic corticosteroids are commonly used in clinically significant inflammatory disease and may improve symptoms, imaging, and pulmonary function, although evidence is based mainly on observational studies and case series rather than randomized trials.

Advanced fibrotic disease may not fully reverse. Patients with progressive disease require specialist interstitial-lung-disease management, and rare severe cases may eventually require lung transplantation.

Skin and Eye Decontamination

For dermal exposure, contaminated clothing should be removed and the skin washed thoroughly with soap and water. Allergic dermatitis is treated with exposure avoidance and standard dermatologic therapy, often including topical corticosteroids.

Ocular exposure requires immediate copious irrigation with water or saline. Persistent pain, photophobia, corneal injury, or visual change warrants ophthalmologic assessment.

Gastrointestinal Decontamination

Induced vomiting and ipecac should not be used. The historical recommendation for routine ipecac is obsolete.

Activated charcoal is not established as useful for isolated cobalt ingestion because there are no good cobalt-specific human outcome data. Routine gastric lavage is also obsolete and would only be considered under exceptional circumstances involving a very recent, massive, potentially lethal ingestion after airway protection and specialist consultation.

Whole-bowel irrigation may occasionally be discussed after a very large ingestion of radiopaque metallic cobalt or other retained cobalt-containing solid material, but it is not routine therapy.

Antidote and Chelation

There is no established specific antidote for cobalt poisoning. Several chelators have been studied or used in case reports, including CaNa₂EDTA, succimer, DMPS, DTPA, and N-acetylcysteine. However, evidence is sparse and largely case-based.

Chelation should therefore not be started merely because a cobalt concentration is elevated. It is best reserved for selected severe cases after consultation with a medical toxicologist, particularly when the source has already been removed or controlled.

Dimercaprol (BAL) is not standard therapy for cobalt poisoning.

Hemodialysis

Hemodialysis is not an established method for reversing cobalt toxicity in patients with normal renal function. Once cobalt has distributed into tissues, extracorporeal removal may not substantially change clinical outcome.

Dialysis should therefore be used mainly for conventional indications such as severe kidney failure, refractory hyperkalemia, metabolic acidosis, or volume overload rather than solely to remove cobalt.

Cardiomyopathy Management

Cobalt-associated cardiomyopathy should be managed according to standard cardiology and critical-care principles. Treatment may include oxygen when required, diuretics for congestion, guideline-directed heart-failure therapy, vasopressors or inotropes for cardiogenic shock, and mechanical circulatory support in extreme cases.

The crucial toxicologic intervention remains removal of ongoing cobalt exposure, particularly revision of a failing implant when clinically indicated.

Polycythemia and Hypothyroidism

Cobalt-associated polycythemia generally improves after the exposure source is removed. Management should also investigate alternative causes of erythrocytosis.

Patients with clinically significant hypothyroidism should receive standard thyroid replacement therapy when appropriate while the cobalt source is identified and controlled.

Occupational Management

Workers with suspected cobalt-related asthma, dermatitis, or interstitial lung disease should be removed from exposure pending evaluation. Workplace assessment should involve occupational medicine and industrial hygiene, with attention to local exhaust ventilation, engineering controls, respiratory protection, skin protection, workplace monitoring, and process substitution where feasible.

Current Workplace Standards

The current federal OSHA permissible exposure limit for cobalt metal, dust, and fume is 0.1 mg/m³ as an 8-hour TWA. The NIOSH recommended exposure limit is 0.05 mg/m³ as a TWA, and the NIOSH IDLH value is 20 mg/m³.

The 20 mg/m³ IDLH should not be interpreted as a proven lethal concentration. It is a protective emergency-exposure benchmark derived conservatively because robust acute human lethality data are lacking.

Monitoring and Follow-Up

Monitoring should be tailored to the organ systems involved. Respiratory disease requires serial symptoms, PFTs, and imaging when appropriate. Systemic cobaltism may require serial CBC, renal and thyroid function, ECG, echocardiography, neurologic assessment, ophthalmologic testing, audiometry, and repeated whole-blood cobalt concentrations.

Trends in cobalt concentration are generally more informative than a single result, especially after implant revision or other source removal.

Prognosis

Minor acute exposures generally resolve after removal from exposure and supportive care. Allergic contact sensitization may persist indefinitely and recur with very small future exposures.

Occupational asthma may improve after removal from cobalt but can become persistent when diagnosis and exposure cessation are delayed. Hard-metal lung disease has a variable course; inflammatory disease may improve substantially, whereas established pulmonary fibrosis can remain permanent.

Systemic cobaltism may also improve following source removal. Polycythemia and thyroid abnormalities can be reversible, and cardiac function may recover in some patients after implant revision or cessation of exposure. Severe established cardiomyopathy, visual injury, auditory injury, or advanced pulmonary fibrosis may leave permanent deficits.

Important Pitfalls

A major pitfall is assuming that because cobalt occurs in vitamin B12, free cobalt exposure is nutritionally harmless. The body requires cobalamin, not free cobalt ions.

Another important error is thinking cobalt toxicity occurs only in industrial workers. Failing orthopedic implants are now a major clinical source of systemic cobaltism and should be considered when cardiomyopathy, hearing loss, visual impairment, hypothyroidism, cognitive abnormalities, or polycythemia occur in a patient with an appropriate prosthesis.

An elevated blood cobalt concentration does not by itself establish clinical poisoning. There is no universal threshold separating toxic from nontoxic patients, and values such as 7 μg/L or 100 μg/L should not be used as absolute cutoffs.

Serum, plasma, and whole-blood cobalt values are not directly interchangeable. For implant-related assessment, standardized whole-blood testing is preferred.

Chelation is not established routine therapy. Treating a cobalt number without controlling a failing prosthesis or occupational source is unlikely to produce durable improvement.

Hard-metal lung disease should not be described simply as “cobalt pulmonary fibrosis.” The cobalt–tungsten carbide mixture is particularly important, and giant cell interstitial pneumonia is a highly characteristic pathologic clue.

The NIOSH IDLH of 20 mg/m³ should also not be mistaken for a proven lethal concentration. Finally, older recommendations for ipecac, routine gastric lavage, and automatic activated charcoal are obsolete.

High-Yield Toxicology Pearls

Cobalt toxicity should make you think of two main settings: occupational lung disease and systemic cobaltism.

A hard-metal worker with cough and progressive dyspnea should raise concern for cobalt-associated occupational asthma or hard-metal interstitial lung disease. A patient with a cobalt-containing hip prosthesis plus cardiomyopathy, hearing or visual changes, hypothyroidism, neurologic symptoms, or polycythemia should raise concern for prosthetic systemic cobaltism.

The classic hard-metal exposure is tungsten carbide plus cobalt, and the characteristic histologic lesion is giant cell interstitial pneumonia. The first and most important treatment is complete removal from exposure.

Systemic cobalt toxicity can cause cardiomyopathy, polycythemia, hypothyroidism, hearing loss, visual impairment, and neurologic dysfunction. Whole-blood cobalt measured by validated ICP-MS is preferred in implant-related evaluation, but no single cobalt concentration establishes toxicity.

Chelation remains specialist-directed and is not routinely indicated. Hemodialysis is not a reliable cobalt antidote. Acute ingestion should not be treated with ipecac or routine gastric lavage.

Current workplace limits are OSHA 0.1 mg/m³ TWA, NIOSH 0.05 mg/m³ TWA, and NIOSH IDLH 20 mg/m³. The IDLH value is an emergency occupational benchmark, not a human lethal concentration.

The most important principle in chronic cobalt poisoning is:

Find and eliminate the source.

Toxicology – Clonidine

Core concept

Clonidine is a central α₂-adrenergic agonist that produces a characteristic sympatholytic, opioid-like toxidrome in overdose.

The classic syndrome is:

CNS depression + miosis + bradycardia ± hypotension + respiratory depression

A useful sequence is:

Central α₂ stimulation → ↓ sympathetic outflow → sedation + bradycardia + hypotension + hypoventilation

A distinctive additional feature is:

Early transient hypertension → later bradycardia/hypotension

because high clonidine concentrations can initially stimulate peripheral vascular α₂ receptors.

The main treatment is:

Supportive airway/ventilatory care + hemodynamic support

Naloxone is not a specific antidote, but modern pediatric evidence supports a trial—sometimes using substantially higher doses than standard opioid reversal doses—in significant CNS/respiratory depression.

Current Forms

Immediate-release tablets

Current U.S. clonidine hydrochloride tablets are available as:

• 0.1 mg
• 0.2 mg
• 0.3 mg

and remain indicated for hypertension. Current labeling notes commonly used therapeutic doses around 0.2–0.6 mg/day, with 2.4 mg/day described as the maximum effective daily dose, although such high doses are rarely used. (DailyMed⁠)

Extended-release clonidine

Extended-release clonidine is currently used for:

Attention-deficit/hyperactivity disorder (ADHD)

either:

• As monotherapy
• Or with stimulant medication

Current labeling establishes efficacy in children/adolescents:

6–17 years

and uses 0.1-mg extended-release tablets titrated gradually. (DailyMed⁠)

This is an important modernization because pediatric clonidine exposure now commonly occurs from medications prescribed directly to children for ADHD or behavioral disorders rather than solely from a grandparent’s antihypertensive medication. Pediatric poison-center data have shown increasing exposure over time. (PubMed⁠)

Transdermal Clonidine

Current Catapres-TTS systems deliver:

• 0.1 mg/day
• 0.2 mg/day
• 0.3 mg/day

for approximately 7 days. (DailyMed⁠)

Crucial toxicology point

The amount inside the patch is far greater than the nominal daily dose.

Current 2026 Catapres-TTS systems contain approximately:

• 0.1-mg/day patch → 3.09 mg total clonidine
• 0.2-mg/day patch → 6.19 mg
• 0.3-mg/day patch → 9.28 mg

(DailyMed⁠)

Therefore:

A swallowed or chewed clonidine patch is a potentially major overdose.

Even after normal use, a patch can still contain clinically important active drug. Current labeling specifically warns that used patches remain dangerous to infants and children and should be folded adhesive-side-to-adhesive-side and discarded securely. (DailyMed⁠)

Current Uses

Clonidine is currently used for:

• Hypertension
• ADHD
• Selected withdrawal syndromes
• Other specialist/off-label indications

Off-label uses may include:

• Opioid withdrawal
• Tic disorders
• Sleep-related/behavioral indications
• Selected autonomic hyperactivity syndromes

The old chapter’s emphasis on migraine, menopausal flushing, and dysmenorrhea is much less relevant to contemporary exposure patterns.

Toxic Dose

There is:

No single reliable toxic dose.

Children can develop significant toxicity from very small absolute quantities.

Current labeling still notes that:

As little as 0.1 mg has produced toxicity in a child. (DailyMed⁠)

A prospective poison-center study of children <12 years found:

• No coma, respiratory depression, or hypotension among reported ingestions <0.3 mg
• The lowest reported dose producing coma and respiratory depression was 0.3 mg ≈ 15 μg/kg

(PubMed⁠)

A more recent pediatric series found:

• No moderate/severe bradycardia or hypotension below 5 μg/kg
• Some severe hemodynamic effects occurred between 5–10 μg/kg

(PubMed⁠)

Important

These are observational risk ranges—not guaranteed safe cutoffs.

Dose histories after accidental ingestion are often inaccurate.

Thus:

A single 0.1-mg tablet can be clinically important in a small child.

Adults

Adults have survived extremely large overdoses.

Current labeling describes survival after ingestion of:

100 mg

with:

• Initial hypertension
• Subsequent hypotension
• Bradycardia
• Apnea
• Semicoma
• Ventricular ectopy

after intensive supportive treatment. (DailyMed⁠)

Therefore:

Dose alone does not reliably predict mortality.

Pathophysiology

Central α₂-Adrenergic Receptor Agonism

Clonidine stimulates α₂ receptors in the:

• Brainstem
• Medulla

producing:

↓ central sympathetic outflow

which results in:

• ↓ Heart rate
• ↓ Peripheral vascular resistance
• ↓ Blood pressure
• ↓ Sympathetic tone
• Sedation

Current labeling describes clonidine as reducing sympathetic outflow and thereby decreasing peripheral resistance, renal vascular resistance, heart rate, and blood pressure. (DailyMed⁠)

Imidazoline Effects

Clonidine is an imidazoline derivative, and stimulation of central imidazoline receptors probably also contributes to its hypotensive and sedative effects.

This helps explain why structurally related agents such as:

• Tetrahydrozoline
• Naphazoline
• Oxymetazoline

can produce clonidine-like poisoning when ingested.

Why Initial Hypertension Occurs

At high concentrations, clonidine can stimulate peripheral vascular α₂ receptors.

Therefore the early sequence may be:

Peripheral vasoconstriction → transient hypertension

followed by:

Dominant central sympatholysis → bradycardia + hypotension

Current labeling specifically describes:

Early hypertension followed by hypotension and bradycardia. (DailyMed⁠)

Why Naloxone Sometimes Works

The mechanism is uncertain.

Proposed explanations include clonidine-associated:

• Release of endogenous opioids
• Interaction with endogenous endorphin/enkephalin pathways
• Secondary modulation of opioid receptors

This is not established as the principal mechanism of clonidine toxicity.

It nevertheless provides a biologic rationale for the observation that some patients—particularly children—wake dramatically after naloxone. (PubMed Central (PMC)⁠)

Pharmacokinetics

Immediate-release oral clonidine has approximately:

70–80% bioavailability

with peak plasma concentrations generally within:

1–3 hours.

Its elimination half-life is approximately:

12–16 hours

in normal renal function. (DailyMed⁠)

Renal Impairment

Approximately:

40–60% of absorbed clonidine may be recovered unchanged in urine

within 24 hours.

In severe renal impairment, the half-life can increase to approximately:

41 hours

(DailyMed⁠)

Therefore:

Renal impairment can meaningfully prolong clonidine toxicity.

Clinical Features

Classic Toxidrome

The most characteristic findings are:

Sleepy + slow + small pupils

Specifically:

• CNS depression
• Miosis
• Bradycardia
• Hypotension
• Respiratory depression
• Hypothermia

This can closely resemble opioid poisoning.

Neurologic

Possible manifestations include:

• Drowsiness
• Lethargy
• Somnolence
• Ataxia
• Hypotonia
• Hyporeflexia
• Confusion
• Stupor
• Coma

CNS depression is particularly prominent in children.

Current labeling notes that CNS depression appears more frequently in children than adults. (DailyMed⁠)

Pupils

Miosis is common

and reinforces the similarity to opioid toxicity.

However:

• Miosis is not universal
• Normal pupils do not exclude clonidine
• Pinpoint pupils do not prove an opioid exposure

Respiratory

Clonidine can cause:

• Bradypnea
• Shallow ventilation
• Hypoventilation
• Apnea

Respiratory depression is generally less profound than after a major potent-opioid overdose, but severe pediatric exposures can require mechanical ventilation.

Patients may appear more responsive during physical stimulation and then drift back into hypoventilation when left undisturbed.

Important

Do not rely on repeatedly stimulating the patient as respiratory treatment.

Use objective assessment:

• Respiratory rate
• Capnography when available
• Blood gas when appropriate
• Oxygenation
• Airway reflexes

and ventilate when necessary.

Cardiovascular

Bradycardia

Sinus bradycardia is extremely common.

Adult overdose data found bradycardia in approximately:

76%

with:

• Median onset ~2.5 hours
• Median duration ~20 hours
• Reported duration as long as ~83 hours

(PubMed⁠)

Importantly:

Bradycardia alone is often well tolerated.

Do not treat the monitor simply because the heart rate is low.

Treat if there is:

• Hypotension
• Altered perfusion
• Ischemia
• Syncope
• Shock

Hypotension

Hypotension may result from:

• Central sympatholysis
• Bradycardia
• Reduced vascular resistance

In a large adult overdose series, hypotension occurred in approximately:

24%

and was generally not profound. (PubMed⁠)

Severe shock is possible but uncommon in isolated adult clonidine poisoning.

Initial Hypertension

High-dose exposure may cause early:

Transient hypertension

Current adult data documented early hypertension particularly after large ingestions around 8–12 mg. (PubMed⁠)

It usually precedes the later sympatholytic phase.

Therefore:

Do not reflexively treat early hypertension with a long-acting antihypertensive.

Doing so may worsen the subsequent hypotensive phase.

Conduction Abnormalities

Large overdoses may occasionally produce:

• Sinus-node dysfunction
• Junctional rhythm
• AV block
• Other reversible conduction abnormalities

Serious malignant dysrhythmias are far less characteristic than profound bradycardia.

Hypothermia

Hypothermia may occur because of:

• CNS depression
• Reduced sympathetic activity
• Environmental exposure during prolonged sedation

Use passive/active rewarming according to severity.

Seizures

Seizures are:

Uncommon

and should prompt consideration of:

• Severe poisoning
• Hypoxia
• Coingestion
• Alternative diagnosis

Differential Diagnosis

The most important mimic is:

Opioid poisoning

because both may cause:

• CNS depression
• Miosis
• Respiratory depression

However, clonidine often produces more marked:

Bradycardia

and naloxone response is much less predictable.

Other α₂ / Imidazoline Toxicants

Consider:

• Guanfacine
• Tizanidine
• Dexmedetomidine
• Brimonidine
• Tetrahydrozoline
• Oxymetazoline
• Naphazoline
• Xylazine

Many can produce variations of:

CNS depression + bradycardia + hypotension + miosis

Other Differential Diagnoses

Also consider:

• Benzodiazepines
• Barbiturates
• Baclofen
• Ethanol
• GHB
• Antipsychotics
• β-blockers
• Calcium-channel blockers

and medical causes such as:

• Hypoglycemia
• Hypoxia
• Sepsis
• Hypothyroidism
• Stroke
• Intracranial hemorrhage
• Postictal state

Diagnosis

Diagnosis is primarily:

Clinical

based on:

Exposure history + characteristic sympatholytic/opioid-like syndrome

There is no routinely available bedside clonidine assay required for management.

Clonidine Serum Levels

Serum/plasma clonidine concentrations can be measured by specialized laboratories but are:

• Rarely rapidly available
• Not necessary for routine management
• Poorly suited to emergency decision-making

Therefore:

Treat the patient rather than a clonidine level.

Routine Drug Screens

Standard hospital urine toxicology screens generally:

Do not test specifically for clonidine.

A negative “drug screen” does not exclude clonidine poisoning.

Initial Investigations

Mild known exposure

A completely asymptomatic patient may require little testing beyond clinical observation.

Symptomatic patient

Obtain:

• Bedside glucose
• ECG
• Continuous cardiac monitoring

Consider:

• Electrolytes
• Bicarbonate
• BUN
• Creatinine

particularly with:

• Hypotension
• Significant bradycardia
• Altered consciousness
• Renal disease

Respiratory Assessment

For CNS or respiratory depression consider:

• Continuous pulse oximetry
• Capnography
• Venous/arterial blood gas if significant hypoventilation

Important

A patient receiving oxygen can maintain a normal SpO₂ despite significant CO₂ retention.

Capnography can therefore be more sensitive for evolving hypoventilation.

Intentional Overdose

Also consider:

• Acetaminophen concentration
• Salicylate concentration
• Pregnancy testing when clinically appropriate
• Additional testing guided by coingestants

Treatment

1. Airway and Ventilation

The cornerstone is:

Supportive care

Assess:

• Mental status
• Respiratory rate
• Airway reflexes
• Ventilation

Provide:

• Oxygen if hypoxemic
• Bag-mask ventilation if needed

Intubate for:

• Persistent apnea
• Severe hypoventilation
• Inability to protect airway
• Refractory coma

However, because naloxone can occasionally rapidly reverse clonidine-associated somnolence—particularly in children—a prompt naloxone trial can sometimes avoid unnecessary intubation provided ventilation is being safely maintained while it is given.

Do not delay airway support in a truly unstable patient.

Naloxone

Is Naloxone an Antidote?

Not reliably.

Clonidine’s primary mechanism is α₂ agonism, not opioid-receptor agonism.

Nevertheless:

Naloxone may reverse clonidine-induced CNS depression in some patients.

Current clonidine labeling continues to describe naloxone as a potentially useful adjunct for:

• Respiratory depression
• Hypotension
• Coma

while warning that paradoxical hypertension has occasionally occurred. (DailyMed⁠)

Pediatric High-Dose Naloxone Evidence

Older studies often concluded that naloxone was ineffective, but most used:

≤2 mg

which may be an inadequate trial.

A later pediatric cohort of 52 exposures found:

• 51 were somnolent
• Naloxone awakened 40/51
• Recurrent sedation in some responded to repeat naloxone
• 20 somnolent/bradycardic patients received 10 mg IV naloxone
• 13/20 awoke
• Hypotension resolved in 7/11
• No adverse events occurred even among patients receiving 10 mg

(PubMed⁠)

A 2025 poison-center review therefore recommends considering high-dose naloxone in significant clonidine-induced CNS depression. (Utah Poison Control⁠)

Practical Naloxone Approach

There is no universally validated regimen.

One contemporary poison-center approach uses:

Naloxone 0.1 mg/kg IV, maximum 2 mg per dose

repeated every:

1–2 minutes

with escalation toward a cumulative dose of approximately:

10 mg

if the clinical situation warrants it. (Utah Poison Control⁠)

Some pediatric patients in the published series received a:

10-mg IV bolus

without reported adverse events. (PubMed⁠)

Important

High-dose therapy is best supported in:

Children with significant pure clonidine toxicity who are opioid-naïve.

Consult a poison center/medical toxicologist when escalating to high-dose therapy.

Adults and Naloxone

Evidence is weaker.

In a series of 108 adult clonidine overdoses:

• 23 received naloxone
• Median total dose was only about 2 mg
• Only one had documented partial improvement in consciousness

(PubMed⁠)

This does not prove that higher doses cannot work in adults, but it reinforces that:

Naloxone response is inconsistent.

Do not repeatedly delay definitive airway management waiting for naloxone to work.

Opioid Dependence / Coingestion

If a patient is chronically opioid-dependent or has an opioid coingestion:

High-dose naloxone may precipitate acute withdrawal.

Therefore titrate according to:

• Ventilation
• Clinical context
• Likelihood of opioid dependence

Naloxone Endpoint

The goal is:

Improved ventilation and clinically useful arousal

not necessarily complete wakefulness.

Persistent isolated bradycardia after the patient wakes is common and usually does not require further naloxone merely to normalize the heart rate.

The pediatric naloxone series specifically found patients who became awake despite persistent bradycardia. (PubMed⁠)

Bradycardia

Most clonidine-associated bradycardia is:

Benign if perfusion and blood pressure are adequate.

Do not automatically treat an asymptomatic heart rate of 40–50/min in an otherwise perfusing adult.

Atropine

Use atropine for:

Clinically important bradycardia with hypotension or poor perfusion.

A contemporary adult ACLS regimen is:

Atropine 1 mg IV every 3–5 minutes

to a maximum of:

3 mg

if appropriate.

Pediatric therapy follows current PALS weight-based dosing.

Important limitation

The effect of atropine may be:

• Incomplete
• Transient

Recent pediatric data found only transient improvement in some patients given atropine. (PubMed⁠)

Pacing

Temporary pacing is:

Rarely required

because the bradycardia usually reflects central sympatholysis rather than irreversible conduction-system failure.

Consider pacing only for:

• Severe refractory symptomatic bradycardia
• High-grade AV block
• Persistent hemodynamic instability

after standard supportive therapies have failed.

Hypotension

First-line

Treat with:

Isotonic IV crystalloid

when clinically volume responsive.

Avoid unnecessary large fluid volumes simply because the blood pressure is mildly low.

Vasopressors

For persistent shock despite appropriate fluids:

Vasopressor therapy is appropriate.

There is no strong evidence establishing one uniquely superior agent for clonidine overdose.

A contemporary physiology-based approach is:

• Norepinephrine for persistent vasodilatory hypotension
• Epinephrine may be useful when substantial bradycardia/low cardiac output accompanies shock

The older rule that dopamine is the preferred clonidine vasopressor should not be treated as a modern standard.

Hypertension

Early clonidine-associated hypertension is often:

Transient

and frequently resolves as central sympatholytic effects predominate.

Therefore:

Do not treat an isolated transient elevated blood pressure unless there is severe hypertension with evidence of end-organ injury.

If therapy is genuinely required:

• Use a short-acting
• Titrated IV antihypertensive

under critical-care/toxicology guidance.

Avoid long-acting treatment because profound hypotension may follow.

Seizures

Treat toxin-induced seizures with:

Benzodiazepines first-line

Examples:

• Midazolam
• Lorazepam
• Diazepam

Refractory seizures:

• Phenobarbital
• Propofol in an intubated patient

Also correct:

• Hypoxia
• Hypoglycemia
• Electrolyte abnormalities

Gastrointestinal Decontamination

Do Not Induce Vomiting

Do not use ipecac or induced emesis.

CNS depression can develop rapidly.

Current labeling specifically advises against ipecac because of the rapid onset of CNS depression. (DailyMed⁠)

Activated Charcoal

Single-dose activated charcoal may be considered after a:

• Recent
• Potentially significant

tablet ingestion if:

• The patient is fully alert with intact airway reflexes

or:

• The airway has been protected

A typical poisoning dose is approximately:

1 g/kg, usually maximum ~50 g

in routine practice.

Critical point

Do not give charcoal to a progressively somnolent child with an unprotected airway.

The benefit of decontamination is secondary to airway safety.

Gastric Lavage

The current drug label still mentions gastric lavage after recent major ingestion, but modern toxicology practice has moved away from routine lavage.

Therefore:

Routine gastric lavage is not recommended.

It should only rarely be contemplated after an exceptionally large, immediately life-threatening, very recent ingestion with:

• Protected airway
• Appropriate expertise
• Poison-center/toxicology input

Extended-Release Tablets

Because extended-release clonidine is now widely used for ADHD, formulation matters.

Large intentional ER ingestions may:

• Delay absorption
• Prolong the clinical course

A patient with a major ER ingestion warrants longer monitoring than a patient with a reliably tiny immediate-release exposure.

Whole-bowel irrigation is not routine, but could occasionally be considered after a very large modified-release ingestion in an appropriate, stable patient because toxicology position statements allow selected use after potentially toxic sustained-release drug ingestions. (PubMed⁠)

Transdermal Exposure

If toxicity develops while patches are being worn:

Remove every clonidine patch immediately.

Current labeling notes that after patch removal:

• Plasma clonidine persists for approximately 8 hours
• Concentrations then decline slowly over several days

(DailyMed⁠)

Thus:

Removing the patch does not immediately terminate toxicity.

Patch Ingestion

This deserves special attention because the patch reservoir can contain milligram quantities of clonidine.

Current Catapres-TTS patches contain up to:

9.28 mg clonidine

in the largest system. (DailyMed⁠)

A patch that is:

• Chewed
• Sucked
• Swallowed

can therefore produce major toxicity.

Whole-Bowel Irrigation After Patch Ingestion

The current Catapres-TTS label states that:

Whole-bowel irrigation may be considered after patch ingestion. (DailyMed⁠)

However, modern WBI guidance emphasizes that:

WBI should not be performed routinely in poisoned patients.

Evidence that it improves outcomes is limited, and it is contraindicated with:

• Ileus
• Obstruction
• GI perforation
• Hemodynamic instability
• Unprotected airway

(PubMed⁠)

Therefore:

Known clonidine-patch ingestion → early poison-center/medical-toxicology consultation.

WBI is a selective option, not an automatic intervention.

Endoscopic Patch Removal

A 2025 toxicology case report described successful:

Upper-endoscopic removal of an intact clonidine patch from the stomach

approximately 5 hours after ingestion, potentially avoiding prolonged exposure and extended WBI. (Taylor & Francis Online⁠)

This is an emerging case-based strategy, not established routine therapy.

It may be considered when:

• A dangerous intact patch is known to be in the stomach
• Presentation is sufficiently early
• Endoscopy can be performed safely

after multidisciplinary toxicology/GI discussion.

Antidote

There is no proven specific antidote for clonidine poisoning.

Naloxone is best regarded as:

A potentially useful adjunct

rather than a definitive antidote. (DailyMed⁠)

Enhanced Elimination

Hemodialysis

Clonidine is:

Poorly removed by hemodialysis.

Current labeling states that only a minimal amount is removed during routine dialysis and that dialysis is unlikely to significantly enhance elimination. (DailyMed⁠)

Therefore:

Do not dialyze a patient merely to remove clonidine.

Dialysis should be used only for an unrelated conventional indication.

Multiple-Dose Activated Charcoal

There is no established role for:

Multiple-dose activated charcoal

for enhanced clonidine elimination.

Urinary Alkalinization / Forced Diuresis

There is no useful role for:

• Urinary alkalinization
• Forced diuresis

in clonidine poisoning.

Time Course

Immediate-release tablets

Current labeling states that overdose manifestations generally begin within:

30 minutes–2 hours

(DailyMed⁠)

Adult data found median onset of bradycardia somewhat later, approximately:

2.5 hours

with some patients developing it beyond 5 hours. (PubMed⁠)

Duration

Symptoms can be prolonged because clonidine’s elimination half-life is relatively long.

Adult bradycardia lasted a median of approximately:

20 hours

and occasionally persisted much longer. (PubMed⁠)

Severe overdose may therefore produce:

• Sedation
• Bradycardia
• Hypotension

for >24 hours.

Renal impairment can prolong toxicity even further.

Patch Exposure

Patch-related toxicity may have:

• Delayed absorption
• Prolonged absorption
• Prolonged symptoms

and after removal, circulating clonidine can persist for hours followed by a gradual decline over several days. (DailyMed⁠)

Observation

The old universal:

“4–6 hours then discharge”

rule requires nuance.

Immediate-release exposure

For a reliably small immediate-release ingestion, a patient who remains:

• Completely asymptomatic
• Normal mental status
• Normal respiratory status
• Hemodynamically stable
• Normal/reassuring ECG

through approximately 4–6 hours is unlikely to develop major delayed toxicity.

Older pediatric data found no subsequent deterioration more than 4 hours after presentation in children who had remained stable. (PubMed⁠)

Longer Observation Is Appropriate For

• Extended-release clonidine
• Patch ingestion
• Unknown dose
• Large intentional ingestion
• Renal impairment
• Coingestants
• Any symptoms

Therefore:

Disposition should be formulation- and symptom-specific rather than based on a single clock time.

Admission

Hospital admission is appropriate for:

• Persistent CNS depression
• Recurrent naloxone requirement
• Respiratory depression
• Apnea
• Hypotension
• Symptomatic bradycardia
• Significant conduction abnormality
• Large intentional overdose
• Significant ER exposure
• Patch ingestion

ICU

ICU-level care is appropriate for:

• Intubation/mechanical ventilation
• Recurrent apnea
• Severe coma
• Shock requiring vasopressors
• Clinically important conduction disturbance
• Severe coingestant toxicity

Important modernization

Not every patient with:

• Mild isolated bradycardia
• Mild somnolence

requires ICU admission.

Recent pediatric series show that many abnormalities are mild despite being common. (PubMed⁠)

Discharge

Discharge should require:

• Normal/baseline mental status
• Normal ventilation
• Stable blood pressure
• Clinically acceptable heart rate/perfusion
• No recurrent sedation
• No ongoing naloxone requirement
• Adequate observation for the specific formulation

Persistent mild bradycardia may not itself require hospitalization if:

• Patient is asymptomatic
• Perfusion is normal
• Other toxicity has resolved

Intentional overdose requires appropriate psychiatric/safety assessment.

Clonidine Withdrawal

An important issue not emphasized enough in older overdose chapters is:

Abrupt clonidine withdrawal can cause severe rebound sympathetic activity.

Symptoms may include:

• Anxiety
• Agitation
• Tremor
• Headache
• Tachycardia
• Severe rebound hypertension

Rare severe complications include:

• Hypertensive encephalopathy
• Cerebrovascular events
• Death

Current labeling specifically warns against abrupt cessation. (DailyMed⁠)

Why This Matters in Toxicology

After a patient with chronic clonidine use recovers from an overdose, clonidine therapy should not necessarily be withheld indefinitely without a plan.

When clinically safe:

Restart/taper decisions should account for withdrawal risk.

Otherwise the patient can transition from:

Clonidine toxicity → clonidine withdrawal hypertension

Pregnancy

The old FDA Pregnancy Category C system is obsolete.

Current extended-release labeling states that several decades of published human experience have not identified a clonidine-associated increased risk of major congenital malformations, miscarriage, or other major adverse maternal/fetal outcomes. (DailyMed⁠)

In overdose:

Maternal airway, ventilation, perfusion, and blood pressure take priority.

Clonidine crosses the placenta, so significant maternal poisoning may also affect the fetus.

Breastfeeding

Clonidine is present in human milk.

Current extended-release labeling reports a relative infant dose around:

4.1–8.4% of the maternal weight-adjusted dose.

Most reported infants have had no adverse effects, but there is a case report of:

• Sedation
• Hypotonia
• Apnea

in an exposed infant. (DailyMed⁠)

Breastfed infants exposed to maternal clonidine should therefore be monitored for:

• Excess sedation
• Lethargy
• Poor feeding
• Hypotonia
• Respiratory depression
• Bradycardia/hypotension

Prognosis

Most patients recover fully with supportive care.

A large adult series of 108 acute overdoses reported:

• Frequent CNS depression
• Bradycardia in 76%
• Hypotension in 24%
• No deaths
• No significant malignant dysrhythmias

(PubMed⁠)

Serious morbidity is more likely from:

• Respiratory failure
• Prolonged hypoxia
• Large pediatric exposure
• Patch ingestion
• Coingestants

than from the bradycardia itself.

Prevention

Clonidine deserves particular caution in households with children.

Tablets

Store:

• Locked
• Out of sight/reach
• In child-resistant containers

A single 0.1-mg tablet can cause symptoms in a small child. (DailyMed⁠)

Patches

Both:

Used AND unused patches remain dangerous.

Current instructions state that after use, patches should be:

Folded in half with sticky sides together

and discarded carefully out of children’s reach. (DailyMed⁠)

Never assume a “used” patch is pharmacologically empty.

Important Pitfalls

1. Mistaking clonidine poisoning for opioid overdose

Both may produce:

Coma + miosis + respiratory depression

but clonidine typically also produces:

Marked bradycardia

A negative opioid screen does not exclude an opioid, and a positive response to naloxone does not prove an opioid was taken.

2. Using lack of response to 2 mg naloxone to rule out clonidine responsiveness

Older studies often used relatively small naloxone doses.

Pediatric evidence suggests some patients respond only after:

Much larger naloxone exposure, up to approximately 10 mg

(PubMed⁠)

3. Calling naloxone a reliable antidote

Response remains inconsistent.

Supportive care remains definitive treatment.

4. Intubating every sleepy child before considering naloxone

If:

• Ventilation is adequate
• Airway can be safely supported

a prompt naloxone trial—potentially high-dose with poison-center guidance—may occasionally avoid unnecessary intubation. (PubMed⁠)

Do not delay intubation when ventilation is genuinely inadequate.

5. Treating every bradycardic patient

Clonidine-associated bradycardia is often:

Hemodynamically benign.

Treat the:

• Perfusion
• Blood pressure
• Symptoms

not merely the heart-rate number.

6. Assuming atropine will normalize the heart rate permanently

Atropine may provide only:

Transient or incomplete improvement.

(PubMed⁠)

7. Treating transient early hypertension too aggressively

High-dose clonidine can cause:

Hypertension first → hypotension later

Long-acting antihypertensive therapy during the first phase may worsen subsequent shock.

8. Using dopamine automatically

The historical dopamine-first recommendation is outdated.

Use contemporary physiology-driven vasopressor selection.

9. Performing routine gastric lavage

Modern poisoning management does not support routine lavage.

Airway protection and supportive care are much more important.

10. Giving charcoal to a somnolent child

Clonidine can cause rapid CNS depression.

Unprotected airway → no charcoal.

11. Applying the same observation period to IR, ER, and patches

These formulations have different absorption patterns.

Patch and extended-release exposures can require:

Longer observation

than an uncomplicated small immediate-release ingestion.

12. Underestimating patch ingestion

The current largest Catapres-TTS system contains approximately:

9.28 mg clonidine

despite delivering only 0.3 mg/day therapeutically. (DailyMed⁠)

13. Assuming a used patch is safe

It still contains active medication and can poison a child. (DailyMed⁠)

14. Automatically performing whole-bowel irrigation for patch ingestion

WBI may be considered, but:

It is not routine and has no proven outcome benefit.

Use specialist consultation and assess airway/GI contraindications. (PubMed⁠)

15. Forgetting endoscopic retrieval as a possible selected option

A recent case demonstrated successful removal of an intact gastric clonidine patch by upper endoscopy.

This is:

Promising but case-based—not established standard therapy. (Taylor & Francis Online⁠)

16. Dialyzing for toxin removal

Clonidine is poorly cleared by dialysis.

Hemodialysis is not an effective enhanced-elimination strategy.

(DailyMed⁠)

17. Forgetting renal impairment

Severe renal impairment can extend clonidine’s half-life from approximately:

12–16 h → up to ~41 h

(DailyMed⁠)

so prolonged toxicity is more plausible.

18. Forgetting clonidine withdrawal

Abrupt discontinuation after chronic use can cause:

Rebound hypertension + sympathetic hyperactivity

and can itself become dangerous. (DailyMed⁠)

High-Yield Toxicology Pearls

Clonidine = opioid-like toxidrome + bradycardia

Think:

Sleepy + pinpoint pupils + slow pulse

Key points:

• Clonidine is a:
• Central α₂ agonist
• Imidazoline derivative
• Central mechanism:
• ↓ sympathetic outflow
• Classic overdose:
• CNS depression
• Miosis
• Bradycardia
• Hypotension
• Respiratory depression
• Hypothermia
• Early transient hypertension can occur from peripheral α₂ stimulation
• Current formulations include:
• IR tablets 0.1, 0.2, 0.3 mg
• ER clonidine for ADHD
• Transdermal 0.1, 0.2, 0.3 mg/day
• A single:
• 0.1-mg tablet
• can produce symptoms in a small child
• Recent pediatric data suggest:
• <5 μg/kg carries relatively low risk of major hemodynamic toxicity
• But this is not an absolute safe threshold
• Immediate-release symptoms usually begin:
• 30 min–2 h
• Adult bradycardia:
• Median onset ~2.5 h
• Median duration ~20 h
• Main treatment:
• Supportive care
• Airway/ventilation first
• Naloxone:
• Not a specific antidote
• May reverse clonidine CNS depression
• Pediatric data support high-dose trials in selected cases
• Contemporary poison-center approach:
• ~0.1 mg/kg naloxone, max 2 mg/dose
• Repeat rapidly
• Consider escalation to ~10 mg total/high-dose trial with specialist guidance
• Do not delay intubation for refractory apnea/hypoventilation
• Isolated bradycardia often:
• Does not require treatment
• Symptomatic bradycardia:
• Atropine
• Response may be transient
• Hypotension:
• Fluids if appropriate
• Vasopressor if persistent
• Norepinephrine/epinephrine selected by physiology
• Do not automatically use dopamine
• Early hypertension:
• Usually transient
• Avoid long-acting antihypertensives
• No ipecac
• Routine gastric lavage is obsolete
• Single-dose charcoal:
• Selected early significant ingestion only
• Only with intact/protected airway
• Patch ingestion is especially dangerous:
• Current patches contain 3.09–9.28 mg total clonidine
• Patch ingestion:
• WBI may be considered selectively
• Early endoscopic retrieval is an emerging case-based option
• Dermal patch toxicity:
• Remove every patch
• Levels can persist ~8 h and decline over several days
• Used patches still contain active clonidine
• Hemodialysis:
• Poorly effective for removal
• Severe renal failure:
• Half-life may increase to ~41 h
• Abrupt cessation after chronic therapy:
• Rebound hypertension
• Pregnancy category letters are obsolete
• Current human pregnancy data have not identified a consistent major congenital-malformation signal
• Clonidine enters breast milk; monitor exposed infants for:
• Sedation
• Hypotonia
• Poor feeding
• Apnea
• With adequate airway and cardiovascular support:
• Prognosis is generally excellent

I can continue the next chapter in the same modernized toxicology-reference format.

Toxicology – Ciguatera Fish Poisoning

Core concept

Ciguatera poisoning is a marine neurotoxin syndrome caused primarily by ingestion of seafood containing ciguatoxins (CTXs).

The classic presentation is:

Reef-fish meal → acute gastroenteritis → paresthesias/cold allodynia ± bradycardia/hypotension

The most characteristic neurologic clue is:

Painful or abnormal sensation from cold objects/water

often historically called “hot–cold reversal.”

The major severe complications are:

Profound bradycardia + hypotension + neuromuscular/respiratory weakness

There is:

No proven specific antidote

and modern treatment is principally supportive and symptom-directed. (CDC)

Terminology

“Ciguatera fish poisoning” remains commonly used, but FDA now increasingly uses:

Ciguatera poisoning (CP)

because ciguatoxins can occasionally accumulate in seafood other than finfish, including some:

• Giant clams
• Gastropods
• Lobsters
• Other marine organisms

although fish remain by far the most important human source. (U.S. Food and Drug Administration)

Source of the Toxin

The older description attributing ciguatera simply to:

Gambierdiscus toxicus

is now incomplete.

Ciguatoxins originate from several benthic dinoflagellates belonging mainly to:

• Gambierdiscus
• Fukuyoa

These microorganisms live on:

• Macroalgae
• Turf algae
• Dead coral
• Other reef substrates

Herbivorous fish and invertebrates ingest the dinoflagellates, introducing toxin into the marine food web.

Predatory fish subsequently consume contaminated organisms and accumulate ciguatoxins in their tissues. Modern ecological work demonstrates substantial species-to-species variation in CTX production within Gambierdiscus/Fukuyoa, so the mere presence or abundance of these dinoflagellates does not reliably predict local poisoning risk. (PubMed Central (PMC))

A simplified pathway is:

Gambierdiscus/Fukuyoa → grazing fish/invertebrates → larger reef fish → human ingestion → ciguatera

Ciguatoxin Is the Main Human Toxin

This is an important modernization.

The older chapter attributes human ciguatera to:

• Ciguatoxin
• Maitotoxin
• Scaritoxin

Modern evidence indicates:

Ciguatoxins are the established principal toxins responsible for human ciguatera.

Maitotoxins are produced by some Gambierdiscus species, but:

• They are water-soluble
• Have relatively poor oral absorption
• Do not significantly accumulate through the fish food chain in the same manner
• Have no proven role in ordinary human ciguatera poisoning

Despite their enormous potency when injected experimentally, their relevance to human foodborne ciguatera remains unproven. (PubMed Central (PMC))

“Scaritoxin” is principally of historical interest and should not be presented as a major established clinical toxin alongside CTX.

Ciguatoxins

CTXs are:

• Lipid-soluble
• Polycyclic polyether neurotoxins
• Extremely potent
• Heat stable
• Acid stable

Different geographic families occur, including:

• Pacific CTXs
• Caribbean/Atlantic CTXs
• Indian Ocean CTXs

Their clinical syndromes overlap, although the relative prominence of GI and neurologic findings varies geographically. (PubMed Central (PMC))

Pathophysiology

Voltage-Gated Sodium Channels

The principal molecular effect is:

Persistent activation of voltage-gated sodium channels

CTXs bind to sodium channels and shift their activation toward more negative membrane potentials.

The result is:

Na⁺ influx → neuronal depolarization → spontaneous/repetitive firing → abnormal sensory nerve activity

This produces:

• Paresthesias
• Dysesthesias
• Cold allodynia
• Neuropathic pain
• Autonomic abnormalities

Cellular sodium entry also promotes:

Water influx → neuronal swelling

which historically provided the theoretical rationale for mannitol therapy.

Autonomic Effects

CTXs can disrupt autonomic nervous-system activity.

Clinically this may produce:

• Bradycardia
• Hypotension
• GI hypermotility
• Salivation
• Sweating

A 2024 systematic review of reported ciguatera cardiotoxicity found that among documented cardiac cases:

• Hypotension occurred in approximately 75%
• Bradycardia in approximately 68%
• Sinus bradycardia was the most frequent ECG abnormality
• AV block also occurred

Supportive care generally produced favorable outcomes. (PubMed)

Geographic Distribution

Ciguatera occurs predominantly in tropical and subtropical marine regions, particularly:

• Caribbean
• Gulf of Mexico
• Florida
• Hawaiʻi
• Pacific islands
• Indian Ocean
• Parts of Southeast Asia
• Northern Australia

FDA describes major risk areas approximately between:

35°N and 35°S

although contaminated seafood is now transported globally, so patients can present far from endemic reefs. (U.S. Food and Drug Administration)

Ciguatera distribution also appears to be changing with:

• Ocean warming
• Coral-reef disturbance
• Storms
• Changes in reef ecology
• Global seafood trade

but local risk remains highly variable and difficult to predict. (PubMed Central (PMC))

Fish Associated With Ciguatera

Commonly implicated fish include:

• Barracuda
• Moray eel
• Grouper
• Snapper
• Amberjack
• Jacks/trevally
• King mackerel
• Spanish mackerel
• Sea bass
• Surgeonfish
• Parrotfish
• Wrasse

FDA has also identified ciguatoxins in lionfish from some regions. (U.S. Food and Drug Administration)

Large Predatory Fish

Larger predatory reef fish frequently represent greater risk because of cumulative dietary exposure.

However:

Fish size alone cannot reliably determine whether a fish is toxic.

Modern studies show substantial variability between:

• Species
• Locations
• Individual fish
• Feeding ecology

so the old rule that fish above a particular weight are necessarily toxic is too simplistic. (PubMed Central (PMC))

For prevention, however, CDC still advises travelers to avoid very large reef fish, particularly those:

>5 lb

and especially:

• Barracuda
• Moray eel. (CDC)

The older 3-lb cutoff should therefore not be treated as a scientific toxicity threshold.

High-Risk Fish Parts

CTX concentrations can be particularly high in:

• Liver
• Intestines/viscera
• Head
• Roe

Therefore:

Avoid viscera, head, and roe of reef fish from ciguatera-risk regions.

(CDC)

Cooking Does NOT Protect You

Ciguatoxins are not reliably destroyed by:

• Cooking
• Frying
• Boiling
• Grilling
• Smoking
• Freezing
• Canning
• Pickling
• Salting

The contaminated fish generally:

Looks normal + smells normal + tastes normal.

(CDC)

Therefore:

Proper cooking does not prevent ciguatera.

Toxic Dose

There is no clinically useful human dose threshold.

Illness depends on:

CTX concentration in fish × amount consumed × individual susceptibility

People eating the same fish can develop different illness severity.

A larger serving tends to increase risk, but:

• Small portions can cause significant toxicity
• Not all portions of a contaminated fish have identical toxin concentrations

Onset

Symptoms often begin:

Within approximately 1–6 hours

although onset can be delayed as long as approximately:

30 hours

after eating the implicated seafood. (CDC)

Neurologic manifestations may occasionally appear later, including up to approximately:

96 hours. (CDC)

Geographic Variation in Presentation

CDC notes a useful regional pattern:

Caribbean-type ciguatera

Often:

GI symptoms first → neurologic symptoms later

Pacific-type ciguatera

Neurologic findings may:

• Predominate early
• Occur before GI symptoms
• Occur with relatively modest GI illness

(CDC)

Therefore:

Absence of prominent vomiting/diarrhea does not exclude ciguatera.

Clinical Features

Gastrointestinal

Usually begins with:

• Nausea
• Vomiting
• Abdominal cramping
• Watery diarrhea

GI symptoms usually resolve much sooner than neurologic symptoms.

The diarrhea is ordinarily:

• Nonbloody
• Toxin-mediated

Significant losses can cause:

• Dehydration
• Orthostatic symptoms
• Electrolyte abnormalities

Neurologic – Hallmark Syndrome

Neurologic manifestations include:

• Perioral paresthesia
• Tingling/numbness of hands and feet
• Burning dysesthesia
• Weakness
• Headache
• Dizziness
• Vertigo
• Ataxia
• Fatigue
• Pruritus
• Tremor

Cold Allodynia

The most characteristic symptom is:

Cold allodynia

Cold objects or water can cause:

• Burning
• Electric sensations
• Pain
• Abnormally intense cold sensation

Classical descriptions call this:

“Hot–cold reversal.”

However, modern neurologic studies suggest many patients experience abnormal/painful cold sensation rather than a literal complete reversal in temperature perception.

Therefore:

“Cold allodynia” is the more accurate term.

It is especially noticeable in:

• Hands
• Feet
• Lips
• Oral mucosa

and is highly suggestive of ciguatera when the exposure history fits. (CDC)

Oral/Dental Symptoms

Characteristic but unusual complaints include:

• Metallic taste
• Burning mouth
• Tooth pain
• Sensation that the teeth are loose

These symptoms can be diagnostically useful when combined with:

• Reef-fish exposure
• GI illness
• Paresthesias

(CDC)

Pruritus

Generalized itching can occur:

• Early
• Or after the initial GI illness

It may persist for weeks.

Important correction

The older suggestion that pruritus commonly leads to “cellulitis” is misleading.

Pruritus can produce:

• Excoriations
• Secondary skin injury

but bacterial cellulitis is not a defining feature of ciguatera.

Neuropsychiatric Symptoms

Some patients develop:

• Difficulty concentrating
• Memory impairment
• Sleep disturbance
• Depression
• Anxiety
• Marked fatigue

These may persist after the acute GI syndrome has resolved. (CDC)

Motor / Cranial Nerve Effects

More severe poisoning may cause:

• Generalized weakness
• Cranial-nerve dysfunction
• Ophthalmoplegia
• Dysarthria
• Ataxia
• Rare paralysis

Profound flaccid weakness should also prompt consideration of:

• Paralytic shellfish poisoning
• Tetrodotoxin
• Botulism
• Organophosphate toxicity
• Other neurologic disorders

Cardiovascular

Important manifestations include:

Bradycardia + hypotension

Possible ECG findings include:

• Sinus bradycardia
• AV block
• Ectopy
• Nonspecific repolarization abnormalities

Cardiovascular toxicity is usually most important early in the illness. (PubMed)

Respiratory

Severe cases may produce:

• Dyspnea
• Respiratory depression
• Respiratory-muscle weakness
• Rare respiratory failure

Mechanical ventilation is rarely required but can be lifesaving.

Musculoskeletal

Possible findings include:

• Myalgia
• Arthralgia
• Weakness
• Muscle cramps

CK elevation/rhabdomyolysis is not a defining feature but may occur after:

• Severe weakness
• Prolonged immobility
• Seizures

Severe CNS Effects

Very severe poisoning can occasionally produce:

• Confusion
• Severe encephalopathy
• Seizures
• Coma

but these are uncommon.

If profound CNS depression dominates, evaluate aggressively for:

• Coingestants
• Hypoxia
• Electrolyte abnormalities
• Alternative marine toxins
• Primary neurologic disease

Genitourinary / Sexual Effects

Case reports describe:

• Painful ejaculation
• Pelvic/genital discomfort
• Dyspareunia in the sexual partner

An old case series suggested possible transfer of ciguatoxin through semen, but toxin detection was not definitive.

Therefore:

Sexual transmission remains a case-report observation, not an established common route of poisoning.

(PubMed)

Recurrent / Chronic Symptoms

Neurologic symptoms usually improve over:

Days to weeks

but may persist for:

Months or occasionally longer.

CDC recognizes persistence of neurologic symptoms for months or years in some patients. (CDC)

Possible chronic symptoms include:

• Cold allodynia
• Paresthesias
• Pruritus
• Fatigue
• Weakness
• Headache
• Neuropsychiatric symptoms

Re-Exposure

Repeated ciguatera exposures have sometimes been associated with more severe or recurrent symptoms.

However:

Severity is not predictably greater with every subsequent exposure.

The older statement that repeated episodes are always more severe is too categorical.

Diagnosis

Diagnosis is primarily:

Clinical

based on:

Compatible seafood exposure + characteristic GI/neurologic syndrome

A particularly compelling history is:

Several people who shared the same reef fish develop gastroenteritis + paresthesias/cold allodynia.

No Routine Human Diagnostic Test

There is currently:

No routine clinically available human blood or urine test that confirms ciguatera.

CDC states that diagnosis is based on:

• Symptoms
• Exposure history

rather than a specific human laboratory assay. (CDC)

Fish Testing

If leftover fish is available, specialized laboratories may use methods such as:

• Neuroblastoma cell-based assays
• Receptor-binding assays
• LC-MS/MS

to identify or quantify CTX activity.

These tests are primarily:

• Public-health
• Regulatory
• Research tools

rather than bedside emergency tests. (PubMed Central (PMC))

Practical pearl

If an outbreak is suspected:

Preserve leftover fish rather than discarding it.

It may help confirm the source and protect others.

Laboratory Evaluation

No routine laboratory tests are required in a mild, classic case.

For moderate/severe illness consider:

• Glucose
• Sodium
• Potassium
• Magnesium
• Calcium
• Bicarbonate
• BUN
• Creatinine

These primarily assess:

• Dehydration
• Vomiting/diarrhea
• Alternative diagnoses

ECG / Cardiac Monitoring

Obtain an ECG in patients with:

• Bradycardia
• Hypotension
• Syncope
• Significant weakness
• Severe poisoning

Continuous telemetry is appropriate for clinically significant cardiovascular toxicity.

A 2024 systematic review found sinus bradycardia and AV block among the most common reported ECG abnormalities in ciguatera cardiotoxicity. (PubMed)

CK

Check CK when there is:

• Marked weakness
• Prolonged immobility
• Severe muscle pain
• Seizures

Routine CK measurement in every mild case is unnecessary.

Neuroimaging / Lumbar Puncture

CT/MRI brain or lumbar puncture is not part of routine ciguatera diagnosis.

Use them only when the presentation raises concern for an alternative diagnosis such as:

• Stroke
• CNS infection
• Intracranial hemorrhage
• Encephalitis

Differential Diagnosis

Scombroid poisoning

Usually:

• Very rapid onset
• Flushing
• Headache
• Palpitations
• Urticaria
• Burning/peppery taste

and responds to antihistamines.

Cold allodynia is not typical.

Paralytic Shellfish Poisoning

Caused by saxitoxin.

Features:

• Perioral numbness
• Weakness
• Rapid paralysis
• Respiratory failure

GI manifestations may occur, but cold allodynia is much more characteristic of ciguatera.

Neurotoxic Shellfish Poisoning

Brevetoxin exposure can also cause:

• GI symptoms
• Neurologic symptoms
• Temperature abnormalities

Seafood source and epidemiology help distinguish it from ciguatera.

Tetrodotoxin Poisoning

Usually after:

• Pufferfish
• Certain other marine species

Produces:

• Perioral numbness
• Rapid ascending paralysis
• Respiratory failure

with a generally faster and more paralytic course than ordinary ciguatera.

Botulism

Consider with:

• Cranial neuropathies
• Descending weakness
• Normal sensation

rather than prominent painful paresthesias/cold allodynia.

Organophosphate / Carbamate Poisoning

Look for:

• Salivation
• Lacrimation
• Bronchorrhea
• Miosis
• Fasciculations
• Diarrhea

A cholinergic toxidrome is distinct from classic ciguatera.

Infectious Gastroenteritis

Common bacterial/viral food poisoning can explain:

• Vomiting
• Diarrhea
• Cramping

but does not explain:

Cold allodynia + perioral/extremity paresthesias

Treatment

1. Supportive Care

The core treatment is:

Supportive and symptom-directed care

CDC states that there is no antidote and management is directed toward:

• Hydration
• Cardiovascular stabilization
• Respiratory support
• Symptom relief. (CDC)

2. Fluids and Electrolytes

Vomiting and diarrhea can cause substantial dehydration.

Use:

• Oral rehydration for mild disease
• IV isotonic crystalloid for significant volume depletion

Replace:

• Potassium
• Magnesium
• Other electrolytes

according to measured abnormalities.

3. Antiemetics

For significant nausea/vomiting, use standard antiemetics such as:

• Ondansetron

or another appropriate agent.

There is no ciguatera-specific antiemetic.

4. Diarrhea

Most acute diarrhea is short-lived.

The priority is:

Fluid/electrolyte replacement

rather than aggressively suppressing all bowel activity.

Antidiarrheal treatment may be considered in selected patients once:

• Serious infectious diarrhea is unlikely
• Volume status has been addressed

5. Symptomatic Bradycardia

For clinically important:

Bradycardia + hypotension/poor perfusion

use:

Atropine

according to standard symptomatic-bradycardia practice.

For adults, a contemporary ACLS-style regimen is:

Atropine 1 mg IV

repeated every:

3–5 minutes

to a maximum total of:

3 mg

when clinically appropriate.

The older 0.5-mg starting dose reflects previous resuscitation guidance.

Refractory Bradycardia

If hemodynamically important bradycardia persists despite atropine:

Consider:

• Epinephrine infusion
• Other chronotropic/vasopressor support
• Temporary pacing if truly refractory

in consultation with critical care/toxicology.

Temporary pacing appears to be required rarely; the recent systematic review of 148 reported ciguatera cardiotoxicity cases found no cases requiring temporary or permanent pacing among those reviewed. (PubMed)

6. Hypotension

Treat initially with:

IV isotonic crystalloid

especially because GI fluid losses are common.

CDC specifically notes that orthostatic hypotension generally responds to:

IV fluid + an α-adrenergic agent when necessary. (CDC)

If significant shock persists:

Norepinephrine is a reasonable contemporary vasopressor

with the choice tailored to:

• Bradycardia
• Vasodilation
• Cardiac function

The older routine preference for dopamine and Trendelenburg positioning is outdated.

7. Respiratory Failure

For severe weakness or respiratory depression:

• Oxygen
• Close ventilatory assessment
• Capnography/blood gases when appropriate

Intubate for:

• Respiratory failure
• Severe neuromuscular weakness
• Inability to protect airway
• Coma

8. Seizures

Seizures are uncommon but should be treated with:

Benzodiazepines first-line

Examples:

• Midazolam
• Lorazepam
• Diazepam

For refractory toxin-induced seizures consider:

• Phenobarbital
• Propofol in an intubated patient

Mannitol

Major modernization

The old chapter presents:

IV mannitol as the primary treatment

with a strong claim that early administration improves neurologic outcome.

That claim is not established.

Historical Regimen

The commonly reported regimen is:

Mannitol 1 g/kg IV over approximately 30–60 minutes

usually within:

• 24 hours historically
• Up to 48–72 hours in some contemporary guidance

after symptom onset.

CDC still states that mannitol may be considered during the first 48–72 hours, while acknowledging that evidence is variable. (CDC)

Randomized Trial Evidence

The only double-blind randomized trial compared mannitol with normal saline in 50 patients.

At 24 hours:

• 96% of mannitol patients improved
• 92% of saline patients improved

There was:

No statistically significant clinical advantage from mannitol

and infusion-site discomfort was substantially more frequent with mannitol. (PubMed)

The trial concluded that the findings did not support single-dose mannitol as standard therapy.

Current Role of Mannitol

Therefore:

Mannitol is not a proven first-line antidote.

A reasonable contemporary interpretation is:

• Supportive care and adequate hydration come first
• Routine mannitol is not mandatory
• It may be considered in selected patients with significant acute neurologic symptoms after poison-center/medical-toxicology discussion
• Evidence of benefit remains low quality and conflicting

A later systematic review likewise concluded that the evidence for all pharmacologic ciguatera therapies remains weak. (PubMed)

Mannitol Precautions

Do not give mannitol to a:

• Dehydrated
• Hypotensive
• Hemodynamically unstable

patient before adequate resuscitation.

Potential harms include:

• Osmotic diuresis
• Worsening volume depletion
• Hypotension
• Electrolyte abnormalities
• Renal complications

Thus:

Rehydrate first.

Activated Charcoal

Do not induce vomiting

The old recommendations for ipecac are obsolete.

Do not induce emesis.

By the time ciguatera becomes symptomatic, the toxin-containing food has generally already progressed through the GI tract, and spontaneous vomiting may already be significant.

Gastric Lavage

Routine gastric lavage is not recommended.

There is no evidence that routine lavage improves outcomes, and it can cause:

• Aspiration
• Procedural injury

The old pediatric/adult lavage algorithms should not be used.

Single-Dose Activated Charcoal

CDC Yellow Book states that activated charcoal may be considered when the patient:

• Presents early after ingestion
• Is not vomiting
• Can safely protect the airway

(CDC)

However:

Clinical evidence for improved outcomes is limited.

Therefore it should be viewed as:

Optional early decontamination—not core treatment.

Do not administer it to a:

• Vomiting
• Somnolent
• Unprotected-airway

patient.

Antidote

There is no specific antidote for ciguatoxin poisoning.

(CDC)

Treatment of Persistent Neuropathic Symptoms

Evidence is limited mainly to case reports and case series.

Agents that have been used include:

• Gabapentin
• Pregabalin
• Amitriptyline
• Duloxetine
• Other neuropathic-pain agents

A review found reports of symptom suppression with several of these agents but no high-quality evidence establishing superiority of any particular drug. (PubMed)

Thus:

Treat persistent neuropathic symptoms similarly to other neuropathic pain syndromes, individualized to the patient.

Pruritus

Possible symptomatic treatment includes:

• Antihistamines

although ciguatera-associated itching is neurologic/toxicologic rather than necessarily histamine-mediated, so response may be variable. CDC includes antihistamines among symptomatic therapies. (CDC)

Chronic Fatigue / Mood Symptoms

CDC Yellow Book lists reported symptomatic treatment including:

• Amitriptyline for persistent paresthesias/depression
• Fluoxetine for chronic fatigue

but supporting evidence is limited.

These should not be presented as ciguatoxin-specific antidotes. (CDC)

Hemodialysis / Enhanced Elimination

There is no established role for:

• Hemodialysis
• Hemoperfusion
• Forced diuresis
• Urinary alkalinization

in toxin elimination.

CTX is highly potent, lipid-soluble, and widely distributed into tissues.

Management remains supportive.

Observation

Not every symptomatic patient requires hospital admission.

The older statement:

“Any symptoms → inpatient admission”

is too conservative.

Mild patients with:

• Stable vital signs
• Mild GI symptoms
• Mild paresthesias
• Adequate oral hydration

may often be treated as outpatients after appropriate evaluation.

Admission

Admit patients with:

• Symptomatic bradycardia
• Hypotension
• AV block or significant dysrhythmia
• Severe dehydration
• Significant electrolyte abnormality
• Severe/progressive weakness
• Respiratory symptoms
• Inability to maintain oral hydration
• Altered mental status
• Severe or atypical neurologic toxicity

ICU

ICU-level care is appropriate for:

• Hemodynamic instability requiring vasopressors
• Severe bradycardia/heart block
• Respiratory failure
• Mechanical ventilation
• Severe progressive neuromuscular weakness
• Seizures/coma

Discharge

Discharge is reasonable when:

• Hemodynamics are stable
• Oral hydration is adequate
• No significant bradycardia remains
• No progressive weakness is present
• Respiratory function is normal
• Neurologic symptoms are mild/stable
• Follow-up and return precautions are understood

A patient does not need all paresthesias to disappear before discharge; sensory symptoms may persist for days or weeks.

Prognosis

Most patients recover.

CDC reports a mortality rate:

<0.1%

although risk depends on toxin burden and access to supportive care. (CDC)

GI symptoms usually resolve first.

Neurologic symptoms may persist much longer:

• Days
• Weeks
• Occasionally months or years

Severe respiratory or cardiovascular complications are uncommon with modern supportive care.

Relapse / Triggered Recurrence

Patients sometimes report recurrence or exacerbation of symptoms after:

• Alcohol
• Fish/seafood
• Caffeine
• Nuts

CDC recommends avoiding these trigger foods for up to approximately 6 months after recovery because symptom relapse has been reported. (CDC)

Important nuance

The evidence supporting specific trigger avoidance is largely:

• Observational
• Anecdotal

rather than based on controlled clinical trials.

Therefore:

Do not expand this into the enormous historical list of prohibited substances without evidence.

The older recommendations to avoid:

• Marijuana
• Herbicides
• Insecticides
• Glues
• Epoxies
• Resins
• Cosmetics
• Solvents

for 3–12 months are not supported by robust clinical data.

A pragmatic recommendation is to avoid:

Alcohol and foods personally associated with symptom recurrence, with temporary avoidance of fish, nuts, and caffeine consistent with CDC advice.

Pregnancy

Human pregnancy data remain extremely limited.

Case reports include:

• Normal fetal outcomes after substantial maternal poisoning
• Rare neonatal neurologic abnormalities after maternal poisoning near term

One reported second-trimester severe exposure resulted in a healthy term infant with normal early development. (PubMed)

Therefore:

Ciguatera has not been shown to produce a predictable human teratogenic syndrome.

In a pregnant patient:

• Treat maternal dehydration
• Treat hypotension/bradycardia
• Maintain oxygenation
• Obtain obstetric assessment according to gestational age and maternal severity

Maternal stabilization remains the priority.

Breastfeeding

LactMed currently recommends that:

A mother suspected of having ciguatera poisoning should not breastfeed until she has recovered.

Human data are extremely sparse, but symptoms have historically been suspected in a breastfed infant after maternal ciguatera. (PubMed)

Therefore:

Temporary interruption of breastfeeding during active maternal illness is reasonable.

Public-Health Reporting

Ciguatera frequently occurs in clusters because several people share the same fish.

If poisoning is suspected:

• Ask whether other diners are ill
• Save leftover fish
• Document where the fish was purchased/caught
• Notify appropriate local public-health or food-safety authorities when required

In the United States, FDA specifically encourages healthcare/public-health reporting of seafood toxin illnesses so contaminated products can be investigated and removed from distribution. (U.S. Food and Drug Administration)

Prevention

Because there is no way for a consumer to tell that a fish contains CTX:

Prevention depends on avoiding high-risk seafood rather than preparation technique.

CDC recommends:

• Avoid barracuda and moray eel from ciguatera-endemic areas
• Avoid very large predatory reef fish
• Avoid reef fish >approximately 5 lb where feasible
• Avoid:
• 
  
• Head
• Liver
• Intestines
• Roe
• Remember cooking/freezing does not destroy toxin. (CDC)

Local knowledge and public-health advisories are particularly valuable because toxicity is often highly localized to individual reefs and species.

Important Pitfalls

1. Attributing ciguatera solely to

Gambierdiscus toxicus

Modern taxonomy recognizes multiple toxin-producing:

Gambierdiscus and Fukuyoa species

involved in CTX ecology. (PubMed Central (PMC))

2. Calling maitotoxin an established human ciguatera toxin

Ciguatoxins are the proven major human toxins.

Maitotoxins have no established role in ordinary human ciguatera. (PubMed Central (PMC))

3. Calling temperature reversal mandatory

Some patients literally report hot–cold reversal.

More commonly:

Cold causes abnormal burning/pain — cold allodynia.

The absence of literal reversal does not exclude ciguatera.

4. Waiting for a toxin level

There is:

No routine human ciguatoxin test.

Diagnosis is clinical. (CDC)

5. Forgetting to ask about fish exposure

Patients may present many hours later and may not volunteer a travel or seafood history.

Ask:

• What fish?
• Where caught?
• When eaten?
• Who else ate it?
• Who else is ill?

6. Confusing ciguatera with scombroid

Scombroid classically produces:

Flushing + headache + urticaria/palpitations

whereas ciguatera favors:

Paresthesias + cold allodynia + bradycardia

7. Treating mannitol as a proven antidote

The only blinded randomized trial found:

No benefit over normal saline at 24 hours

and more infusion-related discomfort. (PubMed)

Mannitol remains optional/controversial, not mandatory treatment.

8. Giving mannitol before correcting dehydration

Mannitol causes osmotic diuresis and may worsen:

• Hypovolemia
• Hypotension
• Electrolyte abnormalities

Rehydrate first.

9. Using ipecac

The old ipecac recommendation is obsolete.

Do not induce vomiting.

10. Performing gastric lavage

Routine lavage offers no established benefit and adds aspiration/procedural risk.

11. Automatically admitting every symptomatic patient

Many mild cases can be treated supportively as outpatients.

Admission should be driven by:

• Hemodynamics
• Respiratory function
• Neurologic severity
• Hydration

rather than simply the presence of paresthesias.

12. Using the old 3-lb fish rule

CDC currently advises avoiding reef fish over approximately:

5 lb

as a preventive strategy, but even this is not a guaranteed toxicity cutoff.

Species + location + individual fish matter more than weight alone.

(CDC)

13. Assuming cooking makes the fish safe

CTX survives:

• Cooking
• Freezing
• Smoking
• Canning

(CDC)

14. Eating the liver because the flesh appeared safe

High-risk tissues include:

Liver + viscera + head + roe

and should be avoided in endemic areas. (CDC)

15. Overprescribing long lists of forbidden foods/chemicals

Evidence for chronic symptom triggers is weak.

The best-supported practical advice focuses on:

• Alcohol
• Fish
• Nuts
• Caffeine

rather than the older extensive lists of chemicals and consumer products.

High-Yield Toxicology Pearls

Ciguatera = reef seafood + gastroenteritis + neurologic dysesthesia

Think:

Diarrhea/vomiting → tingling → cold hurts

Key points:

• Principal toxins:
• 
  
• Ciguatoxins
• Source:
• 
  
• Gambierdiscus/Fukuyoa
• Maitotoxin:
• 
  
• Produced by some dinoflagellates
• No proven major role in human ciguatera
• Mechanism:
• 
  
• Persistent activation of voltage-gated sodium channels
• Neuronal depolarization/hyperexcitability
• High-risk fish:
• 
  
• Barracuda
• Moray eel
• Grouper
• Snapper
• Amberjack
• Large reef predators
• High-risk parts:
• 
  
• Liver
• Viscera
• Head
• Roe
• Toxin does not alter:
• 
  
• Taste
• Smell
• Appearance
• Toxin survives:
• 
  
• Cooking
• Freezing
• Canning
• Smoking
• Typical onset:
• 
  
• 1–6 h
• Can be delayed to ~30 h
• Main acute GI symptoms:
• 
  
• Nausea
• Vomiting
• Watery diarrhea
• Abdominal pain
• Hallmark neurologic findings:
• 
  
• Paresthesias
• Cold allodynia
• Perioral numbness
• Metallic taste
• “Loose teeth” sensation
• Severe autonomic findings:
• 
  
• Bradycardia
• Hypotension
• Diagnosis:
• 
  
• Clinical
• No routine human toxin assay
• Save leftover fish for possible specialized testing/public-health investigation
• Treatment:
• 
  
• Supportive care
• IV/oral fluids
• Electrolytes
• Antiemetics
• Symptomatic bradycardia:
• 
  
• Atropine
• Persistent hypotension:
• 
  
• Fluids
• Vasopressor such as norepinephrine when required
• Severe respiratory weakness:
• 
  
• Intubation/ventilation
• No specific antidote
• Mannitol is controversial
• 
  
• Historical dose: 1 g/kg IV
• RCT showed no superiority to saline
• Not routine first-line therapy
• Rehydrate before any consideration of mannitol
• Do not induce vomiting
• No routine gastric lavage
• Activated charcoal:
• 
  
• Optional only after very recent exposure with intact/protected airway and no significant vomiting
• Persistent neuropathic symptoms:
• 
  
• Gabapentin/pregabalin/amitriptyline may be tried
• Evidence is low quality
• Mortality:
• 
  
• <0.1%
• Neurologic symptoms can persist:
• 
  
• Weeks
• Months
• Rarely years
• After recovery, alcohol and several foods can reportedly trigger symptom recurrence
• CDC advises temporary avoidance of:
• 
  
• Alcohol
• Caffeine
• Fish
• Nuts
• Breastfeeding:
• 
  
• Avoid during active maternal ciguatera until recovery
• Prevention:
• 
  
• Avoid barracuda/moray eel
• Avoid high-risk viscera
• CDC advises avoiding very large reef fish, approximately >5 lb
• Suspected clusters should be reported to public-health authorities